apomorphine has been researched along with Parkinson Disease in 815 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 108 (13.25) | 18.7374 |
| 1990's | 238 (29.20) | 18.2507 |
| 2000's | 197 (24.17) | 29.6817 |
| 2010's | 193 (23.68) | 24.3611 |
| 2020's | 79 (9.69) | 2.80 |
| Authors | Studies |
|---|---|
| Anan, C; Bhidayasiri, R; Chaudhuri, KR; Phimpha, A; Phokaewvarangkul, O; van Laar, T | 1 |
| Larson, D; Simuni, T | 1 |
| De Pandis, MF; Navia, B; Olanow, CW; Peckham, EL; Sciarappa, K; Stocchi, F | 1 |
| Barbosa, P; Djamshidian, A; Lees, AJ; Warner, TT | 1 |
| Alfredson, T; den Heijer, J; Ezzeldin Sharaf, M; Groeneveld, GJ; Hasegawa, D; Keum, K; Lei, M; Mochel, K; Moss, L; Naranda, T; Puibert, D; Thijssen, E; van Brummelen, E; Zeng, W | 1 |
| Gaburo, K; Kirson, N; Mehta, D; Pappert, E; Thach, A; Williams, GR; Yang, K; Zichlin, ML | 1 |
| Alikunju, S; Gao, Y; Ibsen, K; Jaladi, R; Kim, J; Mitragotri, S; Rodrigues, D; Sasmal, PK; Tanner, EEL; Zhao, Z | 1 |
| Barer, Y; Bergmann, L; Chodick, G; Cohen, R; Giladi, N; Gross, R; Gurevich, T; Jalundhwala, YJ; Shalev, V; Thaler, A | 1 |
| Fan, F; Liu, S; Wang, Y; Zheng, Y; Zhou, J | 1 |
| den Heijer, JM; Groeneveld, GJ; Naranda, T; Puibert, D; Thijssen, E; van Brummelen, EMJ | 1 |
| Chaudhuri, KR; Leta, V | 1 |
| Abril, B; Aerts, C; Anheim, M; Arnulf, I; Benard-Serre, N; Castelnovo, G; Corbillé, AG; De Cock, VC; Devos, D; Dodet, P; Doulazmi, M; Drapier, S; Eusebio, A; Fantini, ML; Lacombe, S; Lambert, I; Lebouteux, M; Leclair-Visonneau, L; Leu-Semenescu, S; Marques, A; Monaca, C; Olivet, H; Roze, E; Ruppert, E; Sallansonnet-Froment, M; Vidailhet, M; Vitello, N | 1 |
| Abuleil, A; Ajagbe, AO; Alhendawi, BHM; Badri, R; Chaaya, C; Chalhoub, E; Korkusuz, AK; Onyeaka, H; Uwishema, O; Yücel, AN | 1 |
| Fernandez, HH; Mata, IF; Salles, PA | 1 |
| Ares-Pensado, B; Fernández-Pajarín, G; Martín-Jiménez, I; Sesar-Ignacio, A | 1 |
| Fernandez, HH; Liao, J; Mata, IF; Salles, PA; Shuaib, U | 1 |
| Macaulay, K | 1 |
| Antonini, A; Berg, D; Corvol, JC; Costa, J; Deuschl, G; Fabbrini, G; Ferreira, J; Foltynie, T; Henschke, N; Mir, P; Moro, E; Ruzicka, E; Schrag, A; Selikhova, M; Seppi, K; Śmiłowska, K; Taba, P; Villanueva, G | 2 |
| Agbo, F; Blum, D; De Pandis, MF; Kleiman, R; Navia, B; Olanow, CW; Peckham, EL; Sciarappa, K; Stocchi, F | 1 |
| Mohajeri, D; Nourazar, MA; Sokouti, H | 1 |
| Boura, I; Chaudhuri, KR; Espay, AJ; Jenner, P; Leta, V; Odin, P; Rota, S; Urso, D; van Wamelen, DJ | 1 |
| Alobaidi, A; Antonini, A; Bao, Y; Bergmann, L; Chaudhuri, KR; Isaacson, SH; Kandukuri, PL; Merola, A; Odin, P; Pahwa, R; Parra, JC; Wang, L; Yan, CH; Zadikoff, C | 1 |
| Chan, P; Ding, H; Liu, Y; Ren, Z; Yang, N; Zhou, M | 1 |
| Hallett, M; Katzenschlager, R; Pirker, W; Poewe, W | 1 |
| Franko, O; Gažová, A; Kolesár, D; Kolesárová, M; Kyselovič, J | 1 |
| Bouillot, R; Delabrousse-Mayoux, JP; Leblanc, A; Patat, M; Pouyet, A; Sogni, L; Vérin, M; Viakhireva-Dovganyuk, I; Zagnoli, F; Ziegler, M | 1 |
| Algul, O; Ozcelik, I; Yucel, MA | 1 |
| Bowling, A; Hauser, RA; Isaacson, SH; Navia, B; Ondo, WG; Pappert, E; Zhang, Y | 1 |
| LeWitt, PA; Martinez-Nunez, AE | 1 |
| Auffret, M; Bhidayasiri, R; Borovečki, F; Falup-Pecurariu, C; Jenner, P; Jost, WH; Leta, V; Verin, M; Weiss, D | 1 |
| Bründl, E; Deuter, D; Forras, P; Kohl, Z; Mederer, T; Schlaier, J; Schmidt, NO | 1 |
| Arif, C; Koneru, V; Ondo, WG | 1 |
| Bilal, B; Erbas, O; Erdogan, MA; Kirazlar, M; Yigitturk, G | 1 |
| Bhidayasiri, R; Henriksen, T; Katzenschlager, R; Lees, A; Lockhart, D; Staines, H | 1 |
| Barbosa, RP; Barthelemy, C; Camgrand, E; Chouquet, C; Christine, BC; Fabbri, M; Harroch, E; Leung, C; Ory-Magne, F; Rascol, O | 1 |
| Kobylecki, C; Partington-Smith, L | 1 |
| Batzu, L; Bhattacharya, K; Borgohain, R; Chaudhuri, KR; Dhamija, RK; Falup-Pecurariu, C; Goyal, V; Kumar, NSS; Kumar, S; L K, P; Metta, V; Mrudula, R; Rodriguez-Blazquez, C; S, A | 1 |
| Carbone, F; Djamshidian, A; Poewe, W; Seppi, K | 1 |
| Arabia, G; Augimeri, A; Barbagallo, G; Bianco, MG; Bifone, A; Bordier, C; Cerasa, A; Crasà, M; Fiorillo, A; Morelli, M; Nicolini, C; Nigro, S; Nisticò, R; Olivadese, G; Quattrone, A; Vescio, B | 1 |
| Tian, H; Xiao, W; Xue, B | 1 |
| Abd-Elrahman, KS; Bureau, SC; Derksen, A; Dwyer, Z; Farmer, K; Ferguson, SSG; Fortin, T; Hayley, S; Prowse, NA; Rowe, EM; Rudyk, CA; Thompson, AM | 1 |
| Antonini, A | 1 |
| Bhargava, P; Blum, D; Espay, AJ; Factor, SA; Hauser, RA; Isaacson, S; Leinonen, M; Navia, B; Olanow, CW; Pahwa, R; Sciarappa, K; Shill, HA | 1 |
| Do, JH; Pepe, D | 1 |
| McFarthing, K; Prakash, N; Simuni, T | 1 |
| Bruno, V; Farcy, N; Karnik, V; Zamorano, C | 1 |
| da Costa, RO; de Araújo, DP; de Barros Viana, GS; de Lucena, JD; Gadelha-Filho, CVJ; Lima, FAV; Neves, KRT | 1 |
| Calvão, J; Cardoso, JC; Gonçalo, M; Januário, C; Moreira, F | 1 |
| Mendes, A; Oliveira, V; Videira, G | 1 |
| Anheim, M; Grillon, A; Lipsker, D; Moegle, C; Velter, C | 1 |
| Mariani, LL | 1 |
| Baumann, CR; Oertel, MF; Stieglitz, LH | 1 |
| Benedierks, S; Bhidayasiri, R; Boonmongkol, T; Boonpang, K; Chairangsaris, P; Chaudhuri, KR; Evans, AH; Jagota, P; Kantachadvanich, N; Lolekha, P; Panyakaew, P; Parsons, J; Phokaewvarangkul, O; Phumphid, S; Pisarnpong, A; Sakdisornchai, K; Srivanitchapoom, P; Thongchuam, Y; van Laar, T; Viriyavejakul, A | 1 |
| Colosimo, C; Kaiserová, M; Kaňovský, P; Kurčová, S; Menšíková, K; Nevrlý, M; Vaštík, M | 1 |
| Domb, AJ; Hoffman, A; Itin, C; Komargodski, R | 1 |
| Bergquist, F; Dizdar, N; Hagell, P; Hellqvist, C; Höglund, A; Johansson, A; Johansson, EL; Karlberg, C; Löwed, B; Lundgren, M; Rådberg, J; Sjöström, AC; Willows, T | 1 |
| Müller, T | 1 |
| de Bie, RMA; Dijk, JM; Espay, AJ; Katzenschlager, R | 1 |
| Hoskere Sreenivasa, DK; Iyer, RB; Krishnan, S; Kukkle, PL; Ramachandran, J; Seetharam, R | 1 |
| Chanson, E; Condé, S; Debilly, B; Derost, P; Durif, F; Lauxerois, M; Marques, A | 1 |
| Bhargava, P; Blum, D; Fox, SH; Hui, JS; Navia, B; Neeson, W; Pappert, E | 1 |
| Fu, X; Liu, J; Lu, XJ; Sun, Y; Xia, CL; Zhan, Y; Zhang, Y; Zhao, L | 1 |
| Caughman, CY; Factor, S | 1 |
| Alfaisal, H; Corvol, JC; Lapeyre-Mestre, M; Lastennet, D; Mariani, LL; Rascol, O; Tubach, F; Turc, JD | 1 |
| Barasch, D; Domb, AJ; Hoffman, A; Itin, C; Komargodski, R | 1 |
| Abuirmeileh, AN; Alzoubi, KH; Rababa'h, AM | 1 |
| Calvano, A; Chaudhuri, KR; Martinez-Martin, P; Odin, P; Pietrzykowski, T; Rodriguez-Blazquez, C; Smilowska, K; van Wamelen, DJ | 1 |
| Chaudhuri, KR; Deuschl, G; Henriksen, T; Katzenschlager, R; Lees, A; Lockhart, D; Poewe, W; Rascol, O; Staines, H; Trenkwalder, C; van Laar, T | 1 |
| Bologna, M; Colosimo, C; Marsili, L; Miyasaki, JM | 1 |
| Paton, DM | 1 |
| Bloem, BR; de Bie, RMA; Esselink, R; Groenewoud, H; Meinders, MJ; Nijhuis, FAP; Post, B | 1 |
| Alonso-Canovas, A; Martínez-Castrillo, JC | 1 |
| Abuhamdah, SM; Abuirmeileh, AN; Alzoubi, KH; Ashraf, A | 1 |
| Comella, CL; Hauser, RA; LeWitt, PA | 1 |
| Borgemeester, RWK; Diercks, GFH; van Laar, T | 1 |
| Facheris, MF; Jick, SS; Oleske, DM; Persson, R; Zamudio, J | 1 |
| Antipova, V; Hawlitschka, A; Holzmann, C; Witt, M; Wree, A | 1 |
| Olanow, CW; Poewe, W; Rascol, O; Stocchi, F | 1 |
| Felten, P; Heurtaux, T; Kirchmeyer, M; Koncina, E; Mittelbronn, M; Richart, L; Schohn, H; Uriarte Huarte, O | 1 |
| Ares, B; Castro, A; Fernández-Pajarín, G; Rivas, MT; Sesar, Á | 1 |
| Nemas, M; Nyska, A; Ramot, Y; Rubinski, A; Schiffenbauer, YS; Shaltiel-Karyo, R; Tsarfati, Y; Weinstock, I; Yacoby-Zeevi, O; Zawoznik, E | 1 |
| Aasly, J; Dietrichs, E; Egge, A; Ezat, B; Pihlstrøm, L; Tysnes, OB | 1 |
| Braz, L; Linhares, P; Martins de Campos, A; Rosas, MJ | 1 |
| Mundt-Petersen, U; Odin, P | 1 |
| Ceballos-Baumann, A; Honig, H; Jost, WH; Storch, A; Tönges, L | 1 |
| Dafsari, HS; Florin, E; Gerick, F; Saur, J; Timmermann, L; von Papen, M | 1 |
| Barbiani, D; Benedetti, F; Carlino, E; Dematteis, F; Frisaldi, E; Lanotte, M; Lopiano, L; Zibetti, M | 1 |
| Ai, Y; Andersen, AH; Evans, A; Forman, E; Gash, DM; Grondin, R; Hardy, PA; Yue, G; Yue, J; Zhang, R; Zhang, Z | 1 |
| Chen, YH; Gou, Y; Li, HW; Li, Y; Lin, X; Tang, L; Wen, M; Zhang, Y; Zhou, B | 1 |
| Borgemeester, RWK; van Laar, T | 1 |
| Açikalin, Ö; Bölükbaşi Hatip, F; Hatip-Al-Khatib, I; Kataoka, Y; Tan, R; Yamauchi, A | 1 |
| Lees, AJ | 2 |
| Babayan-Tazehkand, A; Haghdoost-Yazdi, H; Rastgoo, N; Sarbazi-Golezari, A; Sarookhani, MR | 1 |
| Elosua-González, M; Floristán-Muruzábal, U; García-Zamora, E | 1 |
| Auffret, M; Drapier, D; Drapier, S; Duprez, J; Houvenaghel, JF; Robert, G; Sauleau, P; Vérin, M | 1 |
| Auffret, M; Drapier, S; Vérin, M | 1 |
| Bai, J; Cui, JJ; Li, BD; Ma, PF; Qi, C; Song, J; Wang, YR | 1 |
| Antonini, A; Canesi, M; Costanzo, AM; Defazio, G; di Luzio Paparatti, U; Gualberti, G; Latorre, A; Lopiano, L; Marano, P; Melzi, G; Modugno, N; Pontieri, FE; Quatrale, R; Sensi, M; Solla, P; Tambasco, N; Tessitore, A | 1 |
| Arabia, G; Augimeri, A; Barbagallo, G; Bianco, MG; Cerasa, A; Crasà, M; Morelli, M; Nicoletti, G; Nigro, S; Nisticò, R; Novellino, F; Olivadese, G; Quattrone, A; Salsone, M; Vescio, B | 1 |
| Eklund, M; Henriksen, T; Nyholm, D; Odin, P; Sahlström, T; Timpka, J | 1 |
| Babayan-Tazehkand, A; Dargahi, T; Haghdoost-Yazdi, H; Rastgoo, N; Sarbazi Golezari, A; Sarukhani, M | 1 |
| Antonini, A; Nitu, B | 1 |
| Li, K; Li, Y; Na, S; Wu, J; Xie, X; Yang, J; Yang, Z; Yu, X; Yue, J | 1 |
| LeWitt, PA | 2 |
| Chaudhuri, KR; Deuschl, G; Henriksen, T; Katzenschlager, R; Lees, A; Poewe, W; Rascol, O; Spivey, K; Staines, H; Trenkwalder, C; van Laar, T; Vel, S | 1 |
| Antonini, A; Jost, WH | 1 |
| Borgemeester, RWK; Schuttelaar, MLA; van Laar, T | 1 |
| Barth, J; Borozdina, O; Eskofier, BM; Gaßner, H; Klucken, J; Kohl, Z; Marxreiter, F; Schlachetzki, JCM; Thun-Hohenstein, C; Volc, D; Winkler, J | 1 |
| Antonini, A; Jenner, P | 1 |
| Drapier, D; Drapier, S; Duprez, J; Houvenaghel, JF; Riou, A; Robert, GH; Sauleau, P; Vérin, M | 1 |
| Choudhury, ME; Kubo, M; Miyanishi, K; Nomoto, M; Tanaka, J; Watanabe, M; Yano, H | 1 |
| Arán, E; Ares, B; Castro, A; Fernández-Pajarín, G; Gelabert-González, M; Relova, JL; Rivas, MT; Sesar, Á | 1 |
| Fernandez, HH; Hengartner, D | 1 |
| Lees, AJ; Moro, A; Munhoz, RP; Pessoa, RR; Teive, HAG | 1 |
| Antonini, A; Ashkan, K; Barbe, MT; Borgemeester, RWK; Dafsari, HS; Dos Santos Ghilardi, MG; Ebersbach, G; Evans, J; Fink, GR; Fonoff, ET; Henriksen, T; Kramberger, M; Martinez-Martin, P; Odin, P; Petry-Schmelzer, JN; Pirtošek, Z; Ray Chaudhuri, K; Reddy, P; Rizos, A; Sauerbier, A; Silverdale, M; Timmermann, L; Trost, M; Visser-Vandewalle, V | 1 |
| Papuć, E; Rejdak, K; Trzciniecka, O | 1 |
| Centonze, D; Fasano, A; Femiano, C; Lena, F; Modugno, N; Olivola, E; Santilli, M; Varanese, S | 1 |
| Del Val, J; Feliz-Feliz, C; Fortes-Alen, J; Garcia-Ruiz, P; Querejeta-Coma, A; Sánchez-García, J | 1 |
| Bartig, D; Gold, R; Jörges, C; Jost, W; Krogias, C; Richter, D; Stumpe, B; Tönges, L | 1 |
| Castrioto, A; Cavallieri, F; Fraix, V; Krack, P; Meoni, S; Moro, E | 1 |
| Hamzehloei, L; Rajaei, Z; Rezvani, ME | 1 |
| Worth, PF | 1 |
| Frau, L; Morelli, M; Simola, N | 1 |
| Bolondi, C; Cantelli-Forti, G; Hrelia, P; Morroni, F; Sita, G; Tarozzi, A; Zolezzi Moraga, JM | 1 |
| Grosset, DG; Grosset, KA; Malek, N; Morgan, F | 3 |
| Dong, F; Ji, FQ; Li, WS; Sun, HM; Wu, B; Xue, H; Yan, JH; Yang, S; Zhou, DS | 1 |
| Ciucci, MR; Russell, JA; Schaser, AJ | 1 |
| Gao, Y; Han, B; Hu, J; Lu, Y; Shen, J; Wang, T | 1 |
| Akram, MN; Chrétien, F; Despars, G; Domenget, C; Gherardi, R; Honnorat, J; Jurdic, P; Nataf, S; Ressnikoff, D; Touret, M; Uhlrich, J; Virgone-Carlotta, A | 1 |
| Aschermann, Z; Komoly, S; Kovács, N | 1 |
| Bao, X; Tai, W; Wang, X; Ye, X; Zhang, D; Zhao, B | 1 |
| Antonini, A; Chandiramani, C; Chaudhuri, KR; Henriksen, T; Katzenschlager, R; Martin, A; Martinez-Martin, P; Naidu, Y; Odin, P; Reddy, P; Tluk, S; Todorova, A | 1 |
| Aebischer, P; Bensadoun, JC; Coune, PG; Schneider, BL | 1 |
| Erbas, O; Oltulu, F; Taskiran, D | 2 |
| Ray Chaudhuri, K; Todorova, A | 1 |
| Kinfe, TM; Slotty, PJ; Vesper, J; Wille, C | 1 |
| Britto, LR; Café-Mendes, CC; Hernandes, MS; Lima, LS; Munhoz, CD; Santos, GD; Scavone, C | 1 |
| Grauer, SM; Hodgson, R; Hyde, LA | 1 |
| Grandas, F | 1 |
| Britto, LR; Café-Mendes, CC; Hernandes, MS | 1 |
| Bao, XQ; Kong, LB; Kong, XC; Sun, H; Wu, LY; Zhang, D | 1 |
| Du, Y; Lin, L; Lin, X; Shen, J; Yuan, S; Zheng, Z | 1 |
| Capone, JG; Contini, E; Golfre-Andreasi, N; Gragnaniello, D; Preda, F; Quatrale, R; Sensi, M; Sette, E; Tola, MR; Trevisani, L; Tugnoli, V | 1 |
| Illarioshkin, SN; Seliverstov, IuA | 1 |
| Cavalheiro, EA; Cerqueira, GS; Correia, AO; de Barros Viana, GS; de Castro Brito, GA; Machado-Filho, JA; Montenegro, AB; Naffah-Mazzacoratti, Mda G; Neves, KR; Nobre, ME | 1 |
| Gong, X; Liang, X; Liu, L; Wang, X; Zhang, W | 1 |
| Nagy, H; Radics, P; Takáts, A; Tamás, G; Tóth, A | 1 |
| Annic, A; Defebvre, L; Destée, A; Devos, D; Dujardin, K; Kreisler, A; Moreau, C; Mutez, E; Rambour, M; Salleron, J; Simonin, C | 1 |
| Katunina, EA; Titova, NV | 1 |
| Björklund, A; Carta, M; Devoto, P; Rogers, JT; Shin, E | 1 |
| Büchele, F; Döbrössy, M; Hackl, C; Jiang, W; Nikkhah, G; Papazoglou, A | 1 |
| Hattori, N; Nomoto, M | 1 |
| Chang, YM; Chen, CY; Chen, YL; Chou, JS; Lu, CS; Wang, HL; Weng, YH; Yeh, TH | 1 |
| Colosimo, C; Fabbrini, G; Homann, CN; Wenzel, K | 1 |
| Chen, G; Feng, J; Feng, W; Huang, Z; Niu, J; Shi, L; Wang, Y; Ye, C; Zhu, G | 1 |
| Bähr, M; Koch, JC; Lingor, P; Saal, KA; Szegő, ÉM; Tatenhorst, L; Tönges, L | 1 |
| Henriksen, T | 1 |
| Kaiserova, M; Kanovsky, P; Kurcova, S; Mensikova, K; Vastik, M | 1 |
| Campbell, JC; Chen, N; De La Cruz, P; Jeyamohan, SB; Pilitsis, JG; Shin, D | 1 |
| Han, B; Jin, HJ; Song, MY; Wang, T; Zhao, H | 1 |
| Clinch, T; Hauser, RA; Isaacson, S | 1 |
| Cantelli-Forti, G; Hrelia, P; Morroni, F; Sita, G; Tarozzi, A | 1 |
| Odin, P; Walter, E | 2 |
| Antonini, A; Bryndum, N; Calandrella, D; Chaudhuri, KR; Dafsari, HS; Ebersbach, G; Glad, A; Henriksen, T; Katzenschlager, R; Kramberger, MG; Martin, A; Martinez-Martin, P; Odin, P; Palhagen, S; Pirtosek, Z; Reddy, P; Reichmann, H; Rizos, A; Samuel, M; Storch, A; Svenningsson, P; Timmermann, L; Todorova, A; Tomantschger, V; Trost, M; Volkmann, J; Wenzel, K | 1 |
| Jeon, SR; Kim, YH; Shin, ES; Yoon, HH | 1 |
| Ba, XH | 1 |
| Kim, JH; Lenz, FA; Liu, CC; Verhagen-Metman, L; Zhao, L | 1 |
| Boyle, A; Ondo, W | 1 |
| Collantes, M; Delgado, M; Ecay, M; Gago, B; Iglesias, E; Juri, C; Marín, C; Molinet-Dronda, F; Obeso, JA; Peñuelas, I; Prieto, E; Quiroga-Varela, A | 1 |
| Nutt, JG | 1 |
| Bonanni, L; Capasso, M; Martino, G; Nasuti, M; Onofrj, M; Thomas, A | 1 |
| Duan, SJ; Han, B; Lu, Y; Wang, LJ; Wang, SY; Wang, T; Zhu, Q | 1 |
| Cheng, CY; Chiu, CH; Chou, TK; Huang, WS; Huang, YS; Li, IH; Liao, MH; Ma, KH; Shiue, CY; Weng, SJ; Wu, SC | 1 |
| Álvarez, R; Bregman, J; de Fabregues, O; Gálvez-Barrón, C; Hernández-Vara, J; Martínez-Castrillo, JC; Pérez-López, C; Pérez-Martínez, DA; Rodríguez-Molinero, A; Romagosa, J; Samà, A | 1 |
| Cui, G; Hua, F; Shen, X; Shi, H; Wang, X; Yang, X; Zhang, S; Zhang, W; Zhang, Z; Zhao, H; Zu, J | 1 |
| Bonuccelli, U; Ceravolo, R; Unti, E | 1 |
| Chen, C; Fan, Q; Huang, J; Pan, X; Wei, H | 1 |
| Baluchnejadmojarad, T; Kiasalari, Z; Roghani, M | 1 |
| Barnett, G; Williams, AC | 1 |
| Baker, M; Ceballos-Baumann, A; Chaudhuri, KR; Deuschl, G; Drapier, S; Ebersbach, G; Evans, A; Fernandez, H; García Ruiz, PJ; Henriksen, T; Isaacson, S; Katzenschlager, R; Lees, A; Lewis, S; LeWitt, P; Martínez Castrillo, JC; Martinez-Martin, P; O'Sullivan, J; Odin, P; Poewe, W; Sesar, Á; Sixel-Döring, F; Tagaris, G; Trenkwalder, C; van Laar, T; Wenzel, K | 1 |
| Du, GH; Du, LD; He, GR; Mu, X; Yuan, X | 1 |
| Borgemeester, RW; Drent, M; van Laar, T | 1 |
| Benedetti, F; Carlino, E; Frisaldi, E; Giudetti, L; Lanotte, M; Lopiano, L; Pampallona, A; Zibetti, M | 1 |
| Atula, S; Autere, J; Eerola-Rautio, J; Kaasinen, V; Kauppinen, M; Martikainen, K; Pekkonen, E; Ruottinen, H; Viljamaa, M | 1 |
| Andre, K; Azulay, JP; Courbon, CB; Defebvre, L; Degos, B; Devos, D; Drapier, S; Durif, F; Eusebio, A; Fraix, V; Moreau, C; Rouaud, T; Roze, E; Tranchant, C; Vérin, M; Viallet, F | 1 |
| Borgemeester, RW; Lees, AJ; van Laar, T | 1 |
| Matute, MS; Matute, R; Merino, P | 1 |
| Burn, DJ; Coleman, SY; Compta, Y; Lashley, T; Lees, AJ; Ling, H; O'Sullivan, SS; Revesz, T; Yarnall, AJ | 1 |
| Bez, F; Cenci, MA; Francardo, V | 1 |
| Marchant, J | 1 |
| Agro, A; Bilbault, T; Dubow, J; Dzyngel, B; Hauser, RA; Isaacson, S; Olanow, CW; Shill, H | 1 |
| Blobaum, AL; Bubser, M; Conn, PJ; Daniels, JS; Engers, DW; Hopkins, CR; Javitch, JA; Jones, CK; Lin, X; Lindsley, CW; Loch, MT; Niswender, CM; Rodriguez, AL; Thompson Gray, A | 1 |
| Bloem, BR; Faber, MJ; Nijhuis, FA; Post, B; van Heek, J | 1 |
| Ares, B; Castro, A; Fernández-Pajarín, G; Sesar, Á | 1 |
| Li, J; Liao, S; Lin, Y; Liu, Y; Quan, H; Yang, Q | 1 |
| Heald, AH; Livingston, M; Stedman, M; Wyrko, Z | 1 |
| Aguiar, LMV; Barros, AS; Bezerra, MM; Cavalcanti, JU; Crispim, RYG; Cristino Filho, G; de Barros Viana, GS; de Vasconcelos, SMM; Lemos, JC; Macêdo, DS; Pinheiro, TFM; Souza, RB | 1 |
| Garcia-Agua Soler, N; Garcia-Ruiz, AJ; Vivancos-Matellano, F | 1 |
| Chaudhuri, KR; Titova, N | 1 |
| Bhidayasiri, R; Garcia Ruiz, PJ; Henriksen, T | 1 |
| Bhidayasiri, R; Boonpang, K; Boonrod, N; Calne, SM; Chaiwong, S; Chaudhuri, KR; Drent, M; Henriksen, T; Jitkritsadakul, O; Sringean, J; Susang, P; Trump, S; van Laar, T | 1 |
| Chaudhuri, KR; Evans, A; Qamar, MA; Rosa-Grilo, M | 1 |
| Anan, C; Bhidayasiri, R; Boonpang, K; Ray Chaudhuri, K; Sringean, J; Thanawattano, C | 1 |
| Jenner, P; Katzenschlager, R | 1 |
| Borgemeester, R; van Laar, T | 1 |
| Djamshidian, A; Poewe, W | 1 |
| Auffret, M; Drapier, S; Houvenaghel, JF; Le Jeune, F; Maurus, A; Robert, GH; Sauleau, P; Vérin, M | 1 |
| Fang, J; Huddy, LJ; Kimber, TE; Thompson, PD | 1 |
| Azevedo, BN; Calice da Silva, C; da Costa, JC; Machado, DC; Martins, LAM; Zimmer, ER | 1 |
| Evans, AH; Fung, VSC; Hayes, M; Iansek, R; Kimber, T; O'Sullivan, JD; Sue, CM; Williams, DR | 1 |
| Defebvre, L; Moreau, C | 1 |
| Bahri, MA; Becker, G; Garraux, G; Hustadt, F; Lemaire, C; Luxen, A; Michel, A; Plenevaux, A | 1 |
| Ankoudinova, I; Bankiewicz, K; Federoff, HJ; Forsayeth, J; Guschin, D; Hadaczek, P; Horovitz, K; Johnston, LC; Maguire-Zeiss, K; Su, X | 1 |
| Antonutti, L; Capus, L; Ferigo, L; Pizzolato, G; Simonetto, M; Zanet, L; Zorzon, M | 1 |
| Sengpiel, F; Vorobyov, V | 1 |
| Askmark, H; Constantinescu, R; Dizdar, N; Holmberg, B; Nyholm, D | 1 |
| Stone, C | 1 |
| Edwards, H; James, CA; Lees, A; Poltawski, L; Todd, A; Watson, T | 1 |
| James, CA; Todd, A | 1 |
| Cabestany, J; Català, A; Pérez-Martínez, DA; Rodríguez-Molinero, A; Yuste, A | 1 |
| Luo, X; Shao, W; Yin, Y; Zhang, X; Zhou, J | 1 |
| Poewe, W | 1 |
| Flores, JM; Ibañez, R; Obeso, JA; Vaamonde, J; Weisser, R | 1 |
| Aebischer, P; Bensadoun, JC; Dusonchet, J; Schneider, BL | 1 |
| Gunzler, SA | 1 |
| Ding-Fang, C; Guo-Hua, W; Hong-Min, T; Hua-Wei, L; Jun, M; Jun-Peng, G; Shan, S; Wen-Wei, L; Xiang-Yu, W; Ya-Ling, H; Yan-Hong, T; Yi, F; Yue, F; Yun-Ke, Y | 1 |
| Stocchi, F | 2 |
| Da Cunha, C; Ferro, MM; Gregório, ML; Silveira, JL; Vital, MA; Wietzikoski, EC | 1 |
| Brus, H; Brus, R; Drab, J; Jochem, J; Körossy, E; Kostrzewa, RM; Noras, L; Nowak, P; Szkilnik, R | 1 |
| Hirabayashi, H; Ishizaka, S; Matsuda, R; Nakase, H; Nishimura, F; Nonaka, J; Ouji, Y; Sakaki, T; Toriumi, H; Yamada, S; Yoshikawa, M | 1 |
| Dagher, A; Doyon, J; Liu, J; Nagano-Saito, A | 1 |
| Antonini, A; Tolosa, E | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Muñoz, A; Tronci, E | 1 |
| Beal, MF; Bogdanov, M; Burke, RE; Geghman, K; Jackson-Lewis, V; Li, C; Li, Y; Liu, W; Oo, TF; Przedborski, S; Tang, Y; Wang, L; Zhou, C | 1 |
| Drent, M; Postma, AG; van Laar, T | 1 |
| Clarke, CE; Grosset, D; Stewart, D; Worth, P | 1 |
| Dewhurst, F; Lee, M; Wood, B | 1 |
| Agid, Y; Azulay, JP; Blin, O; Bonnet, AM; Brefel-Courbon, C; Césaro, P; Damier, P; Debilly, B; Durif, F; Galitzky, M; Grouin, JM; Pennaforte, S; Rascol, O; Villafane, G; Yaici, S | 1 |
| Reichmann, H | 1 |
| Antonini, A; Odin, P | 1 |
| Deuschl, G | 1 |
| Gancher, S; Nutt, J | 1 |
| Mei, J; Niu, C | 1 |
| Frith, CD; Jahanshahi, M; Jones, CR; Katzenschlager, R; Lee, L; Lees, AJ; Quinn, N; Zijlmans, J | 1 |
| San Luciano, M; Saunders-Pullman, R | 1 |
| Björklund, A; Draxler, P; Grealish, S; Mattsson, B | 1 |
| Darbin, O; Dostrovsky, JO; Hutchison, WD; Lafreniere-Roula, M; Lozano, AM; Wichmann, T | 1 |
| Jugel, C; Klostermann, F; Marzinzik, F | 1 |
| Fang, JY; Fu, YS; Huang, YB; Kao, YR; Tsai, MJ; Tsai, YH; Wu, PC | 1 |
| Brefel-Courbon, C; Calvas, F; Dellapina, E; Galitzky, M; Gerdelat-Mas, A; Ory-Magne, F; Payoux, P; Pourcel, L; Simonetta-Moreau, M; Thalamas, C | 1 |
| Antonini, A; Isaias, IU; Landi, A; Natuzzi, F; Pezzoli, G; Rodolfi, G; Siri, C | 1 |
| Anvret, A; Belin, AC; Duester, G; Galter, D; Lindqvist, E; Ogren, SO; Pernold, K; Westerlund, M | 1 |
| Hakimi, R | 1 |
| Cao, G; Chen, J; Chu, CT; Gao, Y; Greenamyre, JT; Hastings, T; Hu, X; Signore, A; Weng, Z; Zhang, L; Zhu, J | 1 |
| Ali, U; Chen, L; Fan, LL; Feng, JJ; Gui, ZH; Hou, C; Liu, J; Wang, T; Wang, Y; Zhang, QJ | 1 |
| Albanese, A; Dollenz, C; Elia, AE; Soliveri, P | 1 |
| Drapier, S; Gillioz, AS; Leray, E; Marchand, A; Péron, J; Rouaud, T; Vérin, M | 1 |
| Bain, P; Ganesalingam, J | 1 |
| Bradberry, TJ; Braun, AR; Contreras-Vidal, JL; Hosey, LA; Lenz, F; Lyons, KE; Metman, LV; Pahwa, R; Schulz, GM; Thompson, JL; van den Munckhof, P | 1 |
| Chen, JJ | 1 |
| Anvret, A; Belin, AC; Duester, G; Felder, MR; Galter, D; Gellhaar, S; Lindqvist, E; Lundströmer, K; Pernold, K; Ran, C; Westerlund, M | 1 |
| Schnitzler, A; Südmeyer, M; Wojtecki, L | 2 |
| Beason-Held, LL; Bhattacharjee, AK; Der, M; Gallardo, KA; Herscovitch, P; Liow, JS; Rapoport, JL; Rapoport, SI; Thambisetty, M; Umhau, JC | 1 |
| Fernandez, HH | 1 |
| Ferrara, JM; Hunter, C; Mostile, G; Ondo, WG | 1 |
| Montgomery, EB | 1 |
| Bradberry, TJ; Braun, AR; Contreras-Vidal, JL; Metman, LV; Schulz, GM | 1 |
| Döbrössy, MD; García, J; Kaindlstorfer, C; Nikkhah, G; Wenning, GK; Winkler, C | 1 |
| Nielsen, KK; Winge, K | 1 |
| Ribarič, S | 1 |
| Burkhard, PR; Vingerhoets, FJ | 1 |
| Kumar, JB; Luthra, PM | 1 |
| Belavic, J | 1 |
| Alegre, M; Alonso-Frech, F; Artieda, J; Guridi, J; López-Azcárate, J; Obeso, JA; Rodríguez-Oroz, MC; Valencia, M | 1 |
| Bach, M; Guger, M; Hödl, S; Ransmayr, G; Struhal, W; Ung, SC | 1 |
| Ahmad, A; Ishrat, T; Islam, F; Khan, A; Khan, MM; Safhi, MM; Shrivastava, P; Tabassum, R; Vaibhav, K | 1 |
| Dunnett, SB; Garcia, J; Klein, A; Krause, M; Maciaczyk, J; Nikkhah, G; Papazoglou, A; Pruszak, J; Rath, A | 1 |
| Bargas, J; Boronat-García, A; Drucker-Colín, R; García-Montes, JR; Guerra-Crespo, M; López-Colomé, AM | 1 |
| Giompres, P; Kouvelas, ED; Makri, G; Matsas, R; Mitsacos, A; Taraviras, S; Thomaidou, D; Ziavra, D | 1 |
| García-Ruiz, PJ; Luquin, MR; Martínez-Castrillo, JC | 1 |
| Burguera, JA; Martínez-Castrillo, JC | 1 |
| Kulisevsky, J; Martí, MJ | 1 |
| Grandas, FJ; Sesar-Ignacio, Á | 1 |
| García-Ruiz, PJ; Luquin, MR | 1 |
| Carballo-Cordero, M; Giménez de Béjar, V | 1 |
| Chacón, JR; Mata, M | 1 |
| Albanese, A; Antonini, A; Chaudhuri, KR; Clarke, CE; de Bie, RM; Deuschl, G; Eggert, K; Houeto, JL; Kulisevsky, J; Nyholm, D; Odin, P; Oertel, W; Poewe, W; Pollak, P; Rabey, JM; Rascol, O; Ruzicka, E; Samuel, M; Speelman, H; Sydow, O; Valldeoriola, F; van der Linden, C; Volkmann, J; Østergaard, K | 1 |
| Kanda, T; Miyauchi, N; Yamada, K | 1 |
| Bezard, E; Björklund, A; Carta, M; Li, Q; Pioli, EY; Porras, G; Tronci, E | 1 |
| Britto, LR; Chaves-Kirsten, GP; Ferreira, AF; Pires, RS; Real, CC; Torrão, AS | 1 |
| Perez-Lloret, S | 1 |
| Heim, C; Kolasiewicz, W; Kurz, T; Schwegler, H; Sontag, KH; Sova, L | 1 |
| Ghika, J; Solida, A; Vingerhoets, F | 1 |
| Calne, DB; de la Fuente-Fernández, R; Phillips, AG; Ruth, TJ; Sossi, V; Stoessl, AJ; Zamburlini, M | 1 |
| Junginger, HE | 1 |
| Lees, AJ; Manson, AJ; Turner, K | 1 |
| Byrne, P; Cameron, H; Eldridge, PR; Fletcher, N; Forster, A; Fox, SH; Littlechild, P; Marshall, A; McIver, K; Steiger, M; Varma, TR | 1 |
| Bassi, A; Brusa, L; Floris, R; Gaudiello S Frasca, F; Pierantozzi, M; Stanzione, P | 1 |
| Albani, G; Astolfi, V; Baudo, S; Bergamasco, B; Calderoni, S; Cavalli, R; Fraschini, F; Gasco, MR; Lopiano, L; Mauro, A; Priano, L; Rizzone, M | 1 |
| Bonuccelli, U; Caltagirone, C; Carlesimo, GA; Costa, A; Dell'Agnello, G; Murri, L; Peppe, A | 1 |
| Loewe, R; Petzelbauer, P; Püspök-Schwarz, M | 1 |
| Bares, M; Brázdil, M; Daniel, P; Jurák, P; Kanovský, P; Kukleta, M; Rektor, I | 1 |
| Gudín, M; Hernández, A; Ibáñez, R; Vaamonde, J | 1 |
| Homann, CN; Ivanic, G; Kriechbaum, N; Ott, E; Suppan, K; Wenzel, K | 1 |
| Jacques, DB; Kpoyov, O; Olds, ME | 1 |
| Carta, AR; Morelli, M; Schibaev, NV; Vorobyov, VV | 1 |
| Bouwstra, JA; Danhof, M; Frederik, PM; Li, GL | 1 |
| Benz, S; Börnke, C; Müller, T; Przuntek, H; Russ, H | 1 |
| Kovar, KA; Lebsanft, HB; Mayerhofer, A; Schmidt, WJ | 1 |
| Daum, I; Köster, O; Müller, T; Peters, S; Przuntek, H; Rusin, J; Schmid, G; Suchan, B | 1 |
| Amalric, M; Baunez, C; Darbaky, Y; Forni, C | 1 |
| Kyriazis, M | 1 |
| STRUPPLER, A; VON UEXKULL, T | 1 |
| ENGLAND, AC; SCHWAB, RS | 1 |
| Ceballos-Baumann, A | 1 |
| Antonini, A; Basile, G; Di Blasi, L; Di Raimondo, G; Di Rosa, AE; Epifanio, A; Imbesi, D; La Spina, P; Martino, G; Morgante, L; Stocchi, F; Tetto, A | 1 |
| Albani, G; Bergamasco, B; Brioschi, A; Calderoni, S; Cavalli, R; Fraschini, F; Gasco, MR; Guastamacchia, G; Lopiano, L; Mauro, A; Priano, L; Rizzone, M | 1 |
| Adachi, T; Hara, H; Kuno, S; Ohta, K; Ohta, M | 1 |
| Bergman, J; Eskola, O; Forsback, S; Grönroos, T; Haapalinna, A; Haaparanta, M; Marjamäki, P; Niemi, R; Rinne, J; Solin, O | 1 |
| Antonini, A; Berto, P; D'Ausilio, A; Marconi, S; Tamma, F; Valzania, F | 1 |
| BARCROFT, H; SCHWAB, RS | 1 |
| AMADOR, LV; LETTVIN, JY; SCHWAB, RS | 1 |
| Stacy, M | 1 |
| Factor, SA | 2 |
| Koller, W; Stacy, M | 1 |
| Swope, DM | 1 |
| Bowron, A | 1 |
| Bailbé, M; Bataille, B; Gil, R; Lavazais, S; Paquereau, J; Vandermarcq, P | 1 |
| Antonini, A; Leenders, KL; Linazasoro, G; Maguire, RP | 1 |
| Benz, S; Börnke, C; Müller, T; Przuntek, H | 1 |
| Lengvári, I; Lubics, A; Reglodi, D; Szalontay, L; Tamás, A | 1 |
| Sobolewski, P | 1 |
| Benedetti, F; Bergamasco, B; Colloca, L; Lanotte, M; Lopiano, L; Melcarne, A; Pesare, M; Torre, E | 1 |
| Benz, S; Müller, T; Przuntek, H | 1 |
| Antonini, A; Basile, G; Di Rosa, AE; Di Rosa, E; Epifanio, A; La Spina, P; Marconi, R; Martino, G; Morgante, L; Nicita-Mauro, V; Spina, E; Stocchi, F | 1 |
| Leenders, KL; Linazasoro, G | 1 |
| Albani, G; Bergamasco, B; Brioschi, A; Calderoni, S; Cavalli, R; Fraschini, F; Gasco, MR; Lopiano, L; Mauro, A; Priano, L; Rizzone, M; Scaglione, F | 1 |
| Deleu, D; Hanssens, Y; Northway, MG | 1 |
| Agnati, LF; Ferré, S; Franco, R; Fuxe, K; Hockemeyer, J; Leo, G; Lluis, C; Martínez, E; Vergoni, AV | 1 |
| Benz, S; Börnke, Ch; Muhlack, S; Müller, T; Przuntek, H; Woitalla, D | 1 |
| Debilly, B; Durif, F; Lees, AJ; Rascol, O; Zijlmans, JC | 1 |
| Bianchi, AM; Foffani, G; Locatelli, M; Moxon, KA; Pellegrini, M; Pesenti, A; Priori, A; Tamma, F; Villani, RM | 1 |
| Coates, PW; Everse, J | 1 |
| Bhatia, K; Evans, A; Hoffman, M; Hughes, A; Katzenschlager, R; Lees, AJ; Manson, AJ; Quinn, N; Swinn, L; Watt, H | 1 |
| Happe, S; Helmschmied, K; Neubert, K; Paulus, W; Tings, T; Trenkwalder, C; Wuttke, W | 1 |
| Alegret, M; Junqué, C; Martí, M; Pilleri, M; Rumià, J; Tolosa, E; Valldeoriola, F | 1 |
| Ebinger, G; Michotte, Y; Sarre, S; Yuan, H | 1 |
| Kleim, JA; Metz, GA; Piecharka, DM; Whishaw, IQ | 1 |
| Bouwstra, JA; Danhof, M; de Vries, JJ; Li, GL; Maas, HJ; Reeuwijk, HJ; van den Bussche, H; van Laar, T; van Steeg, TJ | 1 |
| Fletcher, NA; Fox, SH; Parsons, J; Sinnott, A; Steiger, MJ; Tyne, HL | 1 |
| Dressler, D | 1 |
| Hasoon, M; Macnamara, L; Sharma, JC; Vassallo, M | 1 |
| Burkhard, PR; Castillo, V; Coeytaux, A; Hauser, C; Oppliger, R; Pot, C | 1 |
| Bartolić, A; Pirtosek, Z; Ribaric, S; Rozman, J | 1 |
| Andrén, PE; Klintenberg, R | 1 |
| Axelrod, JD; Barghshoon, S; Chen, CK; Cheyette, BN; Ebert, J; Kovoor, A; Lester, HA; Schwarz, J; Schwarz, S; Seyffarth, P; Simon, MI | 1 |
| Gerlach, M; Reichmann, H; Riederer, P | 1 |
| Kääriäinen, T; Kulkarni, SK; Manáková, S; Männistö, PT; Singh, A; Taari, H | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Comella, C; Widnell, KL | 1 |
| Onofrj, M; Thomas, A | 1 |
| Dewey, RB | 1 |
| Brundin, P; Iancu, R; Mohapel, P; Paul, G | 1 |
| Gao, Q; Geller, AI; Kong, L; Lu, XG; Sun, M; Wang, X | 1 |
| Ballermann, M; Fouad, K; Metz, GA; Smith, LK; Tse, A | 1 |
| Brusa, L; Caltagirone, C; Centonze, D; Koch, G; Oliveri, M; Peppe, A; Stanzione, P | 1 |
| Doering, LC; Kirkham, DL; Meissner, KK | 1 |
| Eggert, K; Möller, JC; Oertel, WH; Sommer, N; Tackenberg, B | 1 |
| Johansson, S; Lee, IH; Olson, L; Spenger, C | 1 |
| Coudoré, F; Durif, F; Eschalier, A; Libert, F; Richard, D | 1 |
| Azzouz, M; Dowd, E; Dunnett, SB; Mazarakis, ND; Monville, C; Torres, EM; Wong, LF | 1 |
| Ingram, WM; Priston, MJ; Sewell, GJ | 1 |
| Chen, JJ; Obering, C | 1 |
| Weiner, WJ | 1 |
| Bonuccelli, U; Pavese, N | 1 |
| Dowd, E; Fitzsimmons, DF; Moloney, TC | 1 |
| Borrett, DS; Kwan, HC; Lenz, FA; Rasouli, G; Rasouli, M; Verhagen, L | 1 |
| Antonini, A; Bonetti, A; Cilia, R; De Gaspari, D; Landi, A; Mariani, CB; Morgante, L; Natuzzi, F; Pezzoli, G; Sganzerla, E; Siri, C | 1 |
| Garcia Ruiz, PJ | 1 |
| Karlsborg, M; Regeur, L | 1 |
| Aniel-Quiroga, MA; Barcena, J; Cruz Lachén, M; Gómez, JC; Hurtado, P; Lezcano, E; Pérez Bas, M; Rouco, I; Velasco, F; Zarranz, JJ | 1 |
| Colonnese, C; Garreffa, G; Giove, F; Giulietti, G; Macrì, MA; Maraviglia, B; Modugno, N; Moraschi, M | 1 |
| Alegre, M; Alonso-Frech, F; Artieda, J; Guridi, J; Manrique, M; Obeso, JA; Rodríguez-Oroz, MC; Valencia, M; Zamarbide, I | 1 |
| Carlsson, T; Georgievska, B; Kirik, D; Lacar, B; Winkler, C | 1 |
| Chen, JJ; Obering, CD; Swope, DM | 1 |
| Asmus, F; Bötzel, K; Deutschländer, A; Gasser, T; Klopstock, T; Marelli, E | 1 |
| Abe, E; Alvarez, JC | 1 |
| Aguiar, LM; Cunha, GM; Freitas, RM; Macêdo, DS; Nobre, HV; Oliveira, AA; Sousa, FC; Vasconcelos, SM; Viana, GS | 1 |
| Field, EF; Metz, GA; Pellis, SM; Whishaw, IQ | 1 |
| Chesselet, MF; Fleming, SM; Hutson, CB; Levine, MS; Masliah, E; Rockenstein, E; Salcedo, J | 1 |
| Chen, SD; Li, B; Liu, WG; Lu, GQ | 1 |
| Drapier, S; Vérin, M | 1 |
| Bustamante, ML; Téllez, C; Toro, P; Venegas, P | 1 |
| Bottini, PB; Gutmann, L; Hull, KL; Pfeiffer, RF; Sherry, JH | 1 |
| Baier, PC; Happe, S; Helmschmied, K; Koch, W; Meller, J; Paulus, W; Tatsch, K; Tings, T; Trenkwalder, C; Welsch, J; Wuttke, W | 1 |
| Dougherty, PM; Kim, JH; Lee, JI; Lenz, FA; Ohara, S; Verhagen Metman, L | 1 |
| Beal, MF; Cleren, C; Goldman, SA; Roy, NS | 1 |
| Brundin, P; Christophersen, NS | 1 |
| Ludin, HP; Surber, Ch | 1 |
| Castaño, B; Giménez-Roldán, S; Mateo, D | 1 |
| Han, ZT; Liu, J; Liu, S; Pang, JX; Wang, TH; Wei, P; Wu, QY; Zhou, HL | 1 |
| Koller, WC; Pahwa, R; Sherry, JH; Trosch, RM | 1 |
| Ardolino, G; D'Adda, E; Nobile-Orazio, E | 1 |
| Menon, R; Stacy, M | 1 |
| Fernandez, HH; Haq, IU; Lewitt, PA | 1 |
| Silver, D; Stacy, M | 1 |
| Boesch, S; Ceballos-Baumann, A; Dressler, D; Eggert, K; Gasser, T; Honig, H; Müller, T; Odin, P; Poewe, W; Reichmann, H; Sieb, JP; Storch, A; Trenkwalder, C | 1 |
| Carlson, NE; Gunzler, SA; Koudelka, C; Nutt, JG; Pavel, M | 1 |
| Debetto, P; Giusti, P; Guidolin, D; Negro, A; Peroni, D; Recchia, A; Rota, D; Skaper, SD | 1 |
| Kääriäinen, TM; Kekki, H; Lecklin, A; Lehtonen, S; Männistö, PT; Nenonen, T; Ossola, B; Piltonen, M; Raasmaja, A | 1 |
| Alonso Frech, F; Alvarez López, M; Arbelo González, J; Ares Pensado, B; Baiges Octavio, J; Burguera Hernández, JA; Calopa Garriga, M; Campos Blanco, D; Carballo Cordero, M; Castaño García, B; Castro García, A; Chacón Peña, J; Espino Ibáñez, A; García Ruiz, PJ; Giménez-Roldán, S; Gorospe Onisalde, A; Granés Ibáñez, P; Hernández Vara, J; Ibáñez Alonso, R; Jiménez Jiménez, FJ; Krupinski, J; Kulisevsky Bojarsky, J; Legarda Ramírez, I; Lezcano García, E; Martínez-Castrillo, JC; Mateo González, D; Miquel Rodríguez, F; Mir, P; Muñoz Fargas, E; Obeso Inchausti, J; Olivares Romero, J; Olivé Plana, J; Otermin Vallejo, P; Pascual Sedano, B; Pérez de Colosía Rama, V; Pérez López-Fraile, I; Planas Comes, A; Puente Periz, V; Rodríguez Oroz, MC; Sesar Ignacio, A; Sevillano García, D; Solís Pérez, P; Suárez Muñoz, J; Vaamonde Gamo, J; Valero Merino, C; Valldeoriola Serra, F; Velázquez Pérez, JM; Yáñez Baña, R; Zamarbide Capdepon, I | 1 |
| Bottini, PB; Silver, D; Trosch, RM | 1 |
| Burton, K; Calne, DB | 1 |
| Wagner, HN | 1 |
| Kurako, IuL; Volianskiĭ, VE | 1 |
| Meltzer, HY | 1 |
| Laakso, K; Laihinen, A; Lönnberg, P; Rinne, JK; Rinne, JO; Rinne, UK | 1 |
| Rebec, GV | 1 |
| Andrews, JS; Biggins, JA; Candy, JM; Edwardson, JA; Keith, AB; Sahgal, A; Turner, JD; Wright, C | 1 |
| Bernardi, F; Corsini, GU; Gessa, GL; Marrosu, F | 1 |
| Bergmann, KJ; Clough, CG; Yahr, MD | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; Del Roscio, S; Falaschi, P; Frajese, G; Mearelli, S; Rocco, A; Ruggieri, S | 1 |
| Seeman, P; Titeler, M | 1 |
| Bilbao, J; Deck, J; Hornykiewicz, O; Lee, T; Seeman, P; Tourtellotte, WW | 1 |
| Stewart, RM | 1 |
| Balldin, J; Granérus, AK; Lindstedt, G; Modigh, K; Wålinder, J | 1 |
| Arca, P; Corsini, GU; Del Zompo, M; Gessa, GL; Tocco, F | 1 |
| Andrade, LA; Azevedo-Silva, SM; Borges, V; Ferraz, HB; Rocha, MS | 1 |
| Cheron, G; Godaux, E; Jacquy, J; Piette, T; Thiriaux, A | 1 |
| Leiguarda, R; Merello, M | 1 |
| Danhof, M; Jansen, EN; Neef, C; Roos, RA; van Laar, T | 1 |
| Corboy, DL; Sage, JI; Wagner, ML | 1 |
| Boisen, E; Christensen, PB; Dupont, E; Ingwersen, SH; Jensen, NB; Lindvall, O; Odin, P; Ostergaard, L; Schmiegelow, M; Werdelin, L | 1 |
| Broussolle, E; Chazot, G; Muguet, D | 1 |
| Donaldson, D; Ferreira, M; Jackson-Lewis, V; Jiang, H; Levivier, M; Przedborski, S; Togasaki, DM | 1 |
| Barnéoud, P; Blanchard, JC; Boireau, A; Dubédat, P; Mazadier, M; Miquet, JM; Parmentier, S | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 2 |
| Barnéoud, P; Castel, MN; Colin, P; Delaère, P; Horellou, P; Mallet, J; Perricaudet, M; Vigne, E | 1 |
| Brookes, RW; Moore, T | 1 |
| Bakheit, AM | 1 |
| Bassetti, MA; Pasqualetti, P; Rossini, PM | 1 |
| Bentlage, C; Björklund, A; Nikkhah, G; Olsson, M | 1 |
| Hastie, IR; Mukherjee, D | 1 |
| Woodcock, DA | 1 |
| Hagell, P | 1 |
| Mecír, P; Roth, J; Růzicka, E | 1 |
| Crabbe, J; Gancher, S; Garland, A; Lea, E; Woodward, W | 1 |
| Bohn, MC; Breakefield, XO; Cunningham, LA; Short, MP | 1 |
| Bowman, CE | 1 |
| Gancher, ST; Nutt, JG; Woodward, WR | 4 |
| Roos, RA; van Hilten, JJ; van Laar, T | 1 |
| Essink, AW; Janssen, EN; Jelliffe, RW; Loohuis, T; Neef, C; van Laar, T | 1 |
| Kempster, PA; Lees, AJ | 1 |
| Aranda, B | 1 |
| Muhiddin, KA; Pearce, VR; Roche, MT | 1 |
| Albani, C; Bächli, E | 1 |
| Bravi, D; Chase, TN; Davis, TL; Mouradian, MM; Roberts, JW; Sohn, YH | 1 |
| Jech, R; Mecír, P; Roth, J; Růzicka, E; Spacková, N | 1 |
| Benabid, AL; Gervason, CL; Jeanneau-Nicolle, E; Limousin, P; Pollak, P | 1 |
| Hofstee, DJ; Jansen, EN; Neef, C; van Laar, T | 1 |
| Fouillet, N; Henry, P; Tison, F | 1 |
| Deffond, D; Dordain, G; Durif, F; Tournilhac, M | 1 |
| Linazasoro, G | 3 |
| Aotsuka, A; Bravi, D; Chase, TN; Linfante, I; Metman, LV; Mouradian, MM; Sohn, YH | 1 |
| Lera, G; Luquin, MR; Obeso, JA; Rodriguez, M; Vaamonde, J | 1 |
| Helscher, RJ; Pinter, MM; Sattler, AP | 1 |
| Broussolle, E; Chazot, G; Cinotti, L; Galy, G; Khalfallah, Y; Landais, P; Lavenne, F; Le Bars, D; Mauguière, F; Pollak, P | 1 |
| Cordes, M; Hierholzer, J; Poewe, W; Schelosky, L; Wissel, J | 1 |
| Essink, AW; Jansen, EN; Neef, C; Oosterloo, S; Roos, RA; van Laar, T | 1 |
| Bernardi, G; Boccasena, P; Martino, G; Pacifici, L; Passarelli, F; Rossini, PM; Stanzione, P; Traversa, R | 1 |
| de Bruin, PF; de Bruin, VM; Lees, AJ; Pride, NB | 1 |
| Brock, S; Clayton, J; Gerhardt, GA; Hoffer, BJ; Hudson, JL; Masserano, J; Strömberg, I; van Horne, CG | 1 |
| Parfait, A | 1 |
| Aranda, B; Cramer, P | 1 |
| Fernandez, W; Lees, AJ; Turjanski, N | 1 |
| Böck, JC; Cordes, M; David, I; Hierholzer, J; Horowski, R; Poewe, W; Sander, B; Schelosky, L | 1 |
| Broussolle, E; Gavend, M; Gervason, CL; Nicolle, E; Pollak, P; Richard, P; Serre-Debeauvais, F | 1 |
| Chollet, F; Marc-Vergnes, JP; Montastruc, JL; Rascol, A; Rascol, OJ; Sabatini, U | 1 |
| Arnold, G; Gasser, T; Kirsch, CM; Oertel, WH; Schwarz, J; Tatsch, K | 1 |
| Baronti, F; Bramante, L; Monge, A; Ruggieri, S; Stefano, E; Stocchi, F; Viselli, F | 1 |
| Bösch, S; Kleedorfer, B; Poewe, W; Schelosky, L; Wagner, M | 1 |
| Deffond, D; Durif, F; Tournilhac, M | 2 |
| Bonuccelli, U; Corsini, GU; Del Dotto, P; Muratorio, A; Piccini, P; Rossi, G | 2 |
| Bishop, S; Fernandez, W; Hughes, AJ; Kleedorfer, B; Lees, AJ; Stern, GM; Turjanski, N | 1 |
| Gervason, CL; Limousin, P; Perret, JE; Pollak, PR | 1 |
| Deffond, D; Dordain, G; Durif, F; Eschalier, A; Lavarenne, J; Paire, M; Tournilhac, M | 1 |
| Edwards, LL; Harned, RK; Hofman, R; Pfeiffer, RF; Quigley, EM | 1 |
| Bösch, S; Kreczy-Kleedorfer, B; Poewe, W; Wagner, M | 1 |
| Miranda, M; Saéz, D | 1 |
| Eblen, F; Kockgether, T; Löschmann, PA; Wachtel, H; Wüllner, U | 1 |
| Esteban Muñoz, J | 1 |
| Clouston, PD; Lim, CL; Morris, JG; Sue, C; Yiannikas, C | 1 |
| Castelli, L; Cordes, M; Felix, R; Hierholzer, J; Poewe, W; Schelosky, L | 1 |
| Colosimo, C; Hughes, AJ; Lees, AJ; Merello, M; Sieradzan, K | 2 |
| Arnold, G; Eichhorn, TE; Gasser, T; Mai, N; Marquardt, C; Oertel, WH; Schwarz, J | 1 |
| Ahlskog, JE; Dewey, RB; Maraganore, DM; Matsumoto, JY | 2 |
| Barbier, P; Corsini, GU; Maggio, R | 1 |
| Gancher, S | 1 |
| Houin, G; Montastruc, JL; Rascol, A; Rascol, O; Senard, JM | 1 |
| de Mari, M; Ferrari, E; Iliceto, G; Lamberti, P; Margari, L | 1 |
| Bassi, A; Cicardi, MC; Loberti, M; Pierantozzi, M; Semprini, R; Stanzione, P; Traversa, R | 1 |
| Baas, H; Bürklin, F; Demisch, L; Fischer, PA; Harder, S; Stecker, K | 1 |
| Mellers, JD; Quinn, NP; Ron, MA | 1 |
| Gálvez-Jiménez, N; Lang, AE | 1 |
| Durrieu, G; Llau, ME; Montastruc, JL; Rascol, O; Senard, JM; Tran, MA | 1 |
| Danhof, M; Neef, C; Roon, KI; Roos, RA; van Laar, T | 1 |
| Barat, M; Fouillet, N; Guatterie, M; Henry, P; Lozano, V; Tison, F; Wiart, L | 1 |
| Crismon, ML; Dalmady-Israel, C; Fagan, SC; Gidal, BE; Graves, NM; Privitera, MD; Wagner, ML | 1 |
| Kraus, PH | 1 |
| Araya, F; Castillo, JL; Miranda, CM; Sáez, D | 1 |
| Bravi, D; Chase, TN; Locatelli, ER; Mouradian, MM; Verhagen Metman, L | 1 |
| Cicardi, MC; Loberti, M; Peppe, A; Pierantozzi, M; Semprini, R; Stanzione, P; Traversa, R | 1 |
| Marsden, CD; Nordera, G; Stocchi, F | 1 |
| Courty, E; Courty, P; Durif, F; Lavarenne, J; Zenut, M | 1 |
| Cammarota, A; Leiguarda, R; Merello, M; Pikielny, R | 1 |
| Clarke, CE; Horsman, A; Lowry, M | 1 |
| Esteban Muñoz, J; Marín, C; Martí, MJ; Tolosa, E | 1 |
| Merello, M; Nouzeilles, MI | 1 |
| Albanese, A; Colosimo, C; Merello, M | 1 |
| Ghafoerkhan, SF; van Hilten, JJ; van Laar, T; Wagemans, EA | 1 |
| Carlsson, A; Merello, M; Pirtosek, Z; Stern, G | 1 |
| Dostrovsky, JO; Hutchinson, WD; Lang, AE; Levy, R; Lozano, AM | 1 |
| Dougherty, PM; Hallett, M; Lenz, FA; Metman, LV; Reich, SG; Suarez, JI | 1 |
| Arnold, G; Gasser, T; Oertel, WH; Schwarz, J; Tatsch, K | 1 |
| Austin, S; Crameri, J; Hughes, AJ; Hunter, PC; Woodward, MC | 1 |
| Miranda, M; Villagra, R | 1 |
| Oertel, WH; Quinn, NP | 1 |
| Araujo, DM; Hilt, DC; Jiao, S; Lapchak, PA; Sheng, J | 1 |
| Bodde, HE; Danhof, M; Gubbens-Stibbe, JM; Kruger, P; van der Geest, R; van Laar, T | 1 |
| Bassi, A; Bernardi, G; Mazzone, P; Stanzione, P; Stefani, A; Vangelista, T | 1 |
| Arnold, G; Gasser, T; Künig, G; Oertel, WH; Pogarell, O; Schwarz, J; Tatsch, K | 1 |
| Boddé, HE; Danhof, M; Gubbens-Stibbe, JM; van der Geest, R; van Laar, T | 1 |
| Itakura, T; Nakai, K; Nakao, N; Ogura, M | 1 |
| Benabid, AL; Benazzouz, A; Hoffmann, D; Koudsie, A; Krack, P; Le Bas, JF; Limousin, P; Pollak, P | 1 |
| Chaudhuri, KR; Clough, C | 1 |
| Brotchie, JM; Crossman, AR; Duty, S; Henry, B | 1 |
| Turgut, M | 1 |
| Beretta, S; Garavaglia, P; Manfredi, L; Pellegrini, G | 1 |
| Colzi, A; Lees, AJ; Turner, K | 1 |
| Betti, O; Cammarota, A; Leiguarda, R; Merello, M; Nouzeilles, MI | 1 |
| Hughes, AJ; O'Sullivan, JD | 1 |
| Sam, EE; Verbeke, N | 1 |
| Baas, H; Demisch, L; Harder, S; Simon, E | 1 |
| Hill-Smith, I | 1 |
| Hagell, P; Odin, P; Pietz, K | 1 |
| Dougherty, PM; Hallett, M; Karp, BI; Lenz, FA; Metman, LV; Reich, SG; Rowland, LH; Suarez, JI | 1 |
| Lange, KW | 1 |
| Balej, J; Betti, O; Cammarota, A; Delfino, M; Leiguarda, R; Merello, M | 1 |
| Ekesbo, A; Låengström, B; Rydin, E; Sydow, O; Tedroff, J; Torstenson, R | 1 |
| Arnold, G; Kraft, E; Oertel, WH; Schwarz, J; Tatsch, K; Vogl, T | 1 |
| Agid, Y; Debilly, B; Durif, F; Vidailhet, M | 1 |
| Poewe, W; Schelosky, L; Scholz, U; Schrag, A | 1 |
| Farina, C; Nordera, G; Ruggieri, S; Stocchi, F | 1 |
| Altibrandi, MG; Bassi, A; Bernardi, G; Mazzone, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| Vaserman-Lehuédé, N; Vérin, M | 1 |
| Balej, J; Cammarota, A; Lees, AJ; Leiguarda, R; Merello, M | 1 |
| Angelini, D; Grasso, R; Lacquaniti, F; Peppe, A; Stanzione, P; Stratta, F; Zago, M | 1 |
| Fiaschi, A; Idone, D; Tezzon, F; Tinazzi, M; Zanette, G | 1 |
| Féger, J; Hassani, OK | 1 |
| Hughes, AJ | 1 |
| MacMahon, DG | 1 |
| Danhof, M; Van der Geest, R; van Laar, T | 1 |
| Bösch, S; Luginger, E; Poewe, W; Wagner, M; Wenning, GK | 1 |
| Berkuzki, T; Grünblatt, E; Mandel, S; Youdim, MB | 1 |
| Almaguer, M; Hunter, C; Jankovic, J; Ondo, W | 1 |
| Ellis, CM; Ray Chaudhuri, K; Reuter, I | 1 |
| Neef, C; van Laar, T | 1 |
| Colin, P; Corti, O; Hamon, M; Hanoun, N; Mallet, J; Sánchez-Capelo, A | 1 |
| Hashimoto, T; Izawa, Y; Kato, T; Moriizumi, T; Yokoyama, H | 1 |
| Sourkes, TL | 2 |
| Alesch, F; Binder, H; Helscher, RJ; Murg, M; Pinter, MM | 1 |
| Altibrandi, MG; Bassi, A; Bernardi, G; Mazzone, P; Peppe, A; Pierantozzi, M; Rossini, PM; Stanzione, P; Stefani, A | 1 |
| Fujimoto, I; Hashimoto, M; Hida, H; Mikoshiba, K; Nagatsu, T; Nakajima, K; Nishino, H; Shimano, Y | 1 |
| Brown, DL; Factor, SA; Molho, ES | 1 |
| Carter, JH; Nutt, JG | 1 |
| Goetz, CG; Kompoliti, K; Leurgans, S; Raman, R; Wang, QE | 1 |
| Andrén, PE; Ekesbo, A; Gunne, LM; Sonesson, C; Tedroff, J | 1 |
| Lees, AJ; O'Sullivan, JD | 1 |
| Dostrovsky, J; Hutchison, W; Lang, AE; Levy, R; Lozano, AM | 1 |
| Filippi, MM; Rossini, PM; Vernieri, F | 1 |
| Büttner, T; Kuhn, W; Müller, T | 1 |
| Hayashi, K; Kuno, S; Mizuta, E; Mizuta, I; Nishimura, M; Ohta, K; Ohta, M | 1 |
| Sit, SY | 1 |
| Marion, MH | 1 |
| Kuritzky, A; Melamed, E; Merims, D; Ziv, I; Zoldan, J | 1 |
| Elwan, MA; Itakura, T; Kakishita, K; Nakao, N; Sakuragawa, N | 1 |
| Poewe, W; Wenning, GK | 1 |
| Bhatia, KP; Münchau, A | 1 |
| Clarke, CE; Davies, P | 1 |
| Antkiewicz-Michaluk, L; Michaluk, J; Papla, I; Romańska, I; Vetulani, J | 1 |
| Gassen, M; Gross, A; Grünblatt, E; Mandel, S; Youdim, MB | 1 |
| Dabbeni-Sala, F; Franceschini, D; Giusti, P; Skaper, SD | 1 |
| Carey, P; Hanagasi, H; Lees, AJ; Manson, AJ; Patsalos, PN; Ratnaraj, N; Turner, K | 1 |
| Altibrandi, MG; Ansaldo, MA; Bassi, A; Bernardi, G; Fedele, E; Giacomini, P; Mazzone, P; Pierantozzi, M; Raiteri, M; Stanzione, P; Stefani, A | 1 |
| Austin, MP; Chan, J; Eyers, K; Hadzi-Pavlovic, D; Hickie, I; Mitchell, P; Parker, G | 1 |
| Sternon, J; Supiot, F; Zegers de Beyl, D | 1 |
| Agid, Y; Dubois, B; el Massioui, F; Pillon, B; Renault, B; Růzicka, E | 1 |
| Hagell, P; Odin, P | 1 |
| Cui, X; Gao, J; Li, C; Li, X; Luo, Y; Sun, AM; Sun, R; Wang, L; Wang, Z; Xi, Z; Xue, Y; Zhou, D | 1 |
| de Luis, P; del Real, MA; Gudín, M; Hernández, A; Ibáñez, R; Vaamonde, J | 1 |
| Haisley, EC; Pollack, AE | 1 |
| Albanese, A; Bonuccelli, U; Brefel, C; Chaudhuri, KR; Colosimo, C; Eichhorn, T; Melamed, E; Pollak, P; Van Laar, T; Zappia, M | 1 |
| Ingvarsson, PE; Johnels, B; Olsson, T; Steg, G | 1 |
| Dépatie, L; Lal, S | 1 |
| Cohen, AD; Miller, GW; Philhower, J; Schallert, T; Tillerson, JL; Zigmond, MJ | 1 |
| Jankovic, J; Le, WD | 1 |
| Dostrovsky, JO; Hutchison, WD; Lang, AE; Levy, R; Lozano, AM; Sime, E | 1 |
| Grünblatt, E; Mandel, S; Maor, G; Youdim, MB | 1 |
| Barbato, L; De Pandis, MF; Ruggieri, S; Stocchi, F; Vacca, L; Valente, M | 1 |
| Grabowski, M; Nilsson, C; Odin, P; Sigurdardóttir, GR | 1 |
| Calne, DB; de la Fuente-Fernández, R; Ruth, TJ; Schulzer, M; Sossi, V; Stoessl, AJ | 1 |
| Armogida, M; Chiacchio, S; Corsini, GU; Pardini, C; Scarselli, M | 1 |
| Dewey, RB; Factor, SA; Hutton, JT; LeWitt, PA | 1 |
| Bankiewicz, KS; Cunningham, J; Harvey-White, J; Sánchez-Pernaute, R | 1 |
| Calne, DB; de La Fuente-Fernández, R; Holden, JE; Lim, AS; Ruth, TJ; Sossi, V; Stoessl, AJ | 1 |
| Bernardi, G; Giacomini, P; Marciani, MG; Palmieri, MG; Pierantozzi, M; Stanzione, P | 1 |
| Altibrandi, MG; Bassi, A; Bernardi, G; Giacomini, P; Mazzone, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| Arnold, G; Einhäupl, KM; Klaffke, S; Kühn, AA; Kupsch, A; Meissner, W; Paul, G; Trottenberg, T | 1 |
| Altibrandi, MG; Bassi, A; Bernardi, G; Gattoni, G; Giacomini, P; Mazzone, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| Giacomini, P; Marciani, MG; Mazzone, P; Palmieri, MG; Peppe, A; Pierantozzi, M; Rossini, PM; Stanzione, P; Stefani, A | 1 |
| Bareš, M; Hortová, H; Kanovský, P; Kubová, D; Rektor, I; Streitová, H; Znojil, V | 1 |
| O'Sullivan, JD | 1 |
| Hungerbühler, JP; Regli, F | 1 |
| Rinne, UK | 1 |
| Parkes, JD | 1 |
| Costentin, J | 1 |
| Corsini, GU; Del Zompo, M; Gessa, GL; Mangoni, A | 1 |
| Filion, M | 1 |
| Horn, AS; Iversen, LL; Miller, RJ | 1 |
| Marais, C | 1 |
| Borison, RL; Diamond, BI | 1 |
| Bianchine, JR; Dandalides, SM; Greenwald, JE; Shaw, GM | 1 |
| Cotzias, GC; Miller, ST; Papavasiliou, PS; Rosal, VL | 1 |
| Agid, Y; Barroche, G; Bonnet, AM; Javoy-Agid, F; Kato, G; Lhermitte, F; Pollak, P; Signoret, JL | 1 |
| Albizzati, MG; Bassi, S; Frattola, L; Passerini, D; Trabucchi, M | 1 |
| Kanapa, DJ; Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Farley, IJ; Hornykiewicz, O; Lee, T; Rajput, A; Seeman, P | 1 |
| Barry, VC; Klawans, HL | 1 |
| Wolfarth, S | 1 |
| David, J; Grewal, RS; Kaul, CL | 1 |
| Pakszys, W | 1 |
| Cotzias, GC; Ginos, JZ; Papavasiliou, PS | 1 |
| Debono, AG; Marsden, CD; Parkes, JD | 1 |
| Ljungberg, T; Ungerstedt, U | 1 |
| Brignone, A; Genco, S; Puca, FM; Serlenga, L; Specchio, LM | 1 |
| McDowell, FH; Sweet, R | 1 |
| Costall, B; Naylor, RJ | 1 |
| Bastard, J; Chanelet, J; Emile, J; Truelle, JL | 1 |
| Bell-Midura, M; Cotzias, GC; Mendez, JS; Papavasiliou, PS; Tolosa, ES | 1 |
| Crossett, P; Dana, N; Klawans, HL | 1 |
| Dolphin, A; Jenner, P; Marsden, CD; Pycock, C; Tarsy, D | 1 |
| Crosset, P; Dana, N; Klawans, HL; Margolin, DI | 1 |
| Bell-Midura, MA; Cotzias, GC; Ginos, JZ; Papavasiliou, PS; Tolosa, E | 1 |
| Cotzias, GC; Tang, LC | 1 |
| Avakian, RM; Dutov, AA; Parkhomenko, VM | 1 |
| Cianchetti, C; Corsini, GU; Mangoni, A; Zompo, MD | 1 |
| Wesemann, W | 1 |
| Deffond, D; Durif, F; Eschalier, A; Tournilhac, M | 1 |
| Cox, M; Markus, HS; Tomkins, AM | 1 |
| Quinn, NP; Steiger, MJ | 1 |
| Grandas, F; Laguna, J; Luquin, MR; Martinez-Lage, JM; Obeso, JA; Vaamonde, J | 1 |
| Diederich, NJ; Goetz, CG | 1 |
| Gershanik, O; Luquin, MR; Obeso, JA; Scipioni, O; Vaamonde, J | 1 |
| Broussolle, E; Marion, MH; Pollak, P | 1 |
| Bishop, S; Lees, AJ; Merello, M; Pirtosek, Z | 1 |
| Clough, CG; Henderson, BT; Hitchcock, ER; Hughes, RC; Kenny, BG | 1 |
| Marsden, CD; Quinn, NP; Steiger, MJ | 1 |
| Albani, C; Fischer, G; Zangger, I | 1 |
| Arnold, G; Gasser, T; Oertel, WH; Schwarz, J; Trenkwalder, C | 1 |
| Colosimo, C; Daniel, SE; Hughes, AJ; Kleedorfer, B; Lees, AJ | 1 |
| Lees, AJ; Merello, M | 1 |
| Brooks, DJ; Fernandez, W; Frackowiak, RS; Jenkins, IH; Lees, AJ; Passingham, RE; Playford, ED | 1 |
| Levivier, M; Przedborski, S | 1 |
| Adba, MA; Aranda, B; Cramer, P | 1 |
| Essink, AW; Jansen, EN; Neef, C; Rutten, WJ; Van Laar, T | 1 |
| Caparros-Lefebvre, D; Petit, H; Vermersch, P | 1 |
| Arnold, G; Gasser, T; Kirsch, CM; Oertel, WH; Schwarz, J; Tatsch, K; Trenkwalder, C | 1 |
| Jansen, EN; Kruyswijk, MR; van Laar, T | 1 |
| Gancher, ST; Grandas, F; Lera, G; Nutt, JG; Obeso, JA; Rodriguez, M | 1 |
| Essink, AW; Jansen, EN; Neef, C; van Laar, T | 1 |
| Bonuccelli, U; Corsini, GU; Muratorio, A; Piccini, P | 1 |
| Jenkins, JR; Pearce, JM | 1 |
| Milner, R; Simpkin, DM; Snell, AP | 1 |
| Deffond, D; Gervason, CL; Perret, JE; Pollak, P | 1 |
| Hildebrand, J; Liard, A; Przedborski, S | 1 |
| Gancher, S; Grandas, F; Lera, G; Nutt, J; Obeso, JA; Rodriguez, M; Woodward, WR | 1 |
| Boyce, S; Crossman, AR; Mitchell, IJ; Sambrook, MA | 1 |
| Bishop, S; Bovingdon, M; Hughes, AJ; Lees, AJ; Stern, GM; Webster, R | 1 |
| Lawrence, MS; Redmond, DE | 1 |
| Carman, LS; Gage, FH; Shults, CW | 1 |
| Celsis, P; Chollet, F; Marc-Vergnes, JP; Montastruc, JL; Rascol, A; Rascol, O; Sabatini, U | 1 |
| Bagheri, H; Gualano, V; Houin, G; Lees, A; Montastruc, JL; Rascol, A; Rascol, O; Senard, JM | 1 |
| Abbott, RJ; D'Costa, DF; Millac, PA; Pye, IF | 1 |
| Becker, JB; Curran, EJ | 1 |
| Deffond, D; Durif, F; Eschalier, A; Jeanneau, E; Serre-Debeauvais, F; Tournilhac, M | 1 |
| Bovingdon, M; Hughes, AJ; Lees, AJ; Stern, GM; Webster, R | 1 |
| Cozzolino, A; Di Chiara, G; Fenu, S; Morelli, M | 1 |
| Gervason, CL; Pollak, P | 1 |
| Baronti, F; Chase, TN; Conant, K; Davis, TL; Giuffra, M; Heuser, IJ; Mouradian, MM | 1 |
| Blunt, S; Jenner, P; Marsden, CD | 1 |
| Graham, SJ; Higgins, BM; Morris, JG; Panegyres, PK; Williams, BK | 1 |
| Celsis, P; Houin, G; Marc-Vergnes, JP; Montastruc, JL; Rascol, A; Rascol, O; Sabatini, U | 1 |
| Lindvall, O; Mangalanayagam, L; Nilsson, B; Odin, P | 1 |
| Hughes, AJ; Lees, AJ; Stern, GM | 3 |
| Gilhus, NE | 1 |
| Christensen, PB; Dupont, E; Jensen, NB | 1 |
| Iansek, R; Kempster, PA; Larmour, I | 1 |
| Drucker-Colín, R; García-Hernández, F; Komisaruk, BR; Mendoza-Ramírez, JL; Pacheco-Cano, MT | 1 |
| Kleedorfer, B; Lees, AJ; Milroy, C; Ryan, R; Stern, GM; Turjanski, N | 1 |
| Abbott, RJ; Millac, PA; Ray-Chaudhuri, K | 1 |
| Kleedorfer, B; Lees, AJ; Stern, GM | 1 |
| Bishop, S; Hughes, AJ; Lees, AJ; Stern, GM | 1 |
| Quinn, N | 1 |
| Carey, RJ | 2 |
| Blunt, SB; Jenner, P; Marsden, CD | 1 |
| Becker, JB; Curran, EJ; Freed, WJ; Poltorak, M | 1 |
| Furuyama, F; Hashitani, T; Hida, H; Ishida, Y; Isobe, Y; Kumazaki, M; Makino, T; Nishino, H; Sakurai, T; Sato, H | 1 |
| Annett, LE; Baker, HF; Dunnett, SB; Marsden, CD; Martel, FL; Ridley, RM; Rogers, DC | 1 |
| Lees, AJ; Turjanski, N | 1 |
| Frankel, JP; Kempster, PA; Lees, AJ; Stern, GM | 2 |
| Bovingdon, M; Frankel, J; Kapoor, R; Kleedorfer, B; Lees, A; Stern, G; Turjanski, N; Webster, R | 1 |
| Bakay, RA; Byrd, LD; Colbassani, HJ; Herring, CJ; Iuvone, PM; Mandir, A; Sweeney, KM; Watts, RL | 1 |
| Benabid, AL; Champay, AS; Gaio, JM; Hommel, M; Perret, J; Pollak, P | 1 |
| Jansen, EN; van Laar, T | 1 |
| Frankel, JP; Hughes, A; Lees, AJ; Stern, GM | 1 |
| Montastruc, JL; Rascol, A; Rascol, O; Sabatini, U | 1 |
| Boucher, B; Gancher, ST; Gliessman, P; Nutt, JG; Woodward, WR | 1 |
| Luquin, MR; Obeso, JA; Vaamonde, J | 2 |
| Aebischer, P; Tresco, PA; Wahlberg, L; Winn, SR | 1 |
| Agnoli, A; Carta, A; Ruggieri, S; Stocchi, F | 1 |
| Benke, T; Gasser, T; Kleedorfer, B; Oertel, W; Poewe, W; Wagner, M | 1 |
| Caron, J; Mounier-Vehier, F; Petit, H; Salomez, JL; Vermersch, P | 1 |
| Kleedorfer, B; Lees, AJ; Montastruc, JL; Peyro Saint-Paul, H; Rascol, A; Rascol, O; Stern, GM; Turjanski, N | 1 |
| Burunat, E; Castellano, MA; Rodríguez, M | 1 |
| Grandas, F; Obeso, JA | 1 |
| Benabid, AL; Champay, AS; Hommel, M; Perret, JE; Pollak, P | 1 |
| Boucher, B; Gancher, ST; Nutt, JG; Woodward, WR | 1 |
| Grandas, F; Martínez-Lage, JM; Obeso, JA; Rosario Luguin, M; Vaamonde, J | 1 |
| Kempster, PA; Lees, AJ; Stern, GM; Stibe, CM | 1 |
| Gerstenbrand, F; Kleedorfer, B; Oertel, W; Poewe, W | 1 |
| Abbott, RJ; Chaudhuri, KR; Critchley, P; Millac, PA; Pye, IF | 1 |
| Crichton, P; Frankel, JP; Kempster, PA; Lees, AJ; Shorvon, P | 1 |
| Horowski, R; Marsden, CD; Obeso, JA | 1 |
| Fahn, S; Hassan, MN; Higgins, D; Traub, M | 1 |
| Holland, OB; Kennedy, B; Lake, CR; Murphy, D; Ziegler, MG | 1 |
| Astedt, B; Björklund, A; Brundin, P; Clarke, DJ; Lindvall, O; Nilsson, OG; Strecker, RE; Widner, H | 1 |
| Gaio, JM; Hommel, M; Mallaret, M; Perret, J; Pollak, P | 1 |
| Herbster, G; Koller, WC | 1 |
| Gancher, ST; Nutt, JG | 1 |
| Grandas, F; Luquin, MR; Martinez Lage, JM; Obeso, JA; Vaamonde, J | 1 |
| Fields, JZ; Gordon, JH; Koller, WC; Perlow, MJ | 1 |
| Bennett, JP; Cruz, CJ; Ferrari, MB | 1 |
| Hardie, RJ; Lees, AJ; Stern, GM | 1 |
| Anagnoste, B; Battista, AF; Goldstein, M; Nakatani, S; Ogawa, M | 1 |
| Boal, D; Le Brun, Y; Lieberman, A; Zolfaghari, M | 1 |
| Brinkmann, R; Strian, F | 1 |
| Cotzias, GC; Mena, I; Mendez, J; Papavasiliou, PS | 1 |
| Cotzias, GC; Mena, I; Papavasiliou, PS | 1 |
| Cotzias, GC | 3 |
| Ljungberg, T; Steg, G; Ungerstedt, U | 1 |
| Ngai, SH | 1 |
| Hornykiewicz, O | 1 |
| Cotzias, GC; Düby, SE; Lawrence, WH; Papavasiliou, PS | 1 |
| Calne, DB; Hilson, A; Rao, SK; Vakil, SD | 1 |
| Benesová, O | 1 |
| Bianchine, JR; Sunyapridakul, L | 1 |
| Ambani, LM; Brown, WA; Van Woert, MH | 1 |
| Cotzias, GC; Fehling, C; Kaufman, B; Mena, I; Papavasiliou, PS | 1 |
| Albert, E | 1 |
| Castaigne, P; Dordain, G; Laplane, D | 1 |
| Cotzias, GC; Dahl, LK; Düby, SE | 1 |
| Braham, J; Goldhammer, Y; Sarova-Pinhas, I | 1 |
| Cotzias, GC; Düby, S; Ginos, JZ; Papavasiliou, PS; Steck, A | 1 |
| Ernst, AM | 1 |
159 review(s) available for apomorphine and Parkinson Disease
| Article | Year |
|---|---|
New dopaminergic therapies for PD motor complications.
Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progression; Dopamine Agents; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2022 |
Neural Stem/Progenitor Cell Transplantation in Parkinson's Rodent Animals: A Meta-Analysis and Systematic Review.
Topics: Animals; Apomorphine; Disease Models, Animal; Humans; Parkinson Disease; Rodentia; Stem Cell Transplantation | 2022 |
[Apomorphine and frontal dysfunction in Parkinson's disease].
Topics: Apomorphine; Humans; Infusions, Subcutaneous; Parkinson Disease | 2022 |
A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2022 |
European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies.
Topics: Apomorphine; Deep Brain Stimulation; Humans; Neurology; Parkinson Disease; Quality of Life; Tremor | 2022 |
Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Humans; Levodopa; Parkinson Disease | 2022 |
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.
Topics: Aged; Apomorphine; Carbidopa; Humans; Levodopa; Middle Aged; Network Meta-Analysis; Parkinson Disease; Quality of Life | 2022 |
Pharmacological Treatment of Tremor in Parkinson's Disease Revisited.
Topics: Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Tremor | 2023 |
Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson's Disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease | 2023 |
Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Humans; Levodopa; Parkinson Disease | 2023 |
Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.
Topics: Animals; Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Dopamine; Humans; Parkinson Disease | 2019 |
Current Status of Pain Management in Parkinson's Disease.
Topics: Acetylcholine Release Inhibitors; Alanine; Analgesics; Antiparkinson Agents; Apomorphine; Benzylamines; Botulinum Toxins, Type A; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Duloxetine Hydrochloride; Humans; Levodopa; Naloxone; Oxycodone; Pain; Pain Management; Pain Measurement; Pain Threshold; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2020 |
Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson's disease management in developing countries.
Topics: Antiparkinson Agents; Apomorphine; Developing Countries; Disease Management; Humans; Parkinson Disease; Thailand | 2020 |
An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Disease Progression; Dopamine Agonists; Humans; Injection Site Reaction; Injections, Subcutaneous; Levodopa; Parkinson Disease; Subcutaneous Tissue | 2020 |
The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Clinical Decision-Making; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2020 |
A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease 'OFF' episodes.
Topics: Antiparkinson Agents; Apomorphine; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2021 |
Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.
Topics: Antiparkinson Agents; Apomorphine; Cost-Benefit Analysis; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
Topics: Activities of Daily Living; Antiparkinson Agents; Apomorphine; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
[Apomorphine: a powerful ally in Parkinson's disease].
Topics: Apomorphine; Dopamine Agonists; Humans; Parkinson Disease | 2021 |
On demand therapy for Parkinson's disease patients: Opportunities and choices.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2021 |
On-Demand Therapy for OFF Episodes in Parkinson's Disease.
Topics: Antiparkinson Agents; Apathy; Apomorphine; Humans; Levodopa; Parkinson Disease | 2021 |
Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2017 |
[Practical use of continuous apomorphine infusion via pump].
Topics: Antiparkinson Agents; Apomorphine; Humans; Infusion Pumps, Implantable; Parkinson Disease; Quality of Life | 2017 |
Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Drug Interactions; Humans; Parkinson Disease; Structure-Activity Relationship | 2018 |
Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson's Disease: a Network Meta-Analysis.
Topics: Apomorphine; Bayes Theorem; Databases, Factual; Dopamine Agonists; Humans; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2018 |
Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Dyskinesias; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2018 |
[Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Duodenum; Humans; Infusions, Intravenous; Infusions, Parenteral; Jejunum; Levodopa; Movement Disorders; Parkinson Disease | 2018 |
The next chapter in symptomatic Parkinson disease treatments.
Topics: Apomorphine; Dopamine Agents; Humans; Levodopa; Parkinson Disease | 2019 |
Apomorphine in the treatment of Parkinson's disease: a review.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2018 |
When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease; Patient Selection | 2013 |
Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease.
Topics: Apomorphine; Dopamine Agonists; Humans; Infusions, Subcutaneous; Parkinson Disease | 2013 |
Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.
Topics: Animals; Apomorphine; Dopamine Agonists; Humans; Infusions, Subcutaneous; Parkinson Disease; Quality of Life; Treatment Outcome | 2013 |
[Prevalence and main methods of treatment of advanced stages of Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Economics, Pharmaceutical; Health Care Costs; Humans; Parkinson Disease; Prevalence | 2013 |
[Treatment possibilities in advanced Parkinson's disease].
Topics: Administration, Oral; Age Factors; Antiparkinson Agents; Apomorphine; Carbidopa; Cognition Disorders; Deep Brain Stimulation; Dopamine Agents; Drug Tolerance; Duodenum; Dyskinesia, Drug-Induced; Gels; Humans; Infusion Pumps, Implantable; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index | 2013 |
[The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agents; Humans; Levodopa; Parkinson Disease | 2013 |
The role of subcutaneous infusion of apomorphine in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; History, 19th Century; History, 20th Century; Humans; Infusions, Subcutaneous; Parkinson Disease | 2014 |
Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.
Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Drug Delivery Systems; Humans; Parkinson Disease | 2014 |
Role of apomorphine in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Drug Delivery Systems; Humans; Parkinson Disease; Randomized Controlled Trials as Topic | 2015 |
Apomorphine hydrochloride for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Humans; Parkinson Disease; Treatment Outcome | 2015 |
Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.
Topics: Antiparkinson Agents; Apomorphine; Consensus; Humans; Parkinson Disease; Practice Patterns, Physicians' | 2015 |
Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence.
Topics: Animals; Apomorphine; Dopamine Agonists; Hallucinations; Humans; Parkinson Disease | 2016 |
Design and Synthesis of Dopaminergic Agonists.
Topics: Apomorphine; Dopamine Agonists; Drug Design; Humans; Indoles; Parkinson Disease; Phenanthridines; Quinolines; Receptors, Dopamine | 2016 |
Apomorphine therapy in Parkinson's and future directions.
Topics: Antiparkinson Agents; Apomorphine; Drug Administration Routes; Drug Delivery Systems; Humans; Parkinson Disease | 2016 |
Practical management of adverse events related to apomorphine therapy.
Topics: Animals; Antiparkinson Agents; Apomorphine; Arrhythmias, Cardiac; Disease Management; Dyskinesia, Drug-Induced; Humans; Hypotension, Orthostatic; Parkinson Disease; Vomiting | 2016 |
Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therpy.
Topics: Antiparkinson Agents; Apomorphine; Humans; Infusions, Subcutaneous; Nurse Specialists; Parkinson Disease | 2016 |
The efficacy of apomorphine - A non-motor perspective.
Topics: Animals; Antiparkinson Agents; Apomorphine; Autonomic Nervous System Diseases; Disruptive, Impulse Control, and Conduct Disorders; Humans; Mental Disorders; Parkinson Disease; Sleep Wake Disorders | 2016 |
Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Humans; Parkinson Disease | 2016 |
The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Drug Administration Routes; Drug Combinations; Gels; Humans; Intestines; Levodopa; Parkinson Disease | 2016 |
Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's.
Topics: Animals; Antiparkinson Agents; Apomorphine; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease | 2016 |
Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
Topics: Antiparkinson Agents; Apomorphine; Australia; Carbidopa; Deep Brain Stimulation; Drug Combinations; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2017 |
[Medical and surgical treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase Inhibitors; Combined Modality Therapy; Deep Brain Stimulation; Disease Progression; Dopamine Agonists; Foreign-Body Reaction; Humans; Intracranial Hemorrhages; Monoamine Oxidase Inhibitors; Mood Disorders; Parkinson Disease; Patient Selection; Quality of Life | 2017 |
Apomorphine nodules in Parkinson's disease: best practice considerations.
Topics: Antiparkinson Agents; Apomorphine; Drug Eruptions; Humans; Infusions, Subcutaneous; Parkinson Disease | 2008 |
Treatments for Parkinson disease--past achievements and current clinical needs.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic alpha-Antagonists; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Cholinesterase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Dyskinesias; Excitatory Amino Acid Antagonists; History, 20th Century; Humans; Levodopa; Parkinson Disease; Serotonin Agents | 2009 |
Apomorphine in the treatment of Parkinson disease and other movement disorders.
Topics: Animals; Apomorphine; Humans; Movement Disorders; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Use of apomorphine in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Dopamine Agonists; Humans; Levodopa; Lisuride; Parkinson Disease | 2008 |
Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.
Topics: Anticonvulsants; Apomorphine; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Patient Selection; Risk Assessment; Risk Factors | 2009 |
Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2009 |
[Diagnosis and therapy of idiopathic Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Deep Brain Stimulation; Diagnosis, Differential; Dopamine Agonists; Humans; Indans; Levodopa; Mental Status Schedule; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2006 |
Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease.
Topics: Animals; Apomorphine; Drug Delivery Systems; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2009 |
[Parkinson's disease - the future of invasive therapy].
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Genetic Therapy; Humans; Levodopa; Parkinson Disease; Stem Cell Transplantation | 2010 |
Substance abuse and movement disorders.
Topics: Alcoholism; Animals; Apomorphine; Humans; Levodopa; Movement Disorders; Parkinson Disease; Substance Withdrawal Syndrome; Substance-Related Disorders | 2009 |
[Therapy options in the case of advanced therapy resistant Morbus Parkinson].
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Cross-Sectional Studies; Deep Brain Stimulation; Drug Resistance; Humans; Infusion Pumps, Implantable; Levodopa; Neurologic Examination; Parkinson Disease; Population Dynamics | 2010 |
Pharmacologic safety concerns in Parkinson's disease: facts and insights.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Enzyme Inhibitors; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease | 2011 |
[Current treatment strategies for Parkinson's disease].
Topics: Aged; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Apomorphine; Critical Care; Deep Brain Stimulation; Dementia; Depression; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Europe; Female; Humans; Infusion Pumps, Implantable; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Psychotic Disorders; Sleep Wake Disorders; Tremor | 2011 |
Updates in the medical management of Parkinson disease.
Topics: Age Factors; Amantadine; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Cholinergic Antagonists; Disease Progression; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease | 2012 |
The pharmacological properties and therapeutic use of apomorphine.
Topics: Alzheimer Disease; Animals; Apomorphine; Dogs; Dopamine Agonists; Erectile Dysfunction; Female; Humans; Male; Parkinson Disease; Receptors, Adrenergic, alpha; Receptors, Dopamine; Receptors, Serotonin; Substance-Related Disorders | 2012 |
[Resistance to treatment in movement disorders].
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Drug Resistance; Essential Tremor; Humans; Levodopa; Movement Disorders; Neurosurgery; Parkinson Disease; Treatment Failure | 2012 |
Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Bromocriptine; Dopamine Agonists; Drug Delivery Systems; Ergolines; Humans; Parkinson Disease; Receptors, Dopamine | 2012 |
[Proposed alternative to standard apomorphine challenge test].
Topics: Antidotes; Antiparkinson Agents; Apomorphine; Carbidopa; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Levodopa; Motor Activity; Parkinson Disease; Severity of Illness Index; Time Factors | 2012 |
[Candidate patient for treatment with continuous apomorphine infusion].
Topics: Aged; Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Cognition Disorders; Contraindications; Depression; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Hallucinations; Humans; Infusions, Intravenous; Middle Aged; Parkinson Disease; Patient Selection; Psychoses, Substance-Induced; Psychotic Disorders | 2012 |
[Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Topics: Aftercare; Ambulatory Care; Antiparkinson Agents; Apomorphine; Benserazide; Carbidopa; Caregivers; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Patient Education as Topic; Patient Selection; Retrospective Studies | 2012 |
[Limits of conventional oral and transdermal medication in Parkinson's disease].
Topics: Administration, Cutaneous; Administration, Oral; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Indans; Injections, Subcutaneous; Levodopa; Meta-Analysis as Topic; Multicenter Studies as Topic; Parkinson Disease | 2012 |
[Candidate patient for subcutaneous apomorphine injection].
Topics: Abnormalities, Drug-Induced; Antiparkinson Agents; Apomorphine; Contraindications; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypotension, Orthostatic; Injections, Subcutaneous; Lactation; Levodopa; Parkinson Disease; Patient Selection; Pregnancy; Pregnancy Complications; Psychoses, Substance-Induced | 2012 |
Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Administration Routes; Evidence-Based Practice; Humans; Levodopa; Parkinson Disease | 2013 |
[Subcutaneous apomorphine injection: rescue management of motor fluctuations associated with levodopa-therapy].
Topics: Animals; Antiparkinson Agents; Apomorphine; Circadian Rhythm; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease; Receptors, Dopamine; Salvage Therapy; Self Administration | 2013 |
DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
Topics: Apomorphine; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Psychomotor Disorders; Randomized Controlled Trials as Topic | 2002 |
Iontophoretic delivery of apomorphine: from in-vitro modelling to the Parkinson patient.
Topics: Administration, Cutaneous; Antiparkinson Agents; Apomorphine; Biological Transport; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Iontophoresis; Models, Biological; Parkinson Disease; Skin; Skin Absorption; Time Factors | 2002 |
Prevention and treatment of motor fluctuations.
Topics: Antiparkinson Agents; Apomorphine; Benzophenones; Dyskinesias; Enzyme Inhibitors; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 2003 |
Neuroprotective, anti-apoptotic effects of apomorphine.
Topics: Antiparkinson Agents; Apomorphine; Apoptosis; Dopamine Agonists; Free Radical Scavengers; Humans; Neuroprotective Agents; Nitric Oxide; Parkinson Disease | 2003 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inhibitors; Clinical Trials as Topic; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Enzyme Inhibitors; Ergot Alkaloids; Family Practice; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Piperidines | 2003 |
Subcutaneously administered apomorphine: pharmacokinetics and metabolism.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Humans; Injections, Subcutaneous; Parkinson Disease | 2004 |
Apomorphine: North American clinical experience.
Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; North America; Parkinson Disease; Safety; Treatment Outcome | 2004 |
Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Dopamine Agonists; Double-Blind Method; Drug Administration Schedule; Humans; Injections, Subcutaneous; Parkinson Disease; Treatment Outcome | 2004 |
Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
Topics: Antiparkinson Agents; Apomorphine; Controlled Clinical Trials as Topic; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Routes; Humans; Injections, Subcutaneous; Parkinson Disease; Patient Selection | 2004 |
Rapid treatment of "wearing off" in Parkinson's disease.
Topics: Antiemetics; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parkinson Disease; Salvage Therapy; Time Factors | 2004 |
Practical considerations in the use of apomorphine injectable.
Topics: Antiemetics; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Nausea; Parkinson Disease; Patient Education as Topic; Practice Guidelines as Topic; Time Factors; United Kingdom | 2004 |
[Treatment of Parkinson disease in patients with surgical problems].
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Health Status; Humans; Levodopa; Parkinson Disease; Postoperative Period | 2003 |
Apomorphine-subcutaneous--Bertek/Britannia.
Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Parkinson Disease | 2004 |
Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Drug Interactions; Evidence-Based Medicine; Humans; Injections, Subcutaneous; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, Dopamine | 2004 |
[Apomorphine in the treatment of Parkinson's Disease].
Topics: Antiparkinson Agents; Apomorphine; Dizziness; Humans; Nausea; Parkinson Disease; Practice Guidelines as Topic; Practice Patterns, Physicians'; Risk Assessment; Risk Factors; Treatment Outcome | 2005 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Topics: Apomorphine; Benzophenones; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Ergolines; Humans; Levodopa; Movement Disorders; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2005 |
A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Economics, Pharmaceutical; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease | 2005 |
Dopamine agonists in the treatment of Parkinson's disease.
Topics: Apomorphine; Dopamine Agonists; Expert Testimony; Humans; Motor Activity; Neuroprotective Agents; Parkinson Disease | 2006 |
Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Dyskinesia, Drug-Induced; Humans; Models, Biological; Molecular Structure; Parkinson Disease | 2006 |
[Prevention and treatment of fluctuations in patients with Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Infusion Pumps, Implantable; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2006 |
Apomorphine in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Contraindications; Drug Administration Routes; Dyskinesias; Humans; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2007 |
Apomorphine therapy in Parkinson's disease: a review.
Topics: Animals; Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Dopamine Agonists; Humans; Parkinson Disease | 2007 |
Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Humans; Injections, Subcutaneous; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Registries | 2008 |
[New directions in contemporary pharmacotherapy of parkinsonism (review)].
Topics: Adrenergic beta-Antagonists; Anti-Anxiety Agents; Antiparkinson Agents; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Lisuride; Oxprenolol; Parkinson Disease; Piracetam; Piribedil; Propranolol | 1984 |
Dopamine autoreceptor stimulation: clinical significance.
Topics: Apomorphine; Dopamine; Haloperidol; Humans; Huntington Disease; Mental Disorders; Neurons; Parkinson Disease; Piribedil; Receptors, Dopamine; Relaxation; Schizophrenia; Sleep; Tourette Syndrome | 1982 |
Radioreceptor labeling of pre- and postsynaptic dopamine receptors.
Topics: Animals; Apomorphine; Binding Sites; Haloperidol; Humans; Parkinson Disease; Radioligand Assay; Receptors, Dopamine; Spiperone; Synapses | 1980 |
Apomorphine for motor fluctuations and freezing in Parkinson's disease.
Topics: Administration, Intranasal; Administration, Rectal; Administration, Sublingual; Apomorphine; Clinical Trials as Topic; Half-Life; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease | 1995 |
Apomorphine in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Humans; Injections, Subcutaneous; Parkinson Disease | 1995 |
Current status of dopamine agonists in Parkinson's disease management.
Topics: Apomorphine; Biological Availability; Dopamine Agents; Ergot Alkaloids; Half-Life; Humans; Parkinson Disease; Piribedil; Receptors, Dopamine | 1993 |
[Limited value of the apomorphine test in Parkinson disease].
Topics: Aged; Apomorphine; Dopamine Agents; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Prognosis; Retrospective Studies | 1994 |
Dopamine agonists in Parkinson's disease: a look at apomorphine.
Topics: Apomorphine; Humans; Parkinson Disease | 1993 |
[Apomorphine].
Topics: Administration, Sublingual; Apomorphine; Dopamine Agonists; Humans; Injections, Subcutaneous; Movement Disorders; Neuroleptic Malignant Syndrome; Parkinson Disease | 1995 |
Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Half-Life; Humans; Movement; Parkinson Disease; Receptors, Dopamine; Stimulation, Chemical | 1995 |
Pharmacokinetics of apomorphine in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Administration Routes; Drug Stability; Humans; Intestinal Absorption; Parkinson Disease; Tissue Distribution | 1995 |
New directions in the drug treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1996 |
Current developments in neurology, Part II: Advances in the pharmacotherapy of Alzheimer disease, Parkinson's disease, and stroke.
Topics: Alzheimer Disease; Anticoagulants; Apomorphine; Aspirin; Cerebrovascular Disorders; Cholinergic Agents; Dopamine Agonists; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Platelet Aggregation Inhibitors; Tacrine | 1996 |
Early diagnosis in Parkinson's disease--limitation of biochemical markers and instrumental methods.
Topics: Apomorphine; Biomarkers; Cell Death; Corpus Striatum; Diagnostic Imaging; Electrophysiology; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Substantia Nigra; Time Factors | 1996 |
Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias.
Topics: Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Globus Pallidus; Humans; Levodopa; Mental Disorders; Movement Disorders; Parkinson Disease; Sleep Wake Disorders; Stereotaxic Techniques; Thalamus | 1997 |
Clinical usefulness of apomorphine in movement disorders.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dystonia; Humans; Huntington Disease; Movement Disorders; Neuroleptic Malignant Syndrome; Parkinson Disease | 1994 |
Parkinson's disease: drug therapy.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Dyskinesia, Drug-Induced; Guidelines as Topic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome | 1997 |
Clinical pharmacology of dopamine agonists in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Ergot Alkaloids; Humans; Indoles; Neuroprotective Agents; Parkinson Disease; Pramipexole; Thiazoles | 1998 |
Dopamine agonists.
Topics: Apomorphine; Benzothiazoles; Bromocriptine; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Receptors, Dopamine; Thiazoles; Treatment Outcome | 1999 |
Shoulder pain in patients with Parkinson's disease.
Topics: Apomorphine; Arthroplasty, Replacement; Dopamine Agonists; Fractures, Bone; Humans; Neck Pain; Osteoporosis; Parkinson Disease; Reflex Sympathetic Dystrophy; Shoulder Pain | 1999 |
Apomorphine test in the assessment of parkinsonian patients: a meta-analysis.
Topics: Apomorphine; Disease Progression; Dopamine Agonists; Humans; Parkinson Disease; Parkinson Disease, Secondary | 1999 |
Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Humans; Injections, Subcutaneous; Movement Disorders; Parkinson Disease; Time Factors | 1999 |
Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Interactions; Humans; Levodopa; Parkinson Disease; Time Factors | 1999 |
"Rational hope" in the early treatment of Parkinson's disease.
Topics: Apomorphine; Aporphines; Harmine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease | 1999 |
Use of apomorphine in Parkinson's disease.
Topics: Apomorphine; Dopamine Agonists; Humans; Parkinson Disease; Salvage Therapy; Treatment Outcome | 1999 |
Neurophysiology of sensorimotor integration in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Evoked Potentials, Somatosensory; Humans; Motor Cortex; Parkinson Disease; Reaction Time; Somatosensory Cortex | 1998 |
Dopamine agonists in the treatment of Parkinson s disease past, present and future.
Topics: Animals; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Ergot Alkaloids; Humans; Levodopa; Parkinson Disease; Structure-Activity Relationship | 2000 |
[Drug treatments and motor complications in advanced stage Parkinson's disease ].
Topics: Antiparkinson Agents; Apomorphine; Dyskinesias; Humans; Parkinson Disease | 2000 |
Apomorphine: an underutilized therapy for Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Subcutaneous; Parkinson Disease; Treatment Outcome | 2000 |
Pharmacological treatment of Parkinson's disease.
Topics: Age Factors; Aged; Amantadine; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Diagnosis, Differential; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease | 2000 |
Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease.
Topics: Apomorphine; Diagnostic Tests, Routine; Humans; Levodopa; Parkinson Disease; Sensitivity and Specificity | 2000 |
Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Apomorphine; Chelating Agents; Dopamine Agonists; Humans; Iron; Parkinson Disease; Parkinsonian Disorders; Reactive Oxygen Species | 2000 |
Apomorphine in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Drug Monitoring; Humans; Infusions, Parenteral; Injections, Subcutaneous; Nursing Assessment; Parkinson Disease; Patient Selection; Treatment Outcome | 2001 |
Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?
Topics: Apomorphine; Brain; Dopamine; Humans; Parkinson Disease; Receptors, Dopamine; Schizophrenia | 2001 |
Are dopamine receptor agonists neuroprotective in Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzothiazoles; Bromocriptine; Cell Culture Techniques; Clinical Trials as Topic; Dopamine Agonists; Humans; Indoles; Models, Animal; Neuroprotective Agents; Parkinson Disease; Pergolide; Pramipexole; Substantia Nigra; Thiazoles | 2001 |
Apomorphine. A novel effect for an old compound.
Topics: Animals; Antiparkinson Agents; Apomorphine; Cell Division; Humans; Parkinson Disease | 2001 |
[Considerations in the drug treatment of parkinsonism (author's transl)].
Topics: Amantadine; Apomorphine; Bromocriptine; Dopamine; Ergolines; Extrapyramidal Tracts; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Parkinson Disease; Phosphodiesterase Inhibitors; Piribedil; Tremor | 1978 |
Recent advances in research on Parkinsonism.
Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarboxylase; Dopamine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Selegiline; Serotonin; Substance P; Tyrosine 3-Monooxygenase | 1978 |
Bromocriptine in the treatment of parkinsonism.
Topics: Apomorphine; Bromocriptine; Catecholamines; Drug Interactions; Ergolines; Humans; Kinetics; Motor Activity; Movement Disorders; Parkinson Disease; Piribedil; Receptors, Drug; Stereotyped Behavior | 1979 |
[Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
Topics: Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior; Corpus Striatum; Dogs; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Hypothermia; Levodopa; Memory; Mice; Opioid-Related Disorders; Parkinson Disease; Psychotic Disorders; Rats; Receptors, Dopamine; Sleep; Stereotyped Behavior; Substantia Nigra; Synapses; Synaptic Transmission | 1979 |
[Duality of dopaminergic receptors. Pharmacologic and clinical perspectives].
Topics: Animals; Apomorphine; Benzamides; Chorea; Fluorescent Antibody Technique; Guinea Pigs; Haloperidol; Humans; Levodopa; Movement Disorders; Parkinson Disease; Rats; Receptors, Dopamine | 1978 |
Clinical aspects of dopamine agonists and antagonists.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Basal Ganglia; Cardiovascular Diseases; Central Nervous System Diseases; Dopamine; Ergot Alkaloids; Humans; Mice; Parkinson Disease; Rats; Receptors, Dopamine; Stereotyped Behavior | 1978 |
Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
Topics: Apomorphine; Bromocriptine; Humans; Levodopa; Parkinson Disease; Piribedil; Receptors, Dopamine | 1979 |
On the role of dopamine in the pathophysiology of anorexia nervosa.
Topics: 17-Ketosteroids; Amphetamine; Anorexia Nervosa; Apomorphine; Compulsive Personality Disorder; Dopamine; Female; Glucose Tolerance Test; Gonadotropins, Pituitary; Humans; Levodopa; Luteinizing Hormone; Male; Movement Disorders; Parkinson Disease; Schizophrenia; Steroids; Thinness | 1976 |
Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Brain; Carbachol; Caudate Nucleus; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Humans; Movement Disorders; Parasympathetic Nervous System; Parasympathomimetics; Parkinson Disease; Parkinson Disease, Secondary; Rabbits; Rats; Receptors, Dopamine; Stereotyped Behavior; Substantia Nigra; Synapses | 1976 |
Motor response to repeated dopaminergic stimulation in Parkinson's disease.
Topics: Animals; Apomorphine; Dopamine Agents; Haplorhini; Humans; Levodopa; Movement; Parkinson Disease | 1992 |
Dopaminergic agonists in the treatment of Parkinson's disease.
Topics: Apomorphine; Bromocriptine; Dopamine Agents; Humans; Lactose; Lisuride; Methylcellulose; Oxazines; Parkinson Disease; Pergolide; Receptors, Dopamine | 1992 |
[Current therapeutic approach in Parkinson disease].
Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Fetal Tissue Transplantation; Humans; Levodopa; Mesencephalon; Parkinson Disease; Selegiline; Vitamin E | 1992 |
[Apomorphine and Parkinson's disease. A major therapeutical progress].
Topics: Apomorphine; Humans; Parkinson Disease | 1992 |
[Use of apomorphine in the treatment of Parkinson's disease].
Topics: Apomorphine; Domperidone; Drug Combinations; Humans; Infusions, Intravenous; Injections, Subcutaneous; Levodopa; Parkinson Disease | 1991 |
The modern management of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Humans; Levodopa; Parkinson Disease; Selegiline | 1990 |
[Apomorphine in the treatment of Parkinson's disease].
Topics: Adult; Apomorphine; Humans; Middle Aged; Parkinson Disease | 1990 |
Continuous dopaminergic stimulation: state of the art and outlook.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Infusion Pumps; Lisuride; Mental Disorders; Movement; Neurology; Parkinson Disease; Stimulation, Chemical | 1988 |
The controversial role of bromocriptine in Parkinson's disease.
Topics: Apomorphine; Bromocriptine; Humans; Levodopa; Parkinson Disease; Time Factors | 1985 |
Parkinsonism, levodopa, and anesthesia.
Topics: Amantadine; Anesthesia; Animals; Apomorphine; Benperidol; Blood-Brain Barrier; Brain; Cardiovascular Diseases; Catecholamines; Dihydroxyphenylalanine; Dopamine; Fentanyl; Humans; Mice; Movement Disorders; Muscle Rigidity; Parkinson Disease; Psychoses, Substance-Induced; Pulmonary Edema; Rats | 1972 |
Dopamine and extrapyramidal motor function and dysfunction.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Butyrophenones; Caudate Nucleus; Dihydroxyphenylalanine; Dopamine; Electric Stimulation; Extrapyramidal Tracts; Humans; Parkinson Disease; Parkinson Disease, Secondary; Phenothiazines; Phenylacetates; Reserpine; Substantia Nigra; Visual Cortex | 1972 |
Augmenting the action of levodopa.
Topics: Amantadine; Antacids; Apomorphine; Carboxy-Lyases; Catechol O-Methyltransferase Inhibitors; Dihydroxyphenylalanine; Dopamine beta-Hydroxylase; Drug Synergism; Humans; Methyldopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease | 1972 |
[Review of current pharmacotherapy of Parkinsonism. Comprehensive review].
Topics: 5-Hydroxytryptophan; Amantadine; Anticonvulsants; Apomorphine; Benztropine; Carboxy-Lyases; Chemical Phenomena; Chemistry; Dihydroxyphenylalanine; Humans; Parasympatholytics; Parkinson Disease; Procyclidine; Trihexyphenidyl | 1973 |
Individualization of levodopa therapy.
Topics: Amantadine; Amphetamine; Anesthetics; Animals; Antihypertensive Agents; Apomorphine; Arrhythmias, Cardiac; Carbidopa; Depression, Chemical; Diet; Disulfiram; Drug Interactions; Drug Therapy, Combination; Endocrine Glands; Glaucoma; Humans; Hydrogen-Ion Concentration; Levodopa; Mice; Parasympatholytics; Parkinson Disease; Stomach | 1974 |
[Therapy and problems of parkinsonism].
Topics: Adult; Aged; Amantadine; Animals; Antidepressive Agents; Apomorphine; Brain Chemistry; Brain Stem; Dihydroxyphenylalanine; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Psychoses, Substance-Induced; Stereotaxic Techniques; Sympathomimetics | 1971 |
108 trial(s) available for apomorphine and Parkinson Disease
| Article | Year |
|---|---|
Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
Topics: Administration, Sublingual; Aged; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Edible Films; Female; Humans; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2021 |
A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009.
Topics: Administration, Inhalation; Antiparkinson Agents; Apomorphine; Cross-Over Studies; Double-Blind Method; Humans; Mental Status and Dementia Tests; Parkinson Disease | 2022 |
Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients.
Topics: Administration, Inhalation; Antiparkinson Agents; Apomorphine; Cross-Over Studies; Double-Blind Method; Humans; Parkinson Disease | 2022 |
Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Cross-Over Studies; Double-Blind Method; Humans; Middle Aged; Parkinson Disease; Quality of Life; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders; Treatment Outcome | 2022 |
A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease.
Topics: Apomorphine; Double-Blind Method; Electrocardiography; Humans; Moxifloxacin; Parkinson Disease | 2022 |
Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson's Disease: Is the Prophylactic Use of an Antiemetic Necessary?
Topics: Antiemetics; Apomorphine; Dopamine Agonists; Humans; Nausea; Parkinson Disease; Vomiting | 2023 |
Practical use of apomorphine infusion in Parkinson's disease: lessons from the TOLEDO study and clinical experience.
Topics: Antiparkinson Agents; Apomorphine; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2023 |
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Topics: Administration, Sublingual; Adult; Aged; Antiparkinson Agents; Apomorphine; Canada; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; United States | 2020 |
Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
Topics: Administration, Sublingual; Aged; Apomorphine; Dopamine Agonists; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index | 2020 |
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study.
Topics: Aged; Apomorphine; Dopamine Agonists; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Subcutaneous; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease | 2021 |
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
Topics: Age Factors; Aged; Analysis of Variance; Antiparkinson Agents; Apomorphine; Double-Blind Method; Female; Gait Disorders, Neurologic; Humans; Infusions, Subcutaneous; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2018 |
Inhaled dry powder apomorphine (VR040) for 'off ' periods in Parkinson's disease: an in-clinic double-blind dose ranging study.
Topics: Administration, Inhalation; Apomorphine; Dopamine Agonists; Double-Blind Method; Dry Powder Inhalers; Female; Humans; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors | 2013 |
Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antiparkinson Agents; Apomorphine; Double-Blind Method; Drug Substitution; Female; Home Care Services; Humans; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2013 |
Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson's disease.
Topics: Aged; Apomorphine; Asian People; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease | 2014 |
Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiemetics; Apomorphine; Benzamides; Dopamine Agonists; Double-Blind Method; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Male; Middle Aged; Nausea; Parkinson Disease; Severity of Illness Index; Time Factors; Vomiting; Young Adult | 2014 |
EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Female; Humans; Infusions, Subcutaneous; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2015 |
Teaching neurons to respond to placebos.
Topics: Aged; Apomorphine; Deep Brain Stimulation; Dopamine Agonists; Female; Humans; Male; Middle Aged; Neurons; Parkinson Disease; Placebo Effect; Placebos | 2016 |
Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Topics: Administration, Sublingual; Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Proof of Concept Study | 2016 |
Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
Topics: Administration, Oral; Aged; Apomorphine; Cross-Over Studies; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Infusions, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Treatment Outcome | 2009 |
Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study.
Topics: Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Eruptions; Female; Hardness; Humans; Infusions, Parenteral; Male; Middle Aged; Parkinson Disease; Pilot Projects; Sample Size; Subcutaneous Tissue; Ultrasonic Therapy | 2009 |
The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease.
Topics: Apomorphine; Dopamine Agonists; Drug Administration Schedule; Humans; Motor Activity; Parkinson Disease; Severity of Illness Index; Time Factors | 2009 |
Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Apomorphine; Domperidone; Female; Hallucinations; Humans; Infusions, Subcutaneous; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Severity of Illness Index | 2010 |
Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.
Topics: Administration, Sublingual; Antiparkinson Agents; Apomorphine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Routes; France; Humans; Logistic Models; Parkinson Disease; Piribedil; Proportional Hazards Models; Severity of Illness Index | 2010 |
Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.
Topics: Aged; Antiparkinson Agents; Apomorphine; Cerebral Cortex; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuralgia; Oxygen Isotopes; Pain Threshold; Parkinson Disease; Positron-Emission Tomography | 2011 |
A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation.
Topics: Aged; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Female; Humans; Infusions, Subcutaneous; Longitudinal Studies; Male; Middle Aged; Neurophysiology; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Subthalamic Nucleus | 2011 |
Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Dyskinesias; Female; Humans; Hypodermoclysis; Infusions, Parenteral; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 2012 |
The utility of (11)C-arachidonate PET to study in vivo dopaminergic neurotransmission in humans.
Topics: Adult; Apomorphine; Arachidonic Acid; Brain; Carbon Isotopes; Cerebrovascular Circulation; Dopamine Agonists; Dopaminergic Neurons; Functional Laterality; Group IV Phospholipases A2; Humans; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Potassium; Radiography; Receptors, Dopamine D1; Receptors, Dopamine D2; Schizophrenia; Synaptic Transmission | 2012 |
Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease.
Topics: Administration, Inhalation; Adult; Aged; Apomorphine; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2013 |
Dopamine release in human ventral striatum and expectation of reward.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Dopamine Antagonists; Humans; Neostriatum; Nucleus Accumbens; Parkinson Disease; Raclopride; Reward; Tomography, Emission-Computed | 2002 |
Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Apomorphine; Delayed-Action Preparations; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance | 2002 |
Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Double-Blind Method; Drug Administration Routes; Drug Tolerance; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2003 |
Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Autoreceptors; Choice Behavior; Dopamine Agents; Double-Blind Method; Drug Tolerance; Female; Humans; Injections, Subcutaneous; Long-Term Care; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Premedication; Psychomotor Performance; Reaction Time; Receptors, Presynaptic | 2004 |
Apomorphine delays simple reaction time in Parkinsonian patients.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Cognition; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Movement; Parkinson Disease; Reaction Time | 2002 |
Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.
Topics: Antiemetics; Apomorphine; Brain; Cognition Disorders; Depression; Domperidone; Dopamine Agonists; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires | 2004 |
Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Apomorphine; Area Under Curve; Drug Therapy, Combination; Emulsions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors | 2004 |
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
Topics: Antiparkinson Agents; Apomorphine; Catechols; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease | 2004 |
Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesias; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Pain Measurement; Parkinson Disease; Prospective Studies; Self-Assessment; Statistics, Nonparametric | 2005 |
Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Disability Evaluation; Dopamine; Dopamine Agonists; Drug Administration Schedule; Female; Human Growth Hormone; Humans; Hydrocortisone; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2004 |
Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment.
Topics: Administration, Cutaneous; Aged; Apomorphine; Female; Humans; Iontophoresis; Male; Middle Aged; Parkinson Disease; Surface-Active Agents | 2005 |
A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Female; Humans; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors; Treatment Outcome | 2004 |
rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.
Topics: Aged; Apomorphine; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Motor Cortex; Neural Pathways; Parkinson Disease; Recovery of Function; Transcranial Magnetic Stimulation; Treatment Outcome | 2005 |
Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Case-Control Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2007 |
[Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
Topics: Aged; Ambulatory Care; Antiparkinson Agents; Apomorphine; Drug Therapy, Combination; Female; Follow-Up Studies; Granuloma; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Outpatient Clinics, Hospital; Parkinson Disease; Prospective Studies; Subcutaneous Tissue; Telephone | 2007 |
Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Apomorphine; Blood Pressure; Case-Control Studies; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Injections, Subcutaneous; Male; Parkinson Disease; Time Factors | 2007 |
Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Cross-Over Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine; Severity of Illness Index; Treatment Outcome | 2008 |
Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label study.
Topics: Aged; Antiparkinson Agents; Apomorphine; Blood Pressure; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Male; Middle Aged; Outpatients; Parkinson Disease; Severity of Illness Index; Time Factors | 2008 |
[Treatment of motor fluctuations in Parkinson's disease with subcutaneous injections of apomorphine].
Topics: Aged; Aged, 80 and over; Analysis of Variance; Apomorphine; Follow-Up Studies; Humans; Injections, Subcutaneous; Middle Aged; Movement; Parkinson Disease; Prospective Studies; Time Factors | 1995 |
Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories.
Topics: Aged; Antiparkinson Agents; Apomorphine; Biological Availability; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Exercise Test; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Suppositories; Treatment Outcome | 1995 |
Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.
Topics: Adult; Aged; Apomorphine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Time Factors | 1995 |
Apomorphine induced cognitive changes in Parkinson's disease.
Topics: Apomorphine; Cognition Disorders; Evoked Potentials, Auditory; Evoked Potentials, Visual; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time | 1994 |
A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1993 |
Apomorphine and lisuride infusion. A comparative chronic study.
Topics: Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Lisuride; Long-Term Care; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease | 1993 |
Apomorphine test for dopaminergic responsiveness: a dose assessment study.
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Receptors, Dopamine | 1993 |
Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease.
Topics: Aged; Apomorphine; Domperidone; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Movement; Parkinson Disease | 1993 |
[Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Dopamine Agents; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1995 |
Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
Topics: Administration, Intranasal; Antiemetics; Antiparkinson Agents; Apomorphine; Benzamides; Carbidopa; Dopamine Agonists; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1996 |
The apomorphine test in gait disorders associated with parkinsonism.
Topics: Aged; Aged, 80 and over; Apomorphine; Female; Follow-Up Studies; Gait; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Fluctuations in Parkinson's disease. Pathogenetic significance of levodopa's cerebral pharmacokinetics and pharmacodynamics.
Topics: Antiparkinson Agents; Apomorphine; Cross-Over Studies; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1995 |
Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
Topics: Antiparkinson Agents; Apomorphine; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Infusions, Intravenous; Levodopa; Parkinson Disease; Psychomotor Performance | 1996 |
A study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patients.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Blood Pressure; Dopamine; Epinephrine; Female; Heart Rate; Human Growth Hormone; Humans; Hypothalamus; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Peripheral Nervous System; Prolactin; Sensitivity and Specificity | 1996 |
A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.
Topics: Administration, Sublingual; Aged; Antiparkinson Agents; Apomorphine; Ascorbic Acid; Biological Availability; Cross-Over Studies; Female; Humans; Injections, Subcutaneous; Male; Metabolic Clearance Rate; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Outcome | 1996 |
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
Topics: Apomorphine; Double-Blind Method; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease; Placebos; Receptors, Dopamine; Receptors, Presynaptic | 1997 |
Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and threshold.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Feasibility Studies; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Motor Activity; Movement; Parkinson Disease | 1997 |
Preclamol and parkinsonian fluctuations.
Topics: Antiparkinson Agents; Apomorphine; Blood Pressure; Dopamine Agonists; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Movement; Parkinson Disease; Piperidines; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1993 |
Effects of apomorphine on globus pallidus neurons in parkinsonian patients.
Topics: Action Potentials; Aged; Antiparkinson Agents; Apomorphine; Electrophysiology; Globus Pallidus; Humans; Middle Aged; Neurons; Parkinson Disease; Time Factors | 1997 |
[123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
Topics: Adult; Aged; Apomorphine; Atrophy; Benzamides; Binding Sites; Cerebral Cortex; Dopamine; Dopamine Agonists; Dopamine Antagonists; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease; Predictive Value of Tests; Putamen; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1997 |
123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Chi-Square Distribution; Disease Progression; Dopamine Agonists; Follow-Up Studies; Humans; Iodine Radioisotopes; Levodopa; Middle Aged; Parkinson Disease; Prognosis; Prospective Studies; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1998 |
Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease.
Topics: Administration, Cutaneous; Antiparkinson Agents; Apomorphine; Cross-Over Studies; Female; Humans; Iontophoresis; Male; Metabolic Clearance Rate; Middle Aged; Parkinson Disease; Skin | 1997 |
Opposite motor effects of pallidal stimulation in Parkinson's disease.
Topics: Apomorphine; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Parkinson Disease; Stereotaxic Techniques; Treatment Outcome | 1998 |
Increased cortical inhibition induced by apomorphine in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Cerebral Cortex; Electromagnetic Fields; Electromyography; Evoked Potentials, Motor; Female; Humans; Male; Motor Cortex; Multiple System Atrophy; Parkinson Disease; Somatosensory Cortex | 1998 |
Dose response and concentration response relationship of apomorphine in patients with Parkinson's disease and end-of-dose akinesia.
Topics: Adult; Aged; Apomorphine; Area Under Curve; Chromatography, High Pressure Liquid; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Middle Aged; Parkinson Disease; Psychomotor Performance | 1998 |
A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
Topics: Administration, Intranasal; Aerosols; Aged; Antiemetics; Antiparkinson Agents; Apomorphine; Benzamides; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects; Premedication; Treatment Outcome | 1998 |
Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors | 1998 |
Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Biperiden; Cholinergic Antagonists; Cross-Over Studies; Dopamine Agonists; Female; Humans; Hypokinesia; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Single-Blind Method; Tremor | 1999 |
Electrophysiological and clinical desensitization to apomorphine administration in parkinsonian patients undergoing stereotaxic neurosurgery.
Topics: Apomorphine; Dopamine Agonists; Electrophysiology; Globus Pallidus; Humans; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Synaptic Transmission | 1999 |
Use of apomorphine in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antiparkinson Agents; Apomorphine; Domperidone; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Parkinson Disease | 1999 |
A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease.
Topics: Administration, Sublingual; Antiparkinson Agents; Apomorphine; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Parkinson Disease; Time Factors; Treatment Outcome | 1999 |
Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Middle Aged; Parkinson Disease; Restless Legs Syndrome; Sleep Wake Disorders | 1999 |
Apomorphine test: a predictor for motor responsiveness to deep brain stimulation of the subthalamic nucleus.
Topics: Aged; Apomorphine; Electric Stimulation Therapy; Electrodes, Implanted; Female; Fingers; Forecasting; Humans; Intraoperative Care; Male; Middle Aged; Movement; Multiple System Atrophy; Parkinson Disease; Subthalamic Nucleus; Time Factors; Treatment Outcome | 1999 |
Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.
Topics: Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors; Treatment Outcome | 2000 |
Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Dopamine; Double-Blind Method; Female; Humans; Larynx; Male; Middle Aged; Parkinson Disease; Speech; Treatment Outcome | 2000 |
Effects of apomorphine on visual functions in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Color Perception; Contrast Sensitivity; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease; Vision Disorders; Vision Tests | 2000 |
[Apomorphine for treatment of "off-periods" in Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Domperidone; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1999 |
Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations.
Topics: Aged; Apomorphine; Catheters, Indwelling; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infections; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Parkinson Disease; Thrombosis; Treatment Outcome | 2001 |
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids.
Topics: Action Potentials; Aged; Apomorphine; Basal Ganglia; Electric Stimulation Therapy; Electrodes, Implanted; Electrophysiology; Female; Globus Pallidus; Humans; Injections, Subcutaneous; Male; Microdialysis; Middle Aged; Neurotransmitter Agents; Parkinson Disease; Stereotaxic Techniques; Substantia Nigra; Subthalamic Nucleus; Treatment Outcome | 2001 |
Effect of apomorphine on motor and cognitive function in melancholic patients: a preliminary report.
Topics: Aged; Apomorphine; Cognition Disorders; Cross-Over Studies; Depressive Disorder, Major; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Disorders; Severity of Illness Index | 2000 |
The Posturo-Locomotion-Manual Test. A simple method for the characterization of neurological movement disturbances.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Diagnosis, Differential; Diagnostic Techniques, Neurological; Humans; Indoles; Levodopa; Locomotion; Middle Aged; Parkinson Disease; Posture | 2001 |
Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease.
Topics: Action Potentials; Aged; Antiparkinson Agents; Apomorphine; Female; Globus Pallidus; Humans; Male; Middle Aged; Neurons; Parkinson Disease; Periodicity; Subthalamic Nucleus | 2001 |
Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results.
Topics: Aged; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Recovery of Function; Time Factors; Treatment Outcome | 2001 |
Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Corpus Striatum; Dopamine; Female; Humans; Male; Middle Aged; Parkinson Disease; Placebo Effect; Placebos; Raclopride; Synapses; Tomography, Emission-Computed | 2001 |
A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.
Topics: Aged; Antiparkinson Agents; Apomorphine; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Inpatients; Male; Middle Aged; Outpatients; Parkinson Disease | 2001 |
Bilateral GPi DBS is useful to reduce abnormal involuntary movements in advanced Parkinson's disease patients, but its action is related to modality and site of stimulation.
Topics: Aged; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Dyskinesias; Electric Stimulation Therapy; Female; Functional Laterality; Globus Pallidus; Humans; Male; Middle Aged; Parkinson Disease | 2001 |
Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the 'indirect pathway'.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Electric Stimulation; Electrophysiology; Evoked Potentials; Female; Globus Pallidus; Humans; Male; Middle Aged; Movement; Neural Pathways; Neurons; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques; Subthalamus | 2002 |
Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.
Topics: Apomorphine; Benzimidazoles; Blood-Brain Barrier; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Parkinson Disease; Piperidines; Placebos; Receptors, Dopamine | 1979 |
Treatment of parkinsonism with N-n-propyl norapomorphine and levodopa (with or without carbidopa).
Topics: Aged; Apomorphine; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1978 |
Actions of dopaminergic agonists in parkinsonism.
Topics: Adult; Aged; Apomorphine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Parkinson Disease; Piperazines; Piribedil | 1975 |
[Polygraphic recording of tremor and of hypertonic phenomena. Application to the action of various drugs].
Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Dopa Decarboxylase; Drug Combinations; Drug Evaluation; Electrodiagnosis; Electromyography; Humans; Levodopa; Medical Records; Muscle Tonus; Oscillometry; Parkinson Disease; Piribedil; Tremor | 1975 |
Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.
Topics: Administration, Oral; Aged; Apomorphine; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Growth Hormone; Humans; Kidney; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Secretory Rate | 1976 |
Naloxone partly counteracts apomorphine side effects.
Topics: Apomorphine; Double-Blind Method; Female; Humans; Male; Naloxone; Nausea; Parkinson Disease; Sleep Stages; Vomiting; Yawning | 1991 |
Sublingual apomorphine solution in Parkinson's disease.
Topics: Administration, Oral; Administration, Sublingual; Apomorphine; Domperidone; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Single-Blind Method | 1991 |
[Subcutaneous apomorphine--a valuable therapeutic alternative in Parkinson disease].
Topics: Aged; Apomorphine; Drug Evaluation; Humans; Infusion Pumps; Injections, Subcutaneous; Middle Aged; Parkinson Disease | 1991 |
[Apomorphine in Parkinson disease].
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Efficacy of sublingual apomorphine in Parkinson's disease.
Topics: Administration, Sublingual; Aged; Apomorphine; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease | 1990 |
Blood pressure effects of apomorphine and domperidone in parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Blood Pressure; Clinical Trials as Topic; Domperidone; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Shy-Drager Syndrome | 1987 |
Injected apomorphine and orally administered levodopa in Parkinsonism.
Topics: Administration, Oral; Aged; Apomorphine; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Antagonism; Drug Synergism; Evaluation Studies as Topic; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Placebos | 1972 |
Similarities between neurologic effects of L-dopa and of apomorphine.
Topics: Adult; Apomorphine; Brain; Child; Clinical Trials as Topic; Cyanides; Dihydroxyphenylalanine; Female; Humans; Male; Manganese Poisoning; Muscular Diseases; Neurologic Manifestations; Parkinson Disease; Placebos; Poisoning | 1970 |
Clinical experimentation with apomorphine in Parkinson's disease.
Topics: Antiemetics; Apomorphine; Clinical Trials as Topic; Humans; Hypotension; Kinetics; Parkinson Disease | 1971 |
548 other study(ies) available for apomorphine and Parkinson Disease
| Article | Year |
|---|---|
Early factors for predicting discontinuation to subcutaneous Apomorphine infusion in Parkinson's disease: A prospective analysis of the Thai Apomorphine Registry.
Topics: Aged; Antiparkinson Agents; Apomorphine; Female; Follow-Up Studies; Humans; Infusions, Subcutaneous; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Registries; Risk Factors; Thailand; Time and Motion Studies; Treatment Outcome; Withholding Treatment | 2021 |
The prevalence of impulsive compulsive behaviors in patients treated with apomorphine infusion: a retrospective analysis.
Topics: Apomorphine; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Dyskinesias; Female; Humans; Impulsive Behavior; Male; Parkinson Disease; Prevalence; Retrospective Studies | 2022 |
Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes.
Topics: Antiparkinson Agents; Apomorphine; Humans; Levodopa; Parkinson Disease; Powders | 2022 |
A deep eutectic-based, self-emulsifying subcutaneous depot system for apomorphine therapy in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Area Under Curve; Delayed-Action Preparations; Drug Implants; Emulsions; Half-Life; Humans; Parkinson Disease; Rats; Subcutaneous Tissue; Swine | 2022 |
Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease.
Topics: Adult; Antiparkinson Agents; Apomorphine; Drug Combinations; Gels; Humans; Israel; Parkinson Disease; Retrospective Studies | 2022 |
Apomorphine infusion for improving sleep in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Humans; Infusions, Subcutaneous; Parkinson Disease; Sleep | 2022 |
The understanding of Parkinson's disease through genetics and new therapies.
Topics: alpha-Synuclein; Apomorphine; Dopaminergic Neurons; Humans; Hypokinesia; Parkinson Disease; Tremor | 2022 |
Looking back the importance of genetics in a patient with Parkinson disease and deep brain stimulation.
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2022 |
Sublingual apomorphine therapy as an alternative to complex continuous infusion pumps in advanced Parkinson's disease treatment: a district nurse-led intervention.
Topics: Administration, Sublingual; Antiparkinson Agents; Apomorphine; Humans; Infusion Pumps; Nurse's Role; Parkinson Disease | 2022 |
European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies.
Topics: Apomorphine; Deep Brain Stimulation; Humans; Neurology; Parkinson Disease; Quality of Life; Tremor | 2022 |
6-Hydroxydopamine-Induced Neurotoxicity in Rat Model of Parkinson's Disease: Is Reversed via Anti-Oxidative Activities of Curcumin and Aerobic Exercise Therapy.
Topics: alpha-Synuclein; Animals; Antioxidants; Apomorphine; Curcumin; Disease Models, Animal; Glutathione Peroxidase; Malondialdehyde; Neuroprotective Agents; Neurotoxicity Syndromes; Neurotoxins; Oxidopamine; Parkinson Disease; Rats; Substantia Nigra | 2022 |
5-(4-Hydroxy-3-dimethoxybenzylidene)-thiazolidinone improves motor functions and exerts antioxidant potential in hemiparkinsonian rats.
Topics: Animals; Antioxidants; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Oxidopamine; Parkinson Disease; Rats; Substantia Nigra; Tyrosine 3-Monooxygenase | 2023 |
New trends in advanced parkinson disease stage therapy.
Topics: Administration, Oral; Apomorphine; Esters; Humans; Parkinson Disease; Slovakia | 2023 |
Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study.
Topics: Antiparkinson Agents; Apomorphine; Feasibility Studies; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life; Treatment Outcome | 2023 |
Machine learning study: from the toxicity studies to tetrahydrocannabinol effects on Parkinson's disease.
Topics: Apomorphine; Dopamine Agonists; Dronabinol; Humans; Molecular Docking Simulation; Parkinson Disease | 2023 |
Factors influencing the reliability of intraoperative testing in deep brain stimulation for Parkinson's disease.
Topics: Apomorphine; Confusion; Deep Brain Stimulation; Humans; Hypnotics and Sedatives; Parkinson Disease; Reproducibility of Results; Retrospective Studies; Sleepiness; Subthalamic Nucleus; Treatment Outcome | 2023 |
Task Specific Tremor in Parkinson's Disease Responds to Apomorphine.
Topics: Apomorphine; Dopamine; Humans; Levodopa; Parkinson Disease; Tremor | 2023 |
Lacosamide exhibits neuroprotective effects in a rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Lacosamide; Male; Malondialdehyde; Mice; Neuroprotective Agents; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Tumor Necrosis Factor-alpha | 2023 |
Discontinuation rate and long-term adverse events path of apomorphine infusion in advanced Parkinson's disease patients.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Humans; Infusions, Parenteral; Parkinson Disease | 2023 |
Home initiation of apomorphine infusion: lessons from the COVID-19 pandemic and implications for current clinical practice.
Topics: Antiparkinson Agents; Apomorphine; COVID-19; Humans; Infusions, Subcutaneous; Pandemics; Parkinson Disease | 2023 |
Safety and tolerability of long-term apomorphine infusion in advanced Parkinson's disease: an Indian multi-center (APO-IND) experience.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Quality of Life | 2023 |
Apomorphine-induced reorganization of striato-frontal connectivity in patients with tremor-dominant Parkinson's disease.
Topics: Aged; Apomorphine; Dopamine Agonists; Electromyography; Female; Frontal Lobe; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neostriatum; Neural Pathways; Parkinson Disease; Single-Blind Method; Tremor | 2019 |
Nei-like 1 inhibition results in motor dysfunction and promotes inflammation in Parkinson's disease mice model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Disease Models, Animal; DNA Glycosylases; Inflammation; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Oxidopamine; Parkinson Disease; Stereotaxic Techniques | 2020 |
mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease.
Topics: Animals; Apomorphine; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Receptor, Metabotropic Glutamate 5 | 2020 |
New routes of dopaminergic drug delivery in patients with Parkinson's disease.
Topics: Apomorphine; Double-Blind Method; Drug Delivery Systems; Humans; Parkinson Disease | 2020 |
Analyzing Apomorphine-Mediated Effects in a Cell Model for Parkinson's Disease with Partial Least Squares Structure Equation Modeling.
Topics: Apomorphine; Dopamine Agonists; Female; Humans; Hypotension, Orthostatic; Least-Squares Analysis; Levodopa; Male; Microarray Analysis; Nausea; Parkinson Disease; Transcriptome | 2020 |
Clinical Trial Highlights - Infusion Therapies.
Topics: Apomorphine; Carbidopa; Clinical Trials as Topic; Dopamine Agonists; Drug Combinations; Gels; Humans; Infusion Pumps, Implantable; Infusions, Subcutaneous; Jejunum; Levodopa; Parkinson Disease | 2020 |
L-linalool exerts a neuroprotective action on hemiparkinsonian rats.
Topics: Acyclic Monoterpenes; Animals; Apomorphine; Brain; Disease Models, Animal; Dopamine; Lipid Peroxidation; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2020 |
Cutaneous adverse drug reaction after continuous subcutaneous apomorphine infusion.
Topics: Apomorphine; Drug-Related Side Effects and Adverse Reactions; Humans; Injections, Subcutaneous; Parkinson Disease; Skin | 2020 |
Loss of Awareness after Continuous Apomorphine Infusion Withdrawal in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Awareness; Humans; Infusions, Intravenous; Lethargy; Male; Parkinson Disease; Substance Withdrawal Syndrome | 2020 |
Impulse control disorder-linked hypersexuality complicated by disseminated gonococcal infection in a patient with Parkinson's disease.
Topics: Amantadine; Apomorphine; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Gonorrhea; Humans; Levodopa; Middle Aged; Parkinson Disease; Sexual Dysfunctions, Psychological; Tetrahydronaphthalenes; Thiophenes | 2020 |
[Continuous and advanced treatment strategies in the old to very old parkinsonian population].
Topics: Advance Care Planning; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Continuity of Patient Care; Deep Brain Stimulation; Disease Progression; Dopamine; Female; Frail Elderly; Humans; Long-Term Care; Male; Parkinson Disease; Quality of Life; Thalamus; Treatment Outcome | 2020 |
[Movement Disorders: What Are You Doing? What Can We Do?]
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Essential Tremor; Humans; Levodopa; Parkinson Disease | 2020 |
The long-term effect of continuous subcutaneous apomorphine infusions on camptocormia in Parkinson's disease.
Topics: Aged; Apomorphine; Dopamine Agonists; Female; Follow-Up Studies; Humans; Infusions, Subcutaneous; Male; Middle Aged; Muscular Atrophy, Spinal; Outcome Assessment, Health Care; Parkinson Disease; Spinal Curvatures | 2020 |
Controlled Delivery of Apomorphine Through Buccal Mucosa, Towards a Noninvasive Administration Method in Parkinson's Disease: A Preclinical Mechanistic Study.
Topics: Administration, Buccal; Animals; Apomorphine; Humans; Mouth Mucosa; Parkinson Disease; Permeability; Swine | 2020 |
Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease; Prospective Studies | 2020 |
Does Apomorphine Have an Effect on Body Weight? An Observational Study.
Topics: Antiparkinson Agents; Apomorphine; Body Weight; Humans; Parkinson Disease | 2021 |
Subcutaneous apomorphine infusion in advanced idiopathic Parkinson's disease and agranulocytosis: a case report.
Topics: Aged; Agranulocytosis; Apomorphine; Dopamine Agonists; Female; Humans; Infusions, Subcutaneous; Parkinson Disease | 2020 |
Engrafted primary type-2 astrocytes improve the recovery of the nigrostriatal pathway in a rat model of Parkinson's disease.
Topics: Adaptor Proteins, Signal Transducing; Adrenergic Agents; Animals; Apomorphine; Astrocytes; Disease Models, Animal; Dopaminergic Neurons; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2021 |
Evaluation of Prescription Practices of Domperidone in Parkinson's Disease: A Cross Sectional Study Among French Neurologists.
Topics: Adult; Age Factors; Apomorphine; Cross-Sectional Studies; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; France; Guideline Adherence; Health Care Surveys; Humans; Male; Middle Aged; Neurologists; Parkinson Disease; Practice Patterns, Physicians'; Time Factors | 2020 |
Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson's Disease: In Vivo Investigations in Pigs.
Topics: Administration, Buccal; Animals; Apomorphine; Biological Availability; Drug Delivery Systems; Mouth Mucosa; Parkinson Disease; Swine | 2021 |
The Effect of Levosimendan on Two Distinct Rodent Models of Parkinson's Disease.
Topics: Animals; Apomorphine; Cardiotonic Agents; Disease Models, Animal; Dopamine; Dopamine Agents; Male; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Simendan; Substantia Nigra; Sympatholytics | 2020 |
Sublingual apomorphine (Kynmobi) for Parkinson's disease.
Topics: Administration, Sublingual; Antiparkinson Agents; Apomorphine; Double-Blind Method; Female; Humans; Male; Parkinson Disease; Randomized Controlled Trials as Topic | 2020 |
Device-aided therapies for advanced Parkinson disease: insights from an international survey.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2021 |
Apomorphine hydrochloride: a sublingual tablet for the OFF episodes in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Humans; Levodopa; Middle Aged; Parkinson Disease; Tablets | 2021 |
Protective effect of caffeine and/or taurine on the 6-hydroxydopamine-induced rat model of Parkinson's disease: Behavioral and neurochemical evidence.
Topics: Animals; Apomorphine; Behavior, Animal; Caffeine; Corpus Striatum; Disease Models, Animal; Dopamine; Oxidopamine; Parkinson Disease; Rats; Taurine | 2021 |
Treatment of subcutaneous nodules after infusion of apomorphine; a biopsy-controlled study comparing 4 frequently used therapies.
Topics: Administration, Topical; Aged; Antiparkinson Agents; Apomorphine; Biopsy; Cross-Over Studies; Dopamine Agonists; Female; Humans; Hydrocortisone; Hypodermoclysis; Infusions, Subcutaneous; Injection Site Reaction; Male; Massage; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Patient Satisfaction; Prospective Studies; Skin Diseases | 2021 |
Epidemiology of skin event rates among users of pumps for the subcutaneous administration of drugs for chronic conditions.
Topics: Adult; Antiparkinson Agents; Apomorphine; Humans; Infusions, Subcutaneous; Insulin; Insulin Infusion Systems; Parkinson Disease; Pharmaceutical Preparations | 2021 |
Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Behavior, Animal; Botulinum Toxins, Type A; Corpus Striatum; Disease Models, Animal; Injections; Male; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Wistar | 2021 |
Apomorphine Reduces A53T α-Synuclein-Induced Microglial Reactivity Through Activation of NRF2 Signalling Pathway.
Topics: alpha-Synuclein; Animals; Antioxidants; Apomorphine; Dopamine; Dopamine Agonists; Free Radical Scavengers; Humans; Mice; Microglia; NF-E2-Related Factor 2; Parkinson Disease; RNA, Small Interfering | 2022 |
Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Cognition Disorders; Cohort Studies; Dopamine Agonists; Dyskinesias; Female; Humans; Infusions, Subcutaneous; Male; Middle Aged; Parkinson Disease; Sensation Disorders; Severity of Illness Index; Treatment Outcome | 2017 |
Magnetic Resonance Imaging as a Noninvasive Method for Longitudinal Monitoring of Infusion Site Reactions Following Administration of a Novel Apomorphine Formulation.
Topics: Animals; Antiparkinson Agents; Apomorphine; Biomarkers; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Injection Site Reaction; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Parkinson Disease; Swine | 2017 |
Use of advanced therapies for Parkinson's disease in Norway.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Utilization; Gels; Healthcare Disparities; Humans; Infusions, Parenteral; Levodopa; Norway; Parkinson Disease; Patient Education as Topic | 2017 |
Deep brain stimulation for Parkinson's disease: Subcutaneous apomorphine as an alternative for patients unable to tolerate surgery under local anesthesia.
Topics: Anesthesia, Local; Apomorphine; Deep Brain Stimulation; Dopamine Agonists; Humans; Male; Middle Aged; Parkinson Disease; Subcutaneous Absorption | 2017 |
Phase-coherence classification: A new wavelet-based method to separate local field potentials into local (in)coherent and volume-conducted components.
Topics: Aged; Algorithms; Apomorphine; Beta Rhythm; Cohort Studies; Deep Brain Stimulation; Dopamine Agonists; Female; Humans; Implantable Neurostimulators; Male; Middle Aged; Motor Activity; Neurons; Parkinson Disease; Subthalamic Nucleus; Synaptic Transmission; Tremor; Wavelet Analysis | 2017 |
The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning.
Topics: Aged; Apomorphine; Dopamine Agents; Female; Follow-Up Studies; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Placebo Effect | 2017 |
Objectively measuring effects of electro-acupuncture in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Electroacupuncture; Female; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Motor Activity; Motor Cortex; Parkinson Disease; Parkinson Disease, Secondary | 2018 |
Alpha Lipoamide Ameliorates Motor Deficits and Mitochondrial Dynamics in the Parkinson's Disease Model Induced by 6-Hydroxydopamine.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Apomorphine; Cell Death; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Exploratory Behavior; Forelimb; Male; Mesencephalon; Microscopy, Electron, Transmission; Mitochondria; Mitochondrial Dynamics; Mitochondrial Proteins; Motor Activity; Motor Disorders; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Sympatholytics; Thioctic Acid | 2018 |
Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
Topics: Aged; Antiparkinson Agents; Apomorphine; Cognitive Dysfunction; Cohort Studies; Dopamine Agonists; Female; Follow-Up Studies; Hallucinations; Humans; Hypotension, Orthostatic; Infusions, Subcutaneous; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2017 |
Effect of varenicline on behavioral deficits in a rat model of Parkinson's disease induced by unilateral 6-hydroxydopamine lesion of substantia nigra.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Male; Motor Activity; Nicotinic Agonists; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Substantia Nigra; Varenicline | 2018 |
From Sgt. Pepper to Dreamachines: My Scientific Odyssey With William S. Burroughs.
Topics: Apomorphine; Banisteriopsis; Brain; Dopamine Agonists; Hallucinations; History, 20th Century; Humans; Light; Literature, Modern; Magnetic Resonance Imaging; Medicine in Literature; Parkinson Disease; Physicians; Psychotropic Drugs; United States | 2017 |
Involvement of adenosine triphosphate-sensitive potassium channels in the neuroprotective activity of hydrogen sulfide in the 6-hydroxydopamine-induced animal model of Parkinson's disease.
Topics: Adenosine Triphosphate; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Hydrogen Sulfide; KATP Channels; Male; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Potassium Channels; Rats; Rats, Wistar; Substantia Nigra | 2018 |
Fat necrosis and subcutaneous abscesses due to apomorphine.
Topics: Abscess; Apomorphine; Dopamine Agonists; Fat Necrosis; Humans; Male; Middle Aged; Parkinson Disease; Subcutaneous Tissue | 2018 |
Continuous subcutaneous apomorphine infusion does not impair the dynamics of cognitive action control in mild to moderate Parkinson's disease.
Topics: Antiparasitic Agents; Apomorphine; Cognition; Conflict, Psychological; Eye Movement Measurements; Eye Movements; Female; Humans; Impulsive Behavior; Infusion Pumps; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Self-Control; Severity of Illness Index; Subcutaneous Absorption; Treatment Outcome | 2018 |
Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Cost of Illness; Cross-Sectional Studies; Drug Combinations; Family; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Quality of Life; Socioeconomic Factors; Surveys and Questionnaires; Treatment Outcome | 2018 |
The placebo effect on resting tremor in Parkinson's disease: an electrophysiological study.
Topics: Accelerometry; Aged; Apomorphine; Dopamine Agonists; Female; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Placebo Effect; Statistics, Nonparametric; Treatment Outcome; Tremor | 2018 |
Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Denmark; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies; Sweden | 2018 |
Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
Topics: Analysis of Variance; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Glutathione Peroxidase; Hydrogen Sulfide; Male; Malondialdehyde; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Postural Balance; Rats; Rats, Wistar; Rotarod Performance Test; Superoxide Dismutase; Sympatholytics | 2018 |
The Protective Role of Brain CYP2J in Parkinson's Disease Models.
Topics: alpha-Synuclein; Animals; Apomorphine; Brain; Cell Line, Tumor; Chromatin Immunoprecipitation; Cytochrome P-450 Enzyme System; Disease Models, Animal; Dopaminergic Neurons; Humans; Lipopolysaccharides; Male; Myeloid Differentiation Factor 88; NF-E2-Related Factor 2; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Signal Transduction; Toll-Like Receptor 4 | 2018 |
At last, a randomised controlled trial of apomorphine infusion.
Topics: Antiparkinson Agents; Apomorphine; Double-Blind Method; Humans; Infusions, Subcutaneous; Parkinson Disease | 2018 |
Cutaneous adverse drug reaction after apomorphine infusion, possibly caused by a systemic type IV hypersensitivity reaction to sodium metabisulfite: Report of 2 cases.
Topics: Adult; Aged; Apomorphine; Dopamine Agonists; Drug Eruptions; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delayed; Infusions, Subcutaneous; Male; Parkinson Disease; Patch Tests; Preservatives, Pharmaceutical; Sulfites | 2018 |
Sensor-based gait analysis of individualized improvement during apomorphine titration in Parkinson's disease.
Topics: Aged; Antiparasitic Agents; Apomorphine; Cross-Sectional Studies; Dopamine Agonists; Female; Gait Analysis; Humans; Male; Middle Aged; Parkinson Disease; Precision Medicine; Treatment Outcome | 2018 |
Apomorphine infusion in advanced Parkinson disease.
Topics: Apomorphine; Disease Progression; Dopamine Agonists; Drug Delivery Systems; Humans; Infusions, Subcutaneous; Parkinson Disease | 2018 |
Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life.
Topics: Antiparkinson Agents; Apomorphine; Cognition; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Subcutaneous; Levodopa; Male; Mental Disorders; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Quality of Life; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2018 |
Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson's disease model.
Topics: Animals; Apomorphine; Behavior Rating Scale; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Male; Motor Activity; Nerve Degeneration; Parkinson Disease; Rats, Wistar; Substantia Nigra | 2019 |
Continuous subcutaneous apomorphine in advanced Parkinson's disease patients treated with deep brain stimulation.
Topics: Aged; Apomorphine; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agonists; Humans; Infusions, Subcutaneous; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies | 2019 |
EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Dopamine Agonists; Female; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2019 |
Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Drug Administration Schedule; Humans; Injections, Subcutaneous; Middle Aged; Parkinson Disease; Pilot Projects | 2019 |
Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Carbidopa; Cognitive Dysfunction; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Substitution; Electronic Health Records; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Severe abdominal panniculitis in a patient treated with continuous subcutaneous apomorphine infusion.
Topics: Abdomen; Apomorphine; Dopamine Agonists; Humans; Infusions, Subcutaneous; Male; Middle Aged; Panniculitis; Parkinson Disease | 2019 |
Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Germany; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Neurology; Parkinson Disease; Practice Patterns, Physicians' | 2019 |
Acute lethargy after abrupt apomorphine withdrawal in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Humans; Infusions, Subcutaneous; Intraoperative Neurophysiological Monitoring; Lethargy; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 2019 |
Effects of carvacrol and physical exercise on motor and memory impairments associated with Parkinson's disease.
Topics: Animals; Apomorphine; Cymenes; Disease Models, Animal; Male; Memory Disorders; Motor Activity; Oxidative Stress; Parkinson Disease; Physical Conditioning, Animal; Rats; Rats, Wistar | 2019 |
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dynorphins; Early Growth Response Protein 1; Enkephalins; Functional Laterality; Gene Expression Regulation; Male; Motor Neurons; Movement; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2013 |
Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease.
Topics: Actinin; Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Caspase 3; Disease Models, Animal; DNA Fragmentation; Dopamine Agonists; Glutathione; Glutathione Reductase; Glutathione Transferase; Isothiocyanates; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rotarod Performance Test; Rotation; Sulfoxides; Tyrosine 3-Monooxygenase | 2013 |
Conditioned medium from human amniotic epithelial cells may induce the differentiation of human umbilical cord blood mesenchymal stem cells into dopaminergic neuron-like cells.
Topics: Amnion; Analysis of Variance; Animals; Apomorphine; Brain-Derived Neurotrophic Factor; Cell Differentiation; Culture Media, Conditioned; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Fetal Blood; Fetus; Flow Cytometry; Homeodomain Proteins; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, trkA; Receptor, trkB; RNA, Messenger; Stereotyped Behavior; Transcription Factors; Tyrosine 3-Monooxygenase | 2013 |
Exercise-induced rescue of tongue function without striatal dopamine sparing in a rat neurotoxin model of Parkinson disease.
Topics: Analysis of Variance; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Electric Stimulation; Forelimb; Functional Laterality; Hypoglossal Nerve; Male; Movement; Muscle Strength; Neurotoxins; Oxidopamine; Parkinson Disease; Physical Conditioning, Animal; Rats; Rats, Inbred F344; Time Factors; Tongue; Tongue Diseases; Tyrosine 3-Monooxygenase | 2013 |
Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Chalcone; Gene Expression Regulation, Enzymologic; Homovanillic Acid; Male; Neostriatum; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Quinones; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Tyrosine 3-Monooxygenase | 2013 |
Mapping and kinetics of microglia/neuron cell-to-cell contacts in the 6-OHDA murine model of Parkinson's disease.
Topics: Adaptor Proteins, Signal Transducing; Adrenergic Agents; Animals; Antigens, Differentiation; Apomorphine; Cell Communication; Cell Count; Disease Models, Animal; Dopamine Agonists; Female; Green Fluorescent Proteins; Imaging, Three-Dimensional; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Microscopy, Confocal; Neurons; Oxidopamine; Parkinson Disease; Receptors, Interleukin-8A; Rotation; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2013 |
[Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Gels; Humans; Intestines; Levodopa; Parkinson Disease | 2013 |
Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models.
Topics: Animals; Apomorphine; Benzeneacetamides; Cell Line; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Encephalitis; Enzyme Activation; Enzyme Activators; Exploratory Behavior; Lipopolysaccharides; Male; Mice; Motor Activity; Parkinson Disease; Phenols; Rats; Rats, Wistar; src-Family Kinases | 2013 |
Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect.
Topics: Aged; Apomorphine; Chi-Square Distribution; Dopamine Agonists; Drug Administration Routes; Female; Humans; Infusions, Subcutaneous; Male; Middle Aged; Observation; Parkinson Disease; Pilot Projects; Quality of Life; Severity of Illness Index | 2011 |
Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Apomorphine; Disease Models, Animal; Dopaminergic Neurons; Exploratory Behavior; Female; Forelimb; Genetic Vectors; Golgi Apparatus; Humans; Male; Mice; Mutation; Parkinson Disease; rab1 GTP-Binding Proteins; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2011 |
Suppression of exaggerated neuronal oscillations by oxytocin in a rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Electroencephalography; Electrophysiological Phenomena; Male; Neostriatum; Neurons; Oxytocin; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotation | 2013 |
Continuous perioperative apomorphine in deep brain stimulation surgery for Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Female; Humans; Infusion Pumps; Male; Middle Aged; Nausea; Parkinson Disease; Perioperative Care; Retrospective Studies; Substance Withdrawal Syndrome | 2014 |
Microglial cells are involved in the susceptibility of NADPH oxidase knockout mice to 6-hydroxy-dopamine-induced neurodegeneration.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Inflammation; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Microglia; Minocycline; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidase 2; NADPH Oxidases; Nerve Degeneration; NF-kappa B; Oxidopamine; Parkinson Disease; Substantia Nigra; Tumor Necrosis Factor-alpha | 2013 |
MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348.
Topics: Adenosine A2 Receptor Antagonists; Aging; Animals; Apomorphine; Benzothiazoles; Disease Models, Animal; Dopamine Agonists; Male; Mice; Mice, Transgenic; Motor Activity; Parkinson Disease; Pramipexole; Prepulse Inhibition; Pyrimidines; Triazoles | 2014 |
NADPH oxidase and the degeneration of dopaminergic neurons in parkinsonian mice.
Topics: Animals; Apomorphine; CD11b Antigen; Dopaminergic Neurons; Enzyme Activation; Glial Fibrillary Acidic Protein; Immunohistochemistry; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; NADPH Oxidase 2; NADPH Oxidases; Neostriatum; Nerve Degeneration; Oxidopamine; Parkinson Disease; Substantia Nigra; Tyrosine 3-Monooxygenase | 2013 |
Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models.
Topics: alpha-Synuclein; Animals; Apomorphine; Benzeneacetamides; Cell Death; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Phenols; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Repressor Proteins; Signal Transduction; Transcription Factors; Tyrosine 3-Monooxygenase | 2014 |
Serum melatonin is an alternative index of Parkinson's disease severity.
Topics: Aged; Aged, 80 and over; Animals; Apomorphine; Biomarkers; Dopamine Agonists; Female; Humans; Male; Melatonin; Middle Aged; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors | 2014 |
Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Drug Administration Routes; Drug Combinations; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Patient Selection; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome | 2014 |
Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Apomorphine; Brain; Caffeine; Cytokines; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Exploratory Behavior; Histone Deacetylases; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2014 |
Relation between microPET imaging and rotational behavior in a parkinsonian rat model induced by medial forebrain bundle axotomy.
Topics: Animals; Apomorphine; Axotomy; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dopamine Uptake Inhibitors; Functional Laterality; Male; Medial Forebrain Bundle; Parkinson Disease; Raclopride; Radionuclide Imaging; Rats; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2014 |
[Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Eruptions; Drug Evaluation; Female; Hallucinations; Humans; Infusions, Subcutaneous; Male; Middle Aged; Parkinson Disease; Patient Acceptance of Health Care; Quality of Life; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2014 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benzylamines; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Nerve Degeneration; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins; Stereotyped Behavior | 2014 |
Two-step grafting significantly enhances the survival of foetal dopaminergic transplants and induces graft-derived vascularisation in a 6-OHDA model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Embryo, Mammalian; Female; Fetal Tissue Transplantation; Graft Survival; Green Fluorescent Proteins; Medial Forebrain Bundle; Nerve Fibers; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Rats, Transgenic; Time Factors | 2014 |
(G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
Topics: Animals; Apomorphine; Cerebral Cortex; Corpus Striatum; Dopamine Agonists; Dopaminergic Neurons; GABA Antagonists; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Long-Term Potentiation; Mice; Mice, Transgenic; Motor Activity; Mutation; Parkinson Disease; Picrotoxin; Protein Serine-Threonine Kinases; Radionuclide Imaging; Serine; Substantia Nigra; Tyrosine 3-Monooxygenase | 2014 |
PEGylated rhFGF-2 conveys long-term neuroprotection and improves neuronal function in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Apoptosis; Astrocytes; Behavior, Animal; Biological Availability; Cell Survival; Disease Models, Animal; Dopaminergic Neurons; Fibroblast Growth Factor 2; Glial Fibrillary Acidic Protein; Male; Neostriatum; Neuroprotective Agents; Oxidopamine; Parkinson Disease; PC12 Cells; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Substantia Nigra; Tyrosine 3-Monooxygenase | 2015 |
Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Male; Mice; Mice, Inbred C57BL; Motor Activity; Muscle Strength; Oxidopamine; Parkinson Disease; Protein Kinase Inhibitors; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2014 |
Treatment of camptocormia with continuous subcutaneous infusions of apomorphine: 1-year prospective pilot study.
Topics: Aged; Apomorphine; Dopamine Agonists; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Muscular Atrophy, Spinal; Parkinson Disease; Pilot Projects; Prospective Studies; Spinal Curvatures; Treatment Outcome | 2015 |
Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Conditioning, Operant; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Functional Laterality; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2014 |
A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Habenula; Homovanillic Acid; Male; Medial Forebrain Bundle; Neurosurgery; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2014 |
Neuroprotection by 6-(methylsulfinyl)hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinson׳s disease.
Topics: Animals; Apomorphine; Apoptosis; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Glutathione Reductase; Glutathione Transferase; Isothiocyanates; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neostriatum; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Rotarod Performance Test; Rotation; Substantia Nigra; Tyrosine 3-Monooxygenase | 2014 |
Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Cost-Benefit Analysis; Deep Brain Stimulation; Drug Administration Schedule; Gels; Germany; Humans; Injections, Subcutaneous; Levodopa; Markov Chains; Models, Econometric; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years | 2015 |
A rat model of striatonigral degeneration generated by simultaneous injection of 6-hydroxydopamine into the medial forebrain bundle and quinolinic acid into the striatum.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Glucose; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Quinolinic Acid; Rats; Rats, Wistar; Striatonigral Degeneration; Touch | 2014 |
Therapeutic effects of GM1 on Parkinson's disease in rats and its mechanism.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Female; G(M1) Ganglioside; Gene Expression Regulation; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; RNA, Messenger; Stereotyped Behavior | 2016 |
EMG activity and neuronal activity in the internal globus pallidus (GPi) and their interaction are different between hemiballismus and apomorphine induced dyskinesias of Parkinson's disease (AID).
Topics: Action Potentials; Adult; Aged; Apomorphine; Arm; Dyskinesias; Electromyography; Globus Pallidus; Humans; Intraoperative Period; Male; Microelectrodes; Movement; Muscle, Skeletal; Parkinson Disease | 2015 |
Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
Topics: Adrenergic Agents; Animals; Apomorphine; Brain; Carbon Radioisotopes; Disease Models, Animal; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Functional Laterality; Longitudinal Studies; Magnetic Resonance Imaging; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Protein Binding; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Tetrabenazine | 2015 |
Continuous levodopa infusion is better—for now.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Dopamine transporter single-photon emission computerized tomography supports diagnosis of akinetic crisis of parkinsonism and of neuroleptic malignant syndrome.
Topics: Aged; Apomorphine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Lewy Body Disease; Male; Neuroleptic Malignant Syndrome; Parkinson Disease; Prospective Studies; Tomography, Emission-Computed, Single-Photon | 2015 |
Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Chalcone; Disease Models, Animal; Levodopa; Male; Motor Activity; Olfaction Disorders; Oxidopamine; Parkinson Disease; Quinones; Rats; Receptors, Dopamine D3; Time Factors | 2015 |
PET Imaging of Serotonin Transporters With 4-[(18)F]-ADAM in a Parkinsonian Rat Model With Porcine Neural Xenografts.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Male; Nerve Degeneration; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins; Substantia Nigra; Swine; Transplantation, Heterologous | 2016 |
Remote control of apomorphine infusion rate in Parkinson's disease: Real-time dose variations according to the patients' motor state. A proof of concept.
Topics: Aged; Apomorphine; Dopamine Agonists; Female; Humans; Infusion Pumps, Implantable; Male; Middle Aged; Parkinson Disease; Pilot Projects; Telemedicine | 2015 |
Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Gene Expression Regulation; Indoles; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neurokinin-1 Receptor Antagonists; Oxidopamine; Parkinson Disease; Piperidines; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 2015 |
Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: Animals; Apomorphine; Benserazide; Combined Modality Therapy; Drug Combinations; Glial Fibrillary Acidic Protein; Glutathione Peroxidase; Hyperbaric Oxygenation; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2015 |
Hypericum Perforatum Hydroalcoholic Extract Mitigates Motor Dysfunction and is Neuroprotective in Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson's Disease.
Topics: Animals; Apomorphine; Catalase; Corpus Striatum; Disease Models, Animal; Ethanol; Glutathione; Hypericum; Male; Malondialdehyde; Mitogen-Activated Protein Kinases; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Plant Extracts; Rats, Wistar; Reaction Time; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase; Water | 2016 |
Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's Disease in the UK and Germany.
Topics: Antiparkinson Agents; Apomorphine; Humans; Parkinson Disease | 2015 |
Reply: Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's Disease in the UK and Germany.
Topics: Antiparkinson Agents; Apomorphine; Humans; Parkinson Disease | 2015 |
Antagonism of quercetin against tremor induced by unilateral striatal lesion of 6-OHDA in rats.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Male; Molecular Structure; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Quercetin; Rats; Rats, Sprague-Dawley; Tremor | 2016 |
Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Apomorphine; Female; Hallucinations; Humans; Infusions, Subcutaneous; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2016 |
[Update on Current Care Guideline: Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Dopamine Agonists; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic | 2016 |
Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.
Topics: Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Female; Follow-Up Studies; France; Humans; Infusion Pumps; Infusions, Subcutaneous; Male; Parkinson Disease; Prospective Studies; Quality of Life; Treatment Outcome | 2016 |
Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?
Topics: Aged; Aged, 80 and over; Amyloid beta-Peptides; Apomorphine; Brain; Dopamine Agonists; Female; Humans; Male; Parkinson Disease | 2016 |
Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.
Topics: Aging; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease | 2016 |
Placebos: Honest fakery.
Topics: Apomorphine; Chronic Pain; Conditioning, Psychological; Dopamine; Endocannabinoids; Endorphins; Humans; Irritable Bowel Syndrome; Magnetic Resonance Imaging; Parkinson Disease; Placebo Effect; Placebos; Prostaglandins; Receptors, Opioid; Self Report | 2016 |
Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Catalepsy; Disease Models, Animal; Dopamine Agonists; Forelimb; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Transfection | 2016 |
Choosing an Advanced Therapy in Parkinson's Disease; is it an Evidence-Based Decision in Current Practice?
Topics: Apomorphine; Carbidopa; Caregivers; Clinical Decision-Making; Consumer Health Information; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Evidence-Based Practice; Humans; Levodopa; Neurologists; Parkinson Disease; Patient Preference; Qualitative Research | 2016 |
Evaluating the Efficacy of Nocturnal Continuous Subcutaneous Apomorphine Infusion in Sleep Disorders in Advanced Parkinson's Disease: The APO-NIGHT Study.
Topics: Aged; Aged, 80 and over; Apomorphine; Dopamine Agonists; Female; Follow-Up Studies; Humans; Infusions, Subcutaneous; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Sleep Wake Disorders | 2016 |
Involvement of microRNA-135a-5p in the Protective Effects of Hydrogen Sulfide Against Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3' Untranslated Regions; Animals; Apomorphine; Astrocytes; Base Sequence; Behavior, Animal; Cell Line; Dopamine; Humans; Hydrogen Sulfide; Male; Mice, Inbred C57BL; MicroRNAs; Models, Biological; Neostriatum; Parkinson Disease; Protective Agents; Protein Biosynthesis; rho-Associated Kinases; RNA, Messenger; Rotation | 2016 |
Higher levels of apomorphine and rotigotine prescribing reduce overall secondary healthcare costs in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Apomorphine; Drug Prescriptions; England; Health Care Costs; Humans; Middle Aged; Parkinson Disease; Practice Patterns, Physicians'; Tetrahydronaphthalenes; Thiophenes | 2016 |
Impact of the Chronic Omega-3 Fatty Acids Supplementation in Hemiparkinsonism Model Induced by 6-Hydroxydopamine in Rats.
Topics: Animals; Apomorphine; Biogenic Monoamines; Brain; Dietary Supplements; Disease Models, Animal; Fatty Acids, Omega-3; gamma-Aminobutyric Acid; Lipid Peroxidation; Male; Motor Activity; Nitrites; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2017 |
[Pharmacoeconomic study of the treatment of advanced Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Cost-Benefit Analysis; Deep Brain Stimulation; Economics, Pharmaceutical; Humans; Levodopa; Parkinson Disease; Quality-Adjusted Life Years | 2016 |
Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson's disease using wearable sensors.
Topics: Aged; Apomorphine; Circadian Rhythm; Dopamine Agonists; Female; Humans; Hypokinesia; Infusions, Subcutaneous; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome; Wearable Electronic Devices | 2016 |
Apomorphine pump in advanced Parkinson's disease: Effects on motor and nonmotor symptoms with brain metabolism correlations.
Topics: Aged; Apomorphine; Brain; Dopamine Agonists; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Motor Activity; Parkinson Disease; Positron-Emission Tomography; Severity of Illness Index; Statistics as Topic; Statistics, Nonparametric | 2017 |
Long-term adherence to apomorphine infusion in patients with Parkinson disease: a 10-year observational study.
Topics: Adult; Aged; Apomorphine; Cohort Studies; Dopamine Agonists; Female; Humans; Infusions, Intravenous; Male; Medication Adherence; Middle Aged; Parkinson Disease; Quality of Life; Time Factors | 2017 |
Dissociation between dopaminergic response and motor behavior following intrastriatal, but not intravenous, transplant of bone marrow mononuclear stem cells in a mouse model of Parkinson's disease.
Topics: Administration, Intravenous; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Green Fluorescent Proteins; Male; Medial Forebrain Bundle; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease; Rotarod Performance Test; Substantia Nigra | 2017 |
Comparative assessment of 6-[
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Fluorine Radioisotopes; Image Processing, Computer-Assisted; Male; Neostriatum; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Receptors, Presynaptic; Stereotyped Behavior; Tyrosine | 2017 |
Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Chromatography, High Pressure Liquid; Dependovirus; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Forelimb; Gene Expression; Gene Expression Profiling; Genetic Therapy; Genetic Vectors; Humans; Hydroxydopamines; Immunohistochemistry; Interleukin-10; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Substantia Nigra | 2008 |
Acute Akinesia, an unusual complication in Parkinson's Disease: a case report.
Topics: Acute Disease; Aged; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Creatine Kinase; Disease Progression; Dopamine Agonists; Drug Resistance; Fever; Humans; Male; Ondansetron; Parkinson Disease; Respiratory Insufficiency; Serotonin Antagonists; Syndrome; Treatment Outcome | 2008 |
Apomorphine-induced differences in cortical and striatal EEG and their glutamatergic mediation in 6-hydroxydopamine-treated rats.
Topics: Alpha Rhythm; Animals; Apomorphine; Behavior, Animal; Beta Rhythm; Cerebral Cortex; Corpus Striatum; Delta Rhythm; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agonists; Drug Interactions; Electroencephalography; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Osmotic Fragility; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Sympatholytics; Theta Rhythm | 2008 |
My husband's journey with Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Combined Modality Therapy; Deep Brain Stimulation; Drug Administration Schedule; Humans; Male; Parkinson Disease | 2008 |
Treatment of Parkinson's disease could be regulated by movement sensors: subcutaneous infusion of varying apomorphine doses according to the intensity of motor activity.
Topics: Apomorphine; Infusions, Subcutaneous; Monitoring, Physiologic; Motor Activity; Parkinson Disease | 2009 |
Crucial roles of MZF-1 in the transcriptional regulation of apomorphine-induced modulation of FGF-2 expression in astrocytic cultures.
Topics: Animals; Animals, Newborn; Apomorphine; Astrocytes; Cells, Cultured; Corpus Striatum; Dopamine; Dopamine Agonists; Fibroblast Growth Factor 2; Gene Expression Regulation; HeLa Cells; Humans; Kruppel-Like Transcription Factors; Neurons; Parkinson Disease; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Transcriptional Activation | 2009 |
Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease.
Topics: Amphetamine; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Dependovirus; Disease Models, Animal; Dopamine; Female; Gene Expression; Green Fluorescent Proteins; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Stereotyped Behavior; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2009 |
New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antibodies; Antiparkinson Agents; Apomorphine; Chemokine CX3CL1; Disease Models, Animal; DNA Nucleotidylexotransferase; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Regulation; Levodopa; Male; Mental Disorders; Nerve Tissue Proteins; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reaction Time; Stereotyped Behavior; Substantia Nigra; Tyrosine 3-Monooxygenase | 2011 |
Nicotine induces sensitization of turning behavior in 6-hydroxydopamine lesioned rats.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Electrochemistry; Functional Laterality; Ganglionic Stimulants; Male; Nicotine; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Time Factors | 2009 |
Histaminergic activity in a rodent model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Animals, Newborn; Apomorphine; Brain; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Exploratory Behavior; Histamine; Histamine Antagonists; Locomotion; Male; Mouth Abnormalities; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2009 |
Treatment of Parkinson's disease model mice with allogeneic embryonic stem cells: necessity of immunosuppressive treatment for sustained improvement.
Topics: Animals; Apomorphine; Corpus Striatum; Cyclosporine; Disease Models, Animal; Embryonic Stem Cells; Immunosuppressive Agents; Lymphocyte Activation; Male; Mice; Mice, Inbred Strains; Motor Activity; Oxidopamine; Parkinson Disease; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Tyrosine 3-Monooxygenase | 2009 |
Dopamine modulates default mode network deactivation in elderly individuals during the Tower of London task.
Topics: Aged; Analysis of Variance; Apomorphine; Brain Mapping; Dopamine; Dopamine Agonists; Female; Gyrus Cinguli; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Net; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Prefrontal Cortex; Problem Solving | 2009 |
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.
Topics: Animals; Apomorphine; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists | 2009 |
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.
Topics: Age Factors; Animals; Antiparkinson Agents; Apomorphine; Brain; Chromosomes, Artificial, Bacterial; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Gene Transfer Techniques; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Mice; Mice, Transgenic; Movement Disorders; Mutation, Missense; Neurons; Nomifensine; Parkinson Disease; Protein Serine-Threonine Kinases | 2009 |
The pragmatic use of apomorphine at the end of life.
Topics: Aged; Antiemetics; Antiparkinson Agents; Apomorphine; Blinking; Deglutition Disorders; Domperidone; Humans; Hypokinesia; Male; Nausea; Parkinson Disease; Terminal Care | 2009 |
Tolerance to apomorphine develops and reverses rapidly.
Topics: Apomorphine; Dopamine Agonists; Drug Tolerance; Humans; Parkinson Disease; Time Factors | 2010 |
Alterations of Hrd1 expression in various encephalic regional neurons in 6-OHDA model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Brain; Disease Models, Animal; Male; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Sympatholytics; Ubiquitin-Protein Ligases; Up-Regulation | 2010 |
Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease.
Topics: Aged; Apomorphine; Brain; Brain Mapping; Corpus Striatum; Dopamine; Dopamine Agonists; Female; Frontal Lobe; Humans; Male; Middle Aged; Motor Activity; Neural Pathways; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Psychomotor Performance; Task Performance and Analysis; Time Factors | 2010 |
Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; Female; Mice; Nerve Degeneration; Neural Pathways; Neuropsychological Tests; Oxidopamine; Parkinson Disease; Substantia Nigra; Sympatholytics | 2010 |
Apomorphine reduces subthalamic neuronal entropy in parkinsonian patients.
Topics: Action Potentials; Apomorphine; Deep Brain Stimulation; Entropy; Humans; Neurons; Parkinson Disease; Subthalamic Nucleus | 2010 |
Benefit from jejunal levodopa in a patient with apomorphine pump.
Topics: Antiparkinson Agents; Apomorphine; Humans; Infusion Pumps, Implantable; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease | 2011 |
Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Brain; Emulsifying Agents; Glycerides; Male; Nanoparticles; Parkinson Disease; Polyethylene Glycols; Rats; Rats, Wistar | 2011 |
Modeling Parkinson's disease genetics: altered function of the dopamine system in Adh4 knockout mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Amphetamine; Analysis of Variance; Animals; Apomorphine; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Locomotion; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Norepinephrine; Odorants; Parkinson Disease; Serotonin; Smell | 2011 |
Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Apomorphine; Brain; Cell Differentiation; Cell Line, Tumor; Cell Survival; Cytochromes; Disease Models, Animal; Dopamine; Enzyme Inhibitors; Female; Gene Expression Regulation; Green Fluorescent Proteins; Humans; Indoles; Male; MAP Kinase Kinase Kinase 5; Mice; Mice, Inbred C57BL; Middle Aged; Motor Activity; Neurodegenerative Diseases; Neuroprostanes; Oxidopamine; Parkinson Disease; Peroxiredoxins; Postmortem Changes; RNA, Small Interfering; Signal Transduction; Thioredoxins | 2011 |
Alterations of emotion, cognition and firing activity of the basolateral nucleus of the amygdala after partial bilateral lesions of the nigrostriatal pathway in rats.
Topics: Action Potentials; Adrenergic Agents; Amygdala; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Cognition; Corpus Striatum; Emotions; Excitatory Amino Acid Agonists; Humans; Ibotenic Acid; Male; Motor Activity; Neural Pathways; Neurons; Neuropsychological Tests; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2011 |
Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications.
Topics: Aged; Antiparkinson Agents; Apomorphine; Contraindications; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Infusions, Subcutaneous; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2012 |
Apomorphine-induced necrotic ulcers.
Topics: Antiparkinson Agents; Apomorphine; Humans; Male; Middle Aged; Necrosis; Parkinson Disease; Skin Diseases; Ulcer | 2011 |
Common and unique responses to dopamine agonist therapy and deep brain stimulation in Parkinson's disease: an H(2)(15)O PET study.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Brain; Brain Mapping; Deep Brain Stimulation; Dopamine Agonists; Female; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Parkinson Disease; Radionuclide Imaging; Treatment Outcome | 2012 |
Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Analysis of Variance; Animals; Apomorphine; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dopamine Agonists; Electrochemical Techniques; Exploratory Behavior; Female; Genotype; Homovanillic Acid; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Olfaction Disorders; Parkinson Disease; Smell; Time Factors | 2012 |
Apomorphine injections: predictors of initial common adverse events and long term tolerability.
Topics: Aged; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Time Factors | 2012 |
H(2)(15)O PET responses to deep brain stimulation.
Topics: Antiparkinson Agents; Apomorphine; Brain; Deep Brain Stimulation; Dopamine Agonists; Female; Humans; Male; Parkinson Disease; Radionuclide Imaging | 2012 |
Reply to letter to the editor "H(2)(15)O PET responses to deep brain stimulation".
Topics: Antiparkinson Agents; Apomorphine; Brain; Deep Brain Stimulation; Dopamine Agonists; Female; Humans; Male; Parkinson Disease; Radionuclide Imaging | 2013 |
Behavioral and histological analysis of a partial double-lesion model of parkinson-variant multiple system atrophy.
Topics: Animals; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopamine and cAMP-Regulated Phosphoprotein 32; Exploratory Behavior; Female; Functional Laterality; Gait Disorders, Neurologic; Motor Activity; Multiple System Atrophy; Oxidopamine; Parkinson Disease; Psychomotor Performance; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2012 |
Bladder dysfunction in advanced Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Denmark; Female; Humans; Linear Models; Lower Urinary Tract Symptoms; Male; Middle Aged; Nocturia; Parkinson Disease; Prevalence; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder; Urinary Bladder Diseases; Urination | 2012 |
Multiple subcutaneous abscesses and necroses due to apomorphine pump treatment.
Topics: Abscess; Aged; Apomorphine; Female; Humans; Infusion Pumps, Implantable; Necrosis; Parkinson Disease; Skin Diseases; Treatment Outcome | 2012 |
Drugs for treating Parkinson disease.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechols; Drug Combinations; Drugs, Generic; Humans; Indans; Levodopa; Nitriles; Parkinson Disease | 2012 |
Subthalamic activity during diphasic dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Cohort Studies; Deep Brain Stimulation; Disease Progression; Dyskinesias; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus; Theta Rhythm | 2012 |
Attempted suicide under high dose dopaminergic therapy including apomorphine.
Topics: Apomorphine; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Male; Middle Aged; Parkinson Disease; Suicide, Attempted | 2012 |
Anti-apoptotic and anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson's rat model.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Apomorphine; Apoptosis; Behavior, Animal; Benzodioxoles; Disease Models, Animal; Male; Oxidative Stress; Oxidopamine; Parkinson Disease; Piperidines; Polyunsaturated Alkamides; Rats; Rats, Wistar | 2013 |
Survival and functional restoration of human fetal ventral mesencephalon following transplantation in a rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Embryo, Mammalian; Female; Graft Survival; Humans; Mesencephalon; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Transplantation, Heterologous; Tyrosine 3-Monooxygenase | 2013 |
Amelioration of rotenone-induced dopaminergic cell death in the striatum by oxytocin treatment.
Topics: Animals; Apomorphine; Behavior, Animal; Body Weight; Cell Death; Dopaminergic Neurons; Male; Neostriatum; Oxytocin; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotenone | 2012 |
Is nicotine protective against Parkinson's disease? An experimental analysis.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine D2 Receptor Antagonists; Dopamine Uptake Inhibitors; Interneurons; Male; Nerve Tissue Proteins; Neuroprotective Agents; Nicotine; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Substantia Nigra | 2012 |
Neural stem cells transplanted in a mouse model of Parkinson's disease differentiate to neuronal phenotypes and reduce rotational deficit.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Cell Differentiation; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Embryo, Mammalian; GABAergic Neurons; Graft Survival; Green Fluorescent Proteins; Membrane Proteins; Mice; Mice, Inbred Strains; Mice, Transgenic; Nerve Tissue Proteins; Neural Stem Cells; Neurons; Oxidopamine; Parkinson Disease; Substantia Nigra; Tubulin | 2012 |
[Presentation].
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Humans; Parkinson Disease | 2012 |
[Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
Topics: Adrenal Cortex Hormones; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Cholinesterase Inhibitors; Combined Modality Therapy; Disease Susceptibility; Dopamine Agonists; Drug Eruptions; Hallucinations; Humans; Infusions, Subcutaneous; Mental Disorders; Parkinson Disease; Physical Therapy Modalities; Psychomotor Agitation; Psychoses, Substance-Induced; Severity of Illness Index; Sleep Wake Disorders | 2012 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors; Tyrosine 3-Monooxygenase | 2013 |
BDNF receptor blockade hinders the beneficial effects of exercise in a rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Apomorphine; Carbazoles; Corpus Striatum; Disease Models, Animal; Enzyme Inhibitors; Exercise Test; Exercise Therapy; Gene Expression Regulation; Indole Alkaloids; Male; Oxidopamine; Parkinson Disease; Putamen; Rats; Rats, Wistar; Receptor, trkB; Stereotyped Behavior; Time Factors; Tyrosine 3-Monooxygenase | 2013 |
Apomorphine for the treatment of refractory motor fluctuations in late stage Parkinson's disease: an old drug revisited.
Topics: Apomorphine; Dopamine Agonists; Female; Humans; Male; Parkinson Disease | 2013 |
Partial loss of dopaminergic neurons in the substantia nigra, ventrotegmental area and the retrorubral area -- model of the early beginning of Parkinson's symptomatology?
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Dopamine; Dopamine Agonists; Male; Maze Learning; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Red Nucleus; Substantia Nigra; Swimming; Tegmentum Mesencephali | 2002 |
Acute dopaminergic challenge tests to assess postural/kinetic tremor of different origin: a case report.
Topics: Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Essential Tremor; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Posture; Receptors, Dopamine | 2002 |
Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2002 |
Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine.
Topics: Aged; Antiparkinson Agents; Apomorphine; Combined Modality Therapy; Dominance, Cerebral; Dose-Response Relationship, Drug; Drug Administration Schedule; Electric Stimulation Therapy; Electrodes, Implanted; Humans; Injections, Subcutaneous; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2003 |
Perfusion-weighted dynamic susceptibility (DSC) MRI: basal ganglia hemodynamic changes after apomorphine in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Basal Ganglia; Cerebrovascular Circulation; Dopamine Agonists; Functional Laterality; Humans; Magnetic Resonance Imaging; Parkinson Disease; Regional Blood Flow | 2002 |
Dopaminergic modulation of visual-spatial working memory in Parkinson's disease.
Topics: Apomorphine; Cognition; Dopamine; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Memory; Middle Aged; Neuropsychological Tests; Parkinson Disease; Task Performance and Analysis; Visual Perception | 2003 |
[Apomorphine hyperpigmentation].
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Aged; Antigens, CD; Antiparkinson Agents; Apomorphine; Diagnosis, Differential; Drug Eruptions; Humans; Hyperpigmentation; Injections, Subcutaneous; Langerhans Cells; Male; Melanins; Melanocytes; Melanoma; Membrane Glycoproteins; Oxidation-Reduction; Parkinson Disease; Skin | 2003 |
The effect of apomorphine administration on smooth pursuit ocular movements in early Parkinsonian patients.
Topics: Adult; Aged; Analysis of Variance; Apomorphine; Electrooculography; Female; Humans; Male; Middle Aged; Parkinson Disease; Pursuit, Smooth | 2003 |
[Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
Topics: Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors | 2003 |
Sleep attacks with apomorphine.
Topics: Antiparkinson Agents; Apomorphine; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Narcolepsy; Parkinson Disease; Polysomnography | 2002 |
Behavioral/neurophysiological investigation of effects of combining a quinolinic acid entopeduncular lesion with a fetal mesencephalic tissue transplant in striatum of the 6-OHDA hemilesioned rat.
Topics: Amphetamine; Animals; Apomorphine; Brain Diseases; Brain Tissue Transplantation; Corpus Striatum; Dopamine Agonists; Dopamine Uptake Inhibitors; Electrophysiology; Entopeduncular Nucleus; Fetal Tissue Transplantation; Fetus; Functional Laterality; Immunohistochemistry; Male; Mesencephalon; Models, Animal; Motor Activity; Neurons; Parkinson Disease; Quinolinic Acid; Rats; Tyrosine 3-Monooxygenase | 2003 |
EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adrenergic Agents; Animals; Apomorphine; Behavior, Animal; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agonists; Drug Interactions; Electroencephalography; Excitatory Amino Acid Antagonists; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2003 |
Pretreatment with a water-based surfactant formulation affects transdermal iontophoretic delivery of R-apomorphine in vitro.
Topics: Adjuvants, Pharmaceutic; Administration, Cutaneous; Apomorphine; Delayed-Action Preparations; Drug Delivery Systems; In Vitro Techniques; Iontophoresis; Parkinson Disease; Pharmaceutical Solutions; Polidocanol; Polyethylene Glycols; Skin Absorption; Surface-Active Agents | 2003 |
Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent?
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Agents; Animals; Apomorphine; Behavior, Animal; Citalopram; Dopamine; Fenclonine; Functional Laterality; Hallucinogens; Male; Medial Forebrain Bundle; Models, Animal; N-Methyl-3,4-methylenedioxyamphetamine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotation; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2003 |
Apomorphine reduces BOLD signal in fMRI during voluntary movement in Parkinsonian patients.
Topics: Antiparkinson Agents; Apomorphine; Brain; Dopamine Agonists; Fingers; Humans; Magnetic Resonance Imaging; Movement; Parkinson Disease | 2003 |
High frequency stimulation of the subthalamic nucleus has beneficial antiparkinsonian effects on motor functions in rats, but less efficiency in a choice reaction time task.
Topics: Adrenergic Agents; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Apomorphine; Catalepsy; Choice Behavior; Cognition; Conditioning, Operant; Electric Stimulation Therapy; Functional Laterality; Haloperidol; Male; Models, Animal; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Long-Evans; Reaction Time; Subthalamic Nucleus | 2003 |
[Studies of mechanism of action of apormorphine on Parkinson's tremor].
Topics: Apomorphine; Humans; Parkinson Disease; Parkinsonian Disorders; Tremor | 1953 |
Problems in the treatment of Parkinsonism by analeptics.
Topics: Amphetamine; Amphetamines; Apomorphine; Central Nervous System Stimulants; Humans; Parkinson Disease; Parkinsonian Disorders; Pentylenetetrazole | 1956 |
Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
Topics: Aged; Apomorphine; Cognition Disorders; Dopamine Agonists; Drug Administration Routes; Drug Administration Schedule; Humans; Levodopa; Longitudinal Studies; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales | 2003 |
Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Apomorphine; Arousal; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Polysomnography; Restless Legs Syndrome; Sleep; Sleep Apnea Syndromes | 2003 |
Apomorphine attenuates 6-hydroxydopamine-induced apoptotic cell death in SH-SY5Y cells.
Topics: Antiparkinson Agents; Apomorphine; Apoptosis; Cell Line, Tumor; DNA Fragmentation; Glutathione; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Reactive Oxygen Species; Sympatholytics | 2003 |
Uptake of 6-[18F]fluoro-L-dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Behavior, Animal; Brain; Brain Mapping; Central Nervous System Stimulants; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine Agonists; Functional Laterality; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Propionates; Radioligand Assay; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2004 |
[Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase].
Topics: Antiparkinson Agents; Apomorphine; Costs and Cost Analysis; Dopamine Agonists; Drug Costs; Electric Stimulation Therapy; Health Resources; Health Surveys; Hospital Costs; Humans; Infusion Pumps; Insurance, Health, Reimbursement; Italy; Levodopa; National Health Programs; Outpatient Clinics, Hospital; Parkinson Disease | 2003 |
The effect of apomorphine and that of adrenalin, on the tremor of Parkinson's disease.
Topics: Apomorphine; Epinephrine; Humans; Parkinson Disease; Tremor | 1951 |
Apomorphine in Parkinson's disease.
Topics: Apomorphine; Humans; Parkinson Disease | 1951 |
[Improvement in swallowing difficulties treated by subcutaneous apomorphine infusion after deep brain stimulation in Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Brain; Deglutition; Electric Stimulation Therapy; Humans; Infusions, Parenteral; Male; Middle Aged; Parkinson Disease | 2004 |
Pharmacological and PET studies in patient's with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications.
Topics: Adult; Age of Onset; Aged; Apomorphine; Biological Transport; Corpus Striatum; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Parkinson Disease; Raclopride; Reaction Time; Tomography, Emission-Computed; Tritium | 2004 |
Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Behavioral Symptoms; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Interactions; Immunohistochemistry; Male; Motor Activity; Neurons; Neuropeptides; Oxidopamine; Parkinson Disease; Pituitary Adenylate Cyclase-Activating Polypeptide; Rats; Rats, Wistar; Rotation; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2004 |
Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus.
Topics: Action Potentials; Apomorphine; Confidence Intervals; Electrodes, Implanted; Humans; Neurons; Odds Ratio; Parkinson Disease; Placebo Effect; Subthalamic Nucleus | 2004 |
New drug helps Parkinson's "off" periods.
Topics: Antiparkinson Agents; Apomorphine; Humans; Parkinson Disease | 2004 |
PET studies and physiopathology of motor fluctuations in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Humans; Levodopa; Movement; Parkinson Disease; Tetrabenazine; Tomography, Emission-Computed | 2004 |
New drugs and dosage forms.
Topics: Adolescent; Anti-Infective Agents; Antitrichomonal Agents; Apomorphine; Child; Contraindications; Diarrhea; Dopamine Agonists; Dosage Forms; Drug Administration Schedule; Humans; Parkinson Disease; Rifamycins; Rifaximin; Tinidazole | 2004 |
Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Therapy, Combination; Dyskinesias; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Phenethylamines; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2004 |
Worsened motor test performance following acute apomorphine injection in previously untreated patients with Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Apomorphine; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 2004 |
Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's disease.
Topics: Action Potentials; Adult; Aged; Alpha Rhythm; Antiparkinson Agents; Apomorphine; Beta Rhythm; Biological Clocks; Dose-Response Relationship, Drug; Electric Stimulation Therapy; Electrodes, Implanted; Humans; Levodopa; Middle Aged; Neurons; Orphenadrine; Parkinson Disease; Periodicity; Subthalamic Nucleus | 2004 |
The cytotoxic activity of lactoperoxidase: enhancement and inhibition by neuroactive compounds.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apomorphine; Aspirin; Brain; Catalysis; Cell Line, Tumor; Dogs; Dopamine; Erythrocytes; Free Radicals; Herbicides; Humans; Lactoperoxidase; Neurons; Parkinson Disease; Peroxidase; Pyridinium Compounds; Spectrophotometry; Time Factors; Uric Acid | 2004 |
Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease.
Topics: Aged; Apomorphine; Cognition Disorders; Deep Brain Stimulation; Dopamine Agonists; Electrodes, Implanted; Female; Functional Laterality; Humans; Injections, Subcutaneous; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Time Factors | 2004 |
Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Dialysis; Disease Models, Animal; Dopamine; Drug Interactions; Electrochemistry; Hydroxybenzoates; Immunohistochemistry; Male; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Wistar; Stereotyped Behavior; Time Factors; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2004 |
Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Brain; Brain Mapping; Cell Count; Disease Models, Animal; Dopamine; Electric Stimulation; Forelimb; Functional Laterality; Immunohistochemistry; Male; Movement; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Long-Evans; Rotation; Sympatholytics; Tyrosine 3-Monooxygenase | 2004 |
Diagnostic and therapeutic value of apomorphine in Parkinsonian patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2004 |
Apomorphine (Apokyn) for advanced Parkinson's Disease.
Topics: Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Humans; Nausea; Parkinson Disease; Vomiting | 2005 |
Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Eruptions; Female; Humans; Hypereosinophilic Syndrome; Middle Aged; Panniculitis; Parkinson Disease | 2005 |
Postural stability of Parkinson's disease patients is improved by decreasing rigidity.
Topics: Antiparkinson Agents; Apomorphine; Humans; Middle Aged; Muscle Rigidity; Parkinson Disease; Posture | 2005 |
Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease.
Topics: Amino Acid Sequence; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Chromatography, Liquid; Corpus Striatum; Disease Models, Animal; Dynorphins; Mass Spectrometry; Microdialysis; Molecular Sequence Data; Oxidopamine; Parkinson Disease; Peptide Fragments; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization | 2005 |
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Mice; Mice, Knockout; Movement Disorders; Parkinson Disease; Patch-Clamp Techniques; Protein Interaction Mapping; Protein Structure, Tertiary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, G-Protein-Coupled; Recombinant Fusion Proteins; Reserpine; RGS Proteins; Subcellular Fractions; Sulpiride; Transfection | 2005 |
Levodopa in the treatment of Parkinson's disease: current controversies.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Lisuride; Parkinson Disease; Pergolide | 2005 |
Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells.
Topics: Animals; Apomorphine; Behavior, Animal; Caspase 3; Caspases; Cell Death; Cell Line, Tumor; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Immunophilins; Male; Motor Activity; Nerve Degeneration; Neuroblastoma; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Random Allocation; Rats; Rats, Wistar; Tacrolimus | 2005 |
Acute akinesia in Parkinson disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Akinetic Mutism; Apomorphine; Body Temperature; Cohort Studies; Comorbidity; Dopamine Agents; Dose-Response Relationship, Drug; Drug Resistance; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Mortality; Neuroleptic Malignant Syndrome; Parkinson Disease; Prospective Studies; Recovery of Function; Treatment Failure | 2005 |
10 questions about using apomorphine for Parkinson disease.
Topics: Antiemetics; Antiparkinson Agents; Apomorphine; Benzamides; Humans; Injections, Intravenous; Parkinson Disease; Recurrence; Vomiting | 2005 |
Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Cell Count; Disease Models, Animal; Drug Interactions; Exploratory Behavior; Female; Functional Laterality; Immunohistochemistry; Linear Models; Medial Forebrain Bundle; Mice; Mice, Inbred CBA; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Predictive Value of Tests; Psychomotor Performance; Rotarod Performance Test; Rotation; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2005 |
Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cell Count; Cell Line; Corpus Striatum; Cricetinae; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Functional Laterality; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Immunohistochemistry; Nerve Growth Factors; Neurons; Oxidopamine; Parkinson Disease; Rats; Rotation; Simplexvirus; Substantia Nigra | 2005 |
The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis.
Topics: Adrenergic Agents; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine Agonists; Electromyography; Extremities; Female; Functional Laterality; Locomotion; Muscle, Skeletal; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Inbred Lew; Stereotyped Behavior; Substantia Nigra | 2005 |
Transplants of neurosphere cell suspensions from aged mice are functional in the mouse model of Parkinson's.
Topics: Aging; Amphetamine; Animals; Apomorphine; Astrocytes; Behavior, Animal; Behavioral Symptoms; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopamine Uptake Inhibitors; Functional Laterality; Glial Fibrillary Acidic Protein; Green Fluorescent Proteins; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurofilament Proteins; Neurons; Oxidopamine; Parkinson Disease; Stem Cell Transplantation; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
Akinetic crisis caused by rectus sheath hematoma and acute anemia due to subcutaneous administration of apomorphine.
Topics: Acute Disease; Aged; Anemia; Antiparkinson Agents; Apomorphine; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Hematoma; Humans; Hypokinesia; Infusions, Parenteral; Leukocytosis; Male; Parkinson Disease; Pneumonia, Pneumococcal; Radiography; Rectus Abdominis | 2006 |
Drug for "off" episodes of Parkinson's--effective but limited.
Topics: Antiparkinson Agents; Apomorphine; Humans; Parkinson Disease | 2005 |
Olfactory ensheathing glial co-grafts improve functional recovery in rats with 6-OHDA lesions.
Topics: Amphetamine; Animals; Apomorphine; Astrocytes; Behavior, Animal; Brain; Cell Culture Techniques; Cell Transplantation; Dopamine; Immunohistochemistry; Male; Mesencephalon; Models, Animal; Myelin Sheath; Nerve Regeneration; Neuroglia; Olfactory Bulb; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Recovery of Function | 2005 |
Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.
Topics: Apomorphine; Catechol O-Methyltransferase Inhibitors; Catechols; Gas Chromatography-Mass Spectrometry; Humans; Nitriles; Parkinson Disease; Reproducibility of Results | 2005 |
Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; beta-Galactosidase; Central Nervous System Stimulants; Conditioning, Operant; Dopamine Agonists; Female; Functional Laterality; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Humans; Immunohistochemistry; Lentivirus; Movement; Parkinson Disease; Rats; Reaction Time; Tyrosine 3-Monooxygenase | 2005 |
Improved assay for R(-)-apomorphine with application to clinical pharmacokinetic studies in Parkinson's disease.
Topics: Apomorphine; Ascorbic Acid; Chromatography, High Pressure Liquid; Drug Stability; Freezing; Humans; Parkinson Disease; Reproducibility of Results; Sensitivity and Specificity | 2006 |
Research update on Parkinson's disease and other movement disorders: highlights from the Eighteenth Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders, October 3, 2004, Toronto, Ontario, Canad
Topics: Antiparkinson Agents; Apomorphine; Glial Cell Line-Derived Neurotrophic Factor; Humans; Parkinson Disease; Tremor | 2005 |
Further validation of the corridor task for assessing deficit and recovery in the hemi-Parkinsonian rat: restoration of bilateral food retrieval by dopamine receptor agonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Feeding Behavior; Functional Laterality; Homovanillic Acid; Oxidopamine; Parkinson Disease; Rats; Recovery of Function; Reproducibility of Results | 2006 |
[Effective therapy option in the late phase of Parkinson disease: subcutaneous apomorphine].
Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Disease Progression; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Neurologic Examination; Parkinson Disease | 2005 |
Fractal characteristics of human Parkinsonian neuronal spike trains.
Topics: Apomorphine; Dopamine Agonists; Fractals; Globus Pallidus; Humans; Membrane Potentials; Neurons; Parkinson Disease | 2006 |
Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
Topics: Aged; Antiparkinson Agents; Apomorphine; Cognition Disorders; Deep Brain Stimulation; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus | 2006 |
Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Circadian Rhythm; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Parkinson Disease; Sleep Initiation and Maintenance Disorders | 2006 |
[New types of dopaminergic treatment. The Danish Society of Movement Disorders].
Topics: Antiparkinson Agents; Apomorphine; Delayed-Action Preparations; Dopamine Agonists; Duodenum; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Parkinson Disease; Tablets | 2006 |
[Utility of the study of the vegetative nervous system in the differential diagnosis between Parkinson's disease and multiple system atrophy].
Topics: Aged; Antiparkinson Agents; Apomorphine; Autonomic Nervous System; Autonomic Nervous System Diseases; Diagnosis, Differential; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Norepinephrine; Parkinson Disease | 2006 |
A cluster-based quantitative procedure in an fMRI study of Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Cluster Analysis; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Parkinson Disease; Psychomotor Performance | 2006 |
Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease.
Topics: Action Potentials; Adult; Aged; Antiparkinson Agents; Apomorphine; Biological Clocks; Combined Modality Therapy; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Electrodes, Implanted; Humans; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2006 |
Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Cell Count; Cell Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Interactions; Female; Glial Cell Line-Derived Neurotrophic Factor; Green Fluorescent Proteins; Motor Activity; Neurons; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Recovery of Function; Rotarod Performance Test; Transplants; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2006 |
Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Apomorphine; Combined Modality Therapy; Deep Brain Stimulation; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Humans; Hypokinesia; Infusions, Intravenous; Injections, Subcutaneous; Levodopa; Middle Aged; Neurologic Examination; Optic Atrophy; Parkinson Disease | 2006 |
Sensitive quantification of apomorphine in human plasma using a LC-ESI-MS-MS method.
Topics: Apomorphine; Chromatography, High Pressure Liquid; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Parkinson Disease; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2006 |
Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats.
Topics: Animals; Apomorphine; Brain; Brain Diseases; Caffeine; Disease Models, Animal; Dopamine Agents; Male; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2006 |
Sexually dimorphic postural adjustments during vertical behaviour are altered in a unilateral 6-OHDA rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Biomechanical Phenomena; Disease Models, Animal; Dopamine Agonists; Female; Functional Laterality; Immunohistochemistry; Male; Movement; Oxidopamine; Parkinson Disease; Posture; Psychomotor Performance; Rats; Rats, Long-Evans; Rotarod Performance Test; Sex Characteristics; Sex Factors; Tyrosine 3-Monooxygenase | 2006 |
Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
Topics: alpha-Synuclein; Amphetamine; Animals; Apomorphine; Behavior, Animal; Benserazide; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Parkinson Disease; Stereotypic Movement Disorder | 2006 |
Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Apomorphine; Behavior, Animal; Cell Count; Cell Line; Disease Models, Animal; Dopamine; Male; Motor Activity; Nerve Tissue Proteins; Neuroprotective Agents; Neurturin; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Stem Cells; Tyrosine 3-Monooxygenase | 2007 |
[Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Humans; Infusions, Parenteral; Parkinson Disease; Treatment Outcome | 2006 |
Addiction to apomorphine: a clinical case-centred discussion.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Female; Humans; Middle Aged; Morphine Dependence; Parkinson Disease | 2006 |
Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Binding, Competitive; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Female; Growth Hormone; Humans; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Substantia Nigra; Tomography, Emission-Computed, Single-Photon; Tropanes | 2007 |
Internal pallidal neuronal activity during mild drug-related dyskinesias in Parkinson's disease: decreased firing rates and altered firing patterns.
Topics: Aged; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electric Stimulation; Electromyography; Electrophysiology; Female; Globus Pallidus; Humans; Intraoperative Period; Male; Microelectrodes; Middle Aged; Models, Neurological; Models, Statistical; Neurons; Neurosurgical Procedures; Parkinson Disease; Poisson Distribution; Postoperative Period | 2007 |
Large stem cell grafts could lead to erroneous interpretations of behavioral results?
Topics: Animals; Apomorphine; Cell Survival; Embryonic Stem Cells; Humans; Motor Activity; Neurons; Parkinson Disease; Rats; Receptors, Dopamine; Stem Cell Transplantation | 2007 |
Large stem cell grafts could lead to erroneous interpretations of behavioral results?
Topics: Animals; Apomorphine; Cell Survival; Embryonic Stem Cells; Humans; Motor Activity; Neurons; Parkinson Disease; Rats; Receptors, Dopamine; Stem Cell Transplantation | 2007 |
Effects of engrafted neural stem cells derived from GFP transgenic mice in Parkinson's diseases rats.
Topics: Animals; Animals, Newborn; Antiparkinson Agents; Apomorphine; Behavior, Animal; Disease Models, Animal; Glial Fibrillary Acidic Protein; Green Fluorescent Proteins; Mice; Mice, Transgenic; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Stem Cells; Stereotyped Behavior; Sympatholytics; Time Factors; Transplantation, Heterologous; Tyrosine 3-Monooxygenase | 2007 |
Recurrent atrial fibrillation after subcutaneous apomorphine.
Topics: Aged; Antiparkinson Agents; Apomorphine; Atrial Fibrillation; Electrocardiography; Humans; Injections, Subcutaneous; Male; Parkinson Disease; Recurrence | 2008 |
[Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement].
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Contraindications; Drug Administration Schedule; Drug Therapy, Combination; Humans; Injections; Injections, Subcutaneous; Levodopa; Neurologic Examination; Parkinson Disease | 2008 |
Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; alpha-Synuclein; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine Agonists; Gene Expression Regulation; Gene Products, tat; Genetic Vectors; Green Fluorescent Proteins; Male; Motor Activity; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2008 |
Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures.
Topics: Amphetamine; Animals; Antioxidants; Apomorphine; Behavior, Animal; Cell Line, Tumor; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Humans; L-Lactate Dehydrogenase; Male; Motor Activity; Neuroblastoma; Oxidopamine; Parkinson Disease; Quercetin; Rats; Rats, Wistar; Substantia Nigra; Tetrazolium Salts; Thiazoles; Tyrosine 3-Monooxygenase | 2008 |
Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Female; Follow-Up Studies; Gait; Humans; Infusion Pumps; Long-Term Care; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2008 |
Dopamine agonists and Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Brain; Bromocriptine; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Neurons; Parkinson Disease; Pergolide; Piribedil; Receptors, Dopamine | 1984 |
Imaging CNS receptors: the dopaminergic system.
Topics: Animals; Antipsychotic Agents; Apomorphine; Binding Sites; Brain; Carbon Radioisotopes; Deoxyglucose; Dyskinesia, Drug-Induced; Fluorine; Haloperidol; Humans; Parkinson Disease; Radioisotopes; Receptors, Dopamine; Schizophrenia; Spiperone; Tomography, Emission-Computed; Tritium | 1984 |
Brain receptor changes in Parkinson's disease in relation to the disease process and treatment.
Topics: Apomorphine; Brain; Bromocriptine; Humans; Levodopa; Parkinson Disease; Prolactin; Receptors, Dopamine; Receptors, Opioid; Thyrotropin-Releasing Hormone | 1983 |
Auto- and postsynaptic dopamine receptors in the central nervous system.
Topics: Animals; Apomorphine; Central Nervous System; Corpus Striatum; Dopamine Antagonists; Humans; Parkinson Disease; Rats; Receptors, Dopamine; Schizophrenia; Substantia Nigra; Synaptic Transmission | 1984 |
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomotor activity without producing a nigrostriatal lesion in the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Corpus Striatum; Depression, Chemical; Disease Models, Animal; Male; Motor Activity; Neural Pathways; Parkinson Disease; Pyridines; Rats; Rats, Inbred Strains; Substantia Nigra | 1984 |
Neuropsychiatric implications of drugs acting on dopamine receptors: the effect of apomorphine.
Topics: Animals; Apomorphine; Bipolar Disorder; Blood-Brain Barrier; Electroencephalography; Humans; Huntington Disease; Motor Activity; Parkinson Disease; Rats; Receptors, Dopamine; Schizophrenia; Sleep | 1980 |
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration.
Topics: Acetylcholine; Adult; Aged; Antiparkinson Agents; Apomorphine; Brain; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Physostigmine; Time Factors | 1984 |
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Prolactin; Receptors, Dopamine; Selegiline; Tremor | 1980 |
Parkinson's disease: low density and presynaptic location of D3 dopamine receptors.
Topics: Aged; Apomorphine; Caudate Nucleus; Dopamine; Humans; Middle Aged; Neural Pathways; Parkinson Disease; Putamen; Receptors, Dopamine; Substantia Nigra | 1981 |
Parkinson's disease: new treatments.
Topics: Acetylcholine; Amantadine; Apomorphine; Bromocriptine; Carbidopa; Counseling; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Manifestations; Parkinson Disease; Physical Therapy Modalities; Receptors, Dopamine; Thalamus | 1981 |
Predictors for improvement after electroconvulsive therapy in parkinsonian patients with on-off symptoms.
Topics: Aged; Apomorphine; Electroconvulsive Therapy; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Prolactin | 1981 |
Drugs acting on dopamine receptors: usefulness of a peripheral blocker in Parkinson's disease.
Topics: Apomorphine; Behavior; Benzimidazoles; Domperidone; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Parkinson Disease; Piperidines; Receptors, Dopamine | 1980 |
[Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Domperidone; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1995 |
Somatosensory evoked potentials at rest and during movement in Parkinson's disease: evidence for a specific apomorphine effect on the frontal N30 wave.
Topics: Aged; Aged, 80 and over; Apomorphine; Electroencephalography; Evoked Potentials, Somatosensory; Female; Frontal Lobe; Humans; Male; Middle Aged; Movement; Parkinson Disease; Reaction Time; Rest | 1994 |
Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.
Topics: Animals; Apomorphine; Autoradiography; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Mazindol; Neural Pathways; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 1995 |
Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat.
Topics: Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine; Forelimb; Parkinson Disease; Rats; Rats, Inbred Strains; Rotation | 1995 |
Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease.
Topics: Adenoviridae; Animals; Apomorphine; Behavior, Animal; beta-Galactosidase; Brain; Corpus Striatum; Denervation; Female; Gene Transfer Techniques; Genetic Vectors; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Recombination, Genetic; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 1994 |
Drug-licensing anomalies and Parkinson's disease.
Topics: Apomorphine; Drug Approval; Humans; Parkinson Disease; Sterilization | 1995 |
Early diagnosis of Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Facial Expression; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease | 1995 |
Median nerve somatosensory evoked potentials. Apomorphine-induced transient potentiation of frontal components in Parkinson's disease and in parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Electroencephalography; Evoked Potentials, Somatosensory; Female; Frontal Lobe; Humans; Male; Median Nerve; Middle Aged; Parietal Lobe; Parkinson Disease; Parkinson Disease, Secondary; Reaction Time | 1995 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphine; Brain Tissue Transplantation; Carbidopa; Dextroamphetamine; Disease Models, Animal; Dopamine; Dopamine Agonists; Ergolines; Female; Fetal Tissue Transplantation; Forelimb; Functional Laterality; Levodopa; Motor Activity; Movement Disorders; Norepinephrine; Oxidopamine; Parkinson Disease; Quinpirole; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Transplantation, Heterotopic | 1995 |
Parkinson's disease.
Topics: Apomorphine; Brain; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1995 |
Formulating apomorphine for Parkinson's disease.
Topics: Apomorphine; Drug Approval; Humans; Parkinson Disease; Sterilization; United Kingdom | 1995 |
[Treatment of Parkinsonism--apomorphine increases therapeutic arsenal].
Topics: Apomorphine; Humans; Parkinson Disease | 1994 |
[The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience].
Topics: Aged; Apomorphine; Diagnosis, Differential; Female; Humans; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary | 1994 |
Dose- and duration-dependent tolerance to rotational effects of apomorphine in a rat model of Parkinsonism.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Tolerance; Dyskinesia, Drug-Induced; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley | 1995 |
Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease.
Topics: Adrenal Medulla; Animals; Animals, Genetically Modified; Apomorphine; Astrocytes; Cells, Cultured; Disease Models, Animal; Male; Motor Activity; Neostriatum; Nerve Growth Factors; Parkinson Disease; Rats; Recombinant Proteins; Rotation; Transplantation, Heterotopic | 1994 |
Drug-licensing anomalies and Parkinson's disease.
Topics: Apomorphine; Clozapine; Drug Approval; Humans; Parkinson Disease; United Kingdom | 1995 |
Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance.
Topics: Administration, Cutaneous; Adult; Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Monitoring; Drug Tolerance; Humans; Infusion Pumps; Middle Aged; Parkinson Disease | 1995 |
Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters.
Topics: Administration, Intranasal; Adult; Aged; Apomorphine; Biological Availability; Creatinine; Drug Monitoring; Drug Therapy, Computer-Assisted; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Models, Biological; Models, Chemical; Parkinson Disease; Software; Tissue Distribution | 1994 |
Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.
Topics: Apomorphine; Brain; Functional Laterality; Humans; Levodopa; Motor Skills; Parkinson Disease | 1994 |
[Vesical sphincter disorders in Parkinson disease].
Topics: Aged; Aged, 80 and over; Apomorphine; Domperidone; Female; Humans; Male; Middle Aged; Parkinson Disease; Urinary Bladder Diseases; Urination Disorders; Urodynamics | 1993 |
Subcutaneous apomorphine infusion in Parkinson's disease: does it have a role?
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Apomorphine; Humans; Infusion Pumps; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 1994 |
[Akinetic crisis in Parkinson disease].
Topics: Aged; Aged, 80 and over; Apomorphine; Benserazide; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1994 |
Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
Topics: Apomorphine; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Half-Life; Humans; Levodopa; Middle Aged; Movement; Neuronal Plasticity; Parkinson Disease; Receptors, Dopamine; Severity of Illness Index | 1994 |
External and implanted pumps for apomorphine infusion in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Animals; Apomorphine; Female; Humans; Infusion Pumps, Implantable; Macaca fascicularis; Male; Middle Aged; Motor Activity; Parkinson Disease; Receptors, Dopamine | 1993 |
Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses.
Topics: Apomorphine; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Models, Biological; Motor Activity; Parkinson Disease | 1994 |
Apomorphine increases blood glucose concentrations in Parkinson's disease.
Topics: Aged; Apomorphine; Blood Glucose; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1994 |
Apomorphine and diphasic dyskinesia.
Topics: Aged; Apomorphine; Circadian Rhythm; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
[Subcutaneous apomorphine in the treatment of Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 1994 |
Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease.
Topics: Apomorphine; Cell Survival; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Neurons; Parkinson Disease; Reaction Time | 1994 |
Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.
Topics: Apomorphine; Dose-Response Relationship, Drug; Female; Functional Laterality; Humans; Levodopa; Male; Movement; Parkinson Disease; Time Factors | 1994 |
[Apomorphine test in Parkinson disease--dose and corresponding parameters].
Topics: Adult; Aged; Anthropometry; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1993 |
Relief of akinesia by apomorphine and cerebral metabolic changes in Parkinson's disease.
Topics: Aged; Apomorphine; Brain; Cerebral Cortex; Cerebrovascular Circulation; Corpus Striatum; Female; Glucose; Humans; Male; Parkinson Disease; Receptors, Dopamine; Tomography, Emission-Computed | 1993 |
Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
Topics: Adult; Aged; Apomorphine; Basal Ganglia; Benzamides; Binding Sites; Brain; Corpus Striatum; Female; Humans; Male; Middle Aged; Parkinson Disease; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1993 |
Parkinson's disease and somatosensory evoked potentials: apomorphine-induced transient potentiation of frontal components.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Evoked Potentials, Somatosensory; Female; Humans; Male; Middle Aged; Movement; Parkinson Disease | 1993 |
Effects of treatment on airway dynamics and respiratory muscle strength in Parkinson's disease.
Topics: Adult; Apomorphine; Female; Humans; Male; Middle Aged; Muscle Contraction; Parkinson Disease; Pulmonary Ventilation; Respiratory Mechanics; Respiratory Muscles | 1993 |
Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Female; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Ventral Tegmental Area | 1993 |
[The apomorphine test in Parkinson's disease: diagnostic value].
Topics: Apomorphine; Female; Humans; Injections, Subcutaneous; Male; Parkinson Disease; Receptors, Dopamine; Reproducibility of Results | 1993 |
[Injections of apomorphine: educational projects].
Topics: Apomorphine; Humans; Parkinson Disease; Patient Education as Topic; Self Administration | 1993 |
Effects of apomorphine and L-dopa on the parkinsonian bladder.
Topics: Aged; Aged, 80 and over; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reflex, Abnormal; Urinary Bladder | 1993 |
The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease.
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine; Substance Withdrawal Syndrome | 1993 |
[The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Contrast Media; Diagnosis, Differential; Dopamine D2 Receptor Antagonists; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Parkinson Disease; Pyrrolidines; Time Factors; Tomography, Emission-Computed, Single-Photon | 1993 |
Pharmacokinetics of apomorphine in parkinsonian patients.
Topics: Abdomen; Aged; Apomorphine; Biological Availability; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Thigh | 1993 |
Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
Topics: Aged; Apomorphine; Brain; Dopamine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Activity; Motor Cortex; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parkinson Disease; Regional Blood Flow; Somatosensory Cortex; Tomography, Emission-Computed, Single-Photon | 1993 |
IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Apomorphine; Benzamides; Corpus Striatum; Dopamine D2 Receptor Antagonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Pyrrolidines; Receptors, Dopamine D1; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1993 |
Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusion Pumps; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1993 |
Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.
Topics: Administration, Sublingual; Aged; Apomorphine; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease | 1993 |
Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
Topics: Adult; Aged; Apomorphine; Female; Follow-Up Studies; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1993 |
Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson's disease.
Topics: Administration, Sublingual; Adult; Aged; Apomorphine; Chromatography, High Pressure Liquid; Female; Humans; Male; Middle Aged; Parkinson Disease | 1993 |
Defecatory function in Parkinson's disease: response to apomorphine.
Topics: Aged; Anal Canal; Apomorphine; Defecation; Female; Humans; Male; Manometry; Middle Aged; Muscle, Smooth; Parkinson Disease; Rectum | 1993 |
[Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease].
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary | 1993 |
Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Lamotrigine; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Reserpine; Rotation; Stereotyped Behavior; Substantia Nigra; Sympatholytics; Triazines | 1995 |
Apomorphine can increase cutaneous inhibition of motor activity in Parkinson's disease.
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Electromyography; Female; Humans; Kinetics; Male; Middle Aged; Motor Activity; Parkinson Disease; Time Factors | 1996 |
[Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs].
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Brain; Contrast Media; Dopamine Agonists; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Parkinson Disease; Pyrrolidines; Tomography, Emission-Computed, Single-Photon | 1996 |
Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Topics: Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1996 |
Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Brain; Carbidopa; Drug Therapy, Combination; Female; Handwriting; Humans; Levodopa; Male; Microcomputers; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Signal Processing, Computer-Assisted; Treatment Outcome | 1996 |
Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
Topics: Administration, Sublingual; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Humans; Parkinson Disease; Pilot Projects | 1995 |
Changes in the amplitude of the N30 frontal component of SEPs during apomorphine test in parkinsonian patients.
Topics: Adult; Aged; Apomorphine; Electric Stimulation; Evoked Potentials, Somatosensory; Female; Frontal Lobe; Humans; Male; Median Nerve; Middle Aged; Parkinson Disease; Reaction Time | 1995 |
N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Case-Control Studies; Dopamine Agonists; Evoked Potentials, Somatosensory; Humans; Levodopa; Median Nerve; Middle Aged; Parkinson Disease; Psychotic Disorders; Reaction Time; Reference Values | 1995 |
Psychotic and depressive symptoms in Parkinson's disease. A study of the growth hormone response to apomorphine.
Topics: Aged; Apomorphine; Depressive Disorder; Female; Growth Hormone; Hallucinations; Humans; Male; Middle Aged; Neurocognitive Disorders; Parkinson Disease; Receptors, Dopamine; Receptors, Serotonin; Reference Values | 1995 |
Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone.
Topics: Administration, Rectal; Aged; Apomorphine; Domperidone; Female; Humans; Male; Middle Aged; Parkinson Disease; Perioperative Nursing | 1996 |
Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Brain; Deglutition Disorders; Domperidone; Dopamine Antagonists; Drug Therapy, Combination; Female; Fluoroscopy; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Video Recording | 1996 |
[Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Electric Stimulation; Evoked Potentials, Somatosensory; Female; Frontal Lobe; Humans; Levodopa; Male; Median Nerve; Middle Aged; Motor Skills; Parietal Lobe; Parkinson Disease; Reaction Time; Selegiline; Walking | 1996 |
N30 wave of somatosensory evoked potentials in Parkinson's disease: a pharmacological approach.
Topics: Aged; Apomorphine; Dopamine Agents; Dopamine Agonists; Evoked Potentials, Somatosensory; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reference Values; Time Factors | 1996 |
Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Overdose; Humans; Male; Middle Aged; Parkinson Disease; Self Administration; Sexual Dysfunctions, Psychological | 1997 |
Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy.
Topics: Aged; Apomorphine; Aspartic Acid; Basal Ganglia; Choline; Creatine; Glutamic Acid; Humans; Magnetic Resonance Spectroscopy; Middle Aged; Parkinson Disease | 1997 |
Long-term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa-related motor fluctuations.
Topics: Aged; Antiparkinson Agents; Apomorphine; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Motor Activity; Parkinson Disease | 1997 |
Correlation between results of motor section of UPDRS and Webster Scale.
Topics: Aged; Antiparkinson Agents; Apomorphine; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; Predictive Value of Tests; Retrospective Studies; Severity of Illness Index | 1997 |
Pallidotomy for hemiballismus: efficacy and characteristics of neuronal activity.
Topics: Action Potentials; Aged; Antiparkinson Agents; Apomorphine; Electrophysiology; Globus Pallidus; Humans; Male; Movement Disorders; Neurons; Parkinson Disease | 1997 |
Response of parkinsonian swallowing dysfunction to dopaminergic stimulation.
Topics: Aged; Apomorphine; Barium; Deglutition Disorders; Dopamine Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors | 1997 |
[Subcutaneous apomorphine in Parkinson disease].
Topics: Aged; Apomorphine; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenoviridae; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Enzyme-Linked Immunosorbent Assay; Female; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Humans; Nerve Growth Factors; Nerve Regeneration; Nerve Tissue Proteins; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra; Sympatholytics | 1997 |
Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease.
Topics: Acetic Acid; Antiparkinson Agents; Apomorphine; Chromatography, High Pressure Liquid; Circadian Rhythm; Glucuronates; Glucuronic Acid; Glucuronidase; Humans; Hydrolysis; Infusions, Intravenous; Linear Models; Male; Parkinson Disease; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism; Sulfatases; Sulfates; Time Factors | 1997 |
Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electrophysiology; Globus Pallidus; Humans; Intraoperative Period; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotaxic Techniques | 1997 |
Intrastriatal mesencephalic grafts affect neuronal activity in basal ganglia nuclei and their target structures in a rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Basal Ganglia; Brain Tissue Transplantation; Corpus Striatum; Dopamine; Dopamine Agonists; Electron Transport Complex IV; Fetal Tissue Transplantation; Graft Survival; Male; Mesencephalon; Neurons; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Stereotyped Behavior | 1998 |
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
Topics: Antiparkinson Agents; Apomorphine; Disease Progression; Humans; Levodopa; Motor Activity; Parkinson Disease | 1998 |
Subcutaneous apomorphine in Parkinson's disease.
Topics: Administration, Cutaneous; Antiparkinson Agents; Apomorphine; Humans; Parkinson Disease | 1998 |
Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Apomorphine; Brain; Caudate Nucleus; Disease Models, Animal; Enkephalins; Gene Expression Regulation; In Situ Hybridization; Male; Motor Activity; Nucleus Accumbens; Organ Specificity; Oxidopamine; Parkinson Disease; Protein Precursors; Putamen; Rats; Rats, Sprague-Dawley; Reference Values; Time Factors | 1998 |
Asymmetry of sympathetic activity in a rat model of Parkinson's disease induced by 6-hydroxydopamine: haemodynamic, electrocardiographic and biochemical changes.
Topics: Animals; Apomorphine; Behavior, Animal; Catecholamines; Disease Models, Animal; Electrocardiography; Functional Laterality; Hemodynamics; Immunohistochemistry; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra; Sympathetic Nervous System; Tyrosine 3-Monooxygenase | 1998 |
Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Chronotherapy; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps, Implantable; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Outcome | 1998 |
Confirmation of the antidyskinetic effect of posteroventral pallidotomy by means of an intraoperative apomorphine test.
Topics: Aged; Antiparkinson Agents; Apomorphine; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Intraoperative Complications; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Sensitivity and Specificity; Treatment Outcome | 1998 |
Apomorphine-induced penile erections in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Erectile Dysfunction; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Penile Erection | 1998 |
Free radical scavenging properties of apomorphine enantiomers and dopamine: possible implication in their mechanism of action in parkinsonism.
Topics: Apomorphine; Ascorbic Acid; Corpus Striatum; Dopamine; Free Radicals; Oxidative Stress; Parkinson Disease; Peroxides; Spectrophotometry | 1995 |
Extra cost of subcutaneous apomorphine would pay for personal nurses.
Topics: Antiparkinson Agents; Apomorphine; Community Health Nursing; Drug Costs; Humans; Parkinson Disease; United Kingdom | 1998 |
Pallidal activity during dystonia: somatosensory reorganisation and changes with severity.
Topics: Antiparkinson Agents; Apomorphine; Disease Progression; Dystonia; Female; Globus Pallidus; Humans; Middle Aged; Neuronal Plasticity; Parkinson Disease; Severity of Illness Index | 1998 |
Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Electroencephalography; Evoked Potentials; Female; Globus Pallidus; Humans; Male; Microelectrodes; Middle Aged; Neurologic Examination; Neurons; Parkinson Disease; Signal Processing, Computer-Assisted; Synaptic Transmission | 1999 |
Dopamine autoreceptor function is lost in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Autoreceptors; Brain Chemistry; Carbon Radioisotopes; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2; Tomography, Emission-Computed | 1999 |
Relative quantification of signal on T2-weighted images in the basal ganglia: limited value in differential diagnosis of patients with parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Basal Ganglia; Benzamides; Contrast Media; Diagnosis, Differential; Dopamine Antagonists; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease; Prospective Studies; Pyrrolidines; Tomography, Emission-Computed, Single-Photon | 1999 |
Worsening of levodopa-induced dyskinesias by motor and mental tasks.
Topics: Analysis of Variance; Antiparkinson Agents; Apomorphine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Problem Solving; Severity of Illness Index; Speech; Volition | 1999 |
Implantable venous access system for apomorphine infusion in complicated Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Humans; Infusion Pumps, Implantable; Parkinson Disease; Treatment Outcome | 1999 |
GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine.
Topics: Action Potentials; Apomorphine; Basal Ganglia; Dopamine Agonists; Dose-Response Relationship, Drug; Globus Pallidus; Humans; Male; Middle Aged; Monitoring, Intraoperative; Neurons; Parkinson Disease; Psychomotor Performance; Stereotaxic Techniques; Thalamus; Time Factors | 1999 |
Basal ganglia and gait control: apomorphine administration and internal pallidum stimulation in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Apomorphine; Basal Ganglia; Calibration; Electric Stimulation; Gait; Globus Pallidus; Humans; Infusions, Intravenous; Middle Aged; Neurons; Orientation; Parkinson Disease; Video Recording | 1999 |
Parkinson's disease and lower limb somatosensory evoked potentials: apomorphine-induced relief of the akinetic-rigid syndrome and vertex P37-N50 potentials.
Topics: Aged; Antiparkinson Agents; Apomorphine; Brain Stem; Electrophysiology; Evoked Potentials, Somatosensory; Female; Humans; Leg; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Syndrome | 1999 |
Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats: an electrophysiological and c-Fos study.
Topics: Adrenergic Agents; Animals; Apomorphine; Benzazepines; Dopamine Agonists; Male; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Substantia Nigra; Thalamic Nuclei | 1999 |
Future delivery systems for apomorphine in patients with Parkinson's disease.
Topics: Administration, Cutaneous; Administration, Intranasal; Antiparkinson Agents; Apomorphine; Diffusion; Drug Delivery Systems; Female; Humans; In Vitro Techniques; Iontophoresis; Middle Aged; Motor Activity; Parkinson Disease; Suppositories | 1999 |
Apomorphine protects against MPTP-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Tyrosine 3-Monooxygenase | 1999 |
Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease.
Topics: Adenoviridae; Animals; Anti-Bacterial Agents; Antiparkinson Agents; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Doxycycline; Female; Gene Expression Regulation; Gene Transfer Techniques; Humans; Immunohistochemistry; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase | 1999 |
A new video/computer method to measure the amount of overall movement in experimental animals (two-dimensional object-difference method).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Callithrix; Computer Storage Devices; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Image Interpretation, Computer-Assisted; Movement; Parkinson Disease; Time Factors; Video Recording | 1999 |
The effect of deep brain stimulation on the frontal N30 component of somatosensory evoked potentials in advanced Parkinson's disease patients.
Topics: Antiparkinson Agents; Apomorphine; Electric Stimulation; Evoked Potentials, Somatosensory; Globus Pallidus; Humans; Median Nerve; Middle Aged; Motor Cortex; Parkinson Disease | 1999 |
Dopa-producing astrocytes generated by adenoviral transduction of human tyrosine hydroxylase gene: in vitro study and transplantation to hemiparkinsonian model rats.
Topics: Adenoviridae; Animals; Animals, Newborn; Apomorphine; Astrocytes; beta-Galactosidase; Cells, Cultured; Corpus Striatum; Dihydroxyphenylalanine; Female; Genetic Vectors; Graft Rejection; Humans; Immunosuppressive Agents; Methamphetamine; Mice; Mice, Inbred ICR; Parkinson Disease; Postural Balance; Rats; Rats, Wistar; Sensation Disorders; Tacrolimus; Transfection; Tyrosine 3-Monooxygenase | 1999 |
Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease.
Topics: Aged; Apomorphine; Dopamine Agonists; Female; Humans; Injections, Subcutaneous; Pain, Intractable; Parkinson Disease | 2000 |
Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions.
Topics: Adamantane; Animals; Apomorphine; Benzazepines; Benzopyrans; Callithrix; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Quinpirole; Rotation | 2000 |
Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine.
Topics: Action Potentials; Affect; Apomorphine; Dopamine Agonists; Dyskinesia, Drug-Induced; Electrophysiology; Globus Pallidus; Humans; Neurons; Parkinson Disease; Subthalamic Nucleus | 2000 |
Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes.
Topics: Animals; Antiparkinson Agents; Apomorphine; Astrocytes; Base Sequence; Brain-Derived Neurotrophic Factor; Cells, Cultured; DNA Primers; Dopamine Agonists; Glial Cell Line-Derived Neurotrophic Factor; Humans; Mice; Nerve Growth Factor; Nerve Growth Factors; Nerve Tissue Proteins; Parkinson Disease; RNA, Messenger; Up-Regulation | 2000 |
Human amniotic epithelial cells produce dopamine and survive after implantation into the striatum of a rat model of Parkinson's disease: a potential source of donor for transplantation therapy.
Topics: Amniotic Fluid; Animals; Apomorphine; Behavior, Animal; Catecholamines; Cell Survival; Cell Transplantation; Cells, Cultured; Epithelial Cells; Female; Humans; Parkinson Disease; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Tissue Donors; Tyrosine 3-Monooxygenase | 2000 |
Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol.
Topics: Animals; Antiparkinson Agents; Apomorphine; Binding, Competitive; Brain Chemistry; Catalepsy; Dopamine; Dopamine Antagonists; Haloperidol; Homovanillic Acid; Isoquinolines; Male; Motor Activity; Neurotoxins; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Tetrahydroisoquinolines; Tritium | 2000 |
Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity.
Topics: Adenosine Triphosphatases; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Electron Transport Complex IV; Electrophoresis, Polyacrylamide Gel; Male; Melatonin; Mitochondria; Motor Activity; NAD; Neuroprotective Agents; Oxidative Phosphorylation; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2001 |
[Dopaminergic agonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles | 2000 |
The effects of apomorphine on attentional processing in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Apomorphine; Attention; Dopamine Agonists; Evoked Potentials, Auditory; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time | 1999 |
Microencapsulated bovine chromaffin cell xenografts into hemiparkinsonian rats: a drug-induced rotational behavior and histological changes analysis.
Topics: Animals; Apomorphine; Capsules; Cattle; Cell Survival; Chromaffin Cells; Disease Models, Animal; Female; Microscopy, Fluorescence; Parkinson Disease; Parkinson Disease, Secondary; Psychomotor Disorders; Rats; Rats, Sprague-Dawley; Rotation; Sensitivity and Specificity; Transplantation, Heterologous | 2001 |
[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
Topics: Aged; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Drug Therapy, Combination; Dyskinesias; Humans; Levodopa; Nitriles; Parkinson Disease | 2001 |
NMDA glutamate receptor stimulation is required for the expression of D2 dopamine mediated responses in apomorphine primed 6-hydroxydopamine lesioned rats.
Topics: Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Denervation; Dizocilpine Maleate; Dopamine Agonists; Excitatory Amino Acid Antagonists; Male; Oxidopamine; Parkinson Disease; Piperazines; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Sympatholytics | 2001 |
Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
Topics: Apomorphine; Corpus Striatum; Decision Making; Domperidone; Dopamine Agonists; Dopamine Antagonists; Drug Administration Schedule; Guidelines as Topic; Humans; Levodopa; Parkinson Disease; Substantia Nigra; Time Factors | 2001 |
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Body Temperature; Casts, Surgical; Corpus Striatum; Disease Models, Animal; Dopamine; Forelimb; Homovanillic Acid; Immobilization; Male; Medial Forebrain Bundle; Membrane Glycoproteins; Membrane Transport Proteins; Microinjections; Neural Pathways; Neurons; Neuropeptides; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Substantia Nigra; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2001 |
Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; DNA, Complementary; Dopamine Agents; Gene Expression; In Situ Hybridization; Male; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Parkinson Disease; Parkinson Disease, Secondary; Reverse Transcriptase Polymerase Chain Reaction | 2001 |
Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine.
Topics: Aged; Antiparkinson Agents; Apomorphine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiovascular System; Domperidone; Dopamine Antagonists; Female; Heart Rate; Humans; Infusions, Parenteral; Male; Middle Aged; Parkinson Disease | 2001 |
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dependovirus; Disease Models, Animal; Dopamine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Transduction, Genetic | 2001 |
Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Female; Functional Laterality; Humans; Male; Models, Biological; Parkinson Disease; Presynaptic Terminals; Raclopride; Synapses; Tomography, Emission-Computed | 2001 |
Effect of apomorphine on cortical inhibition in Parkinson's disease patients: a transcranial magnetic stimulation study.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Apomorphine; Dopamine; Electric Stimulation; Electromagnetic Phenomena; Evoked Potentials, Motor; Female; Humans; Male; Middle Aged; Motor Cortex; Neural Inhibition; Parkinson Disease; Statistics, Nonparametric | 2001 |
[Apomorphine therapy versus deep rain stimulation. Clinical and economic aspects in patients with advanced Parkinson disease].
Topics: Aged; Apomorphine; Cost-Benefit Analysis; Electric Stimulation Therapy; Globus Pallidus; Humans; Infusion Pumps, Implantable; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prostheses and Implants; Retrospective Studies; Subthalamic Nucleus | 2001 |
Deep brain stimulation of both subthalamic nucleus and internal globus pallidus restores intracortical inhibition in Parkinson's disease paralleling apomorphine effects: a paired magnetic stimulation study.
Topics: Antiparkinson Agents; Apomorphine; Basal Ganglia; Cerebral Cortex; Electric Stimulation Therapy; Electromagnetic Fields; Evoked Potentials, Motor; Female; Globus Pallidus; Humans; Male; Middle Aged; Parkinson Disease; Subthalamus | 2002 |
Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Treatment Outcome | 2002 |
Apomorphine as an alternative to sildenafil in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Erectile Dysfunction; Humans; Injections, Subcutaneous; Male; Multiple System Atrophy; Parkinson Disease; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones | 2002 |
Editorial: After dopa.
Topics: Apomorphine; Chemoreceptor Cells; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Stimulation, Chemical | 1976 |
Effects of interruption of the nigrostriatal pathway and of dopaminergic agents on the spontaneous activity of globus pallidus neurons in the awake monkey.
Topics: Animals; Apomorphine; Corpus Striatum; Evoked Potentials; Globus Pallidus; Haloperidol; Haplorhini; Harmaline; Macaca mulatta; Movement; Neural Pathways; Neurons; Parkinson Disease; Piperazines; Piribedil; Reserpine; Substantia Nigra | 1979 |
Actions of dopaminergic agonists on cyclic AMP production in rat brain homogenates.
Topics: Animals; Antiparkinson Agents; Apomorphine; Aporphines; Bucladesine; Corpus Striatum; Cyclic AMP; Dopamine; Isoquinolines; Male; Naphthalenes; Parkinson Disease; Piribedil; Rats; Receptors, Drug; Tranquilizing Agents | 1975 |
Enkephalins and nigrostriatal function.
Topics: Animals; Apomorphine; Behavior, Animal; Dextroamphetamine; Endorphins; Enkephalins; Hydroxydopamines; Levodopa; Male; Naloxone; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Rats; Receptors, Opioid; Reserpine; Substantia Nigra | 1978 |
Dopamine receptors and sleep induction in man.
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Receptors, Dopamine; Sleep; Sleep Stages; Time Factors; Vomiting | 1979 |
Bromocriptine-induced behavioral hypersensitivity: implications for the therapy of parkinsonism.
Topics: Animals; Apomorphine; Behavior; Bromocriptine; Dextroamphetamine; Guinea Pigs; Humans; Male; Parkinson Disease; Stereotyped Behavior | 1978 |
Receptor basis for dopaminergic supersensitivity in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Caudate Nucleus; Dopamine; Haloperidol; Homovanillic Acid; Humans; Levodopa; Middle Aged; Parkinson Disease; Putamen; Receptors, Dopamine; Synaptic Membranes | 1978 |
Effect of intracaudate drug injections on the striatal syndrome in reserpinized cats.
Topics: Animals; Apomorphine; Atropine; Cats; Caudate Nucleus; Corpus Striatum; Dextroamphetamine; Disease Models, Animal; Dopamine; Male; Neuromuscular Diseases; Parkinson Disease; Reserpine; Syndrome | 1977 |
[Interaction between L-dopa and other drugs].
Topics: Amantadine; Anti-Arrhythmia Agents; Apomorphine; Chlorpromazine; Drug Antagonism; Drug Interactions; Drug Synergism; Humans; Levodopa; Parkinson Disease; Tranquilizing Agents | 1976 |
Therapeutic approaches in Parkinson's disease: possible roles of growth hormone and somatostatin.
Topics: Amantadine; Apomorphine; Growth Hormone; Humans; Levodopa; Parkinson Disease; Somatostatin | 1976 |
alpha and beta Dopamine receptors?
Topics: Apomorphine; Chorea; Haloperidol; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Torticollis | 1976 |
Reinstatement of eating by dopamine agonists in aphagic dopamine denervated rats.
Topics: Animals; Apomorphine; Denervation; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Humans; Hydroxydopamines; Hypothalamus; Levodopa; Male; Motor Activity; Nerve Degeneration; Parkinson Disease; Piperazines; Rats; Receptors, Dopamine; Stereotyped Behavior; Stimulation, Chemical | 1976 |
[Effects of apomorphine on the vestibulo-ocular reflex in normal subjects and in patients with parkinsonism].
Topics: Apomorphine; Electroencephalography; Electronystagmography; Eye Movements; Humans; Injections, Subcutaneous; Parkinson Disease; Reflex; Reflex, Oculocardiac; Stimulation, Chemical; Vestibule, Labyrinth | 1975 |
Neuropharmacological studies on D145 (1,3-dimethyl-5-aminoadamantan).
Topics: Amantadine; Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Dopamine; Extrapyramidal Tracts; Humans; Hypothalamus; Limbic System; Male; Memantine; Methyltyrosines; Motor Activity; Parkinson Disease; Rats; Reserpine; Reticular Formation; Stereotaxic Techniques; Stereotyped Behavior; Substantia Nigra | 1975 |
Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced dyskinesias.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Guinea Pigs; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Receptors, Drug; Stereotyped Behavior; Time Factors | 1975 |
Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents.
Topics: Animals; Apomorphine; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Humans; Male; Metoclopramide; Mice; Mice, Inbred Strains; Motor Activity; Parkinson Disease; Pimozide; Rats; Receptors, Drug; Reserpine; Rotation; Stereotyped Behavior; Substantia Nigra | 1975 |
Supersensitivity to d-amphetamine- and apomorphine-induced stereotyped behavior induced by chronic d-amphetamine administration.
Topics: Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Disease Models, Animal; Dopamine; Humans; Levodopa; Male; Mice; Movement Disorders; Parkinson Disease; Receptors, Drug; Stereotyped Behavior; Time Factors | 1975 |
Aporphines in Parkinson's disease.
Topics: Apomorphine; Humans; Parkinson Disease | 1975 |
Modification of the actions of some neuroactive drugs by growth hormone.
Topics: Animals; Apomorphine; Behavior, Animal; Dihydroxyphenylalanine; Dopamine; Drug Synergism; Growth Hormone; Levodopa; Male; Mice; Oxotremorine; Parkinson Disease; Psychotropic Drugs; Tyrosine | 1976 |
[Preconvulsive state and hyperfunction of the striatum (clinico-experimental findings)].
Topics: Adolescent; Adult; Aged; Animals; Apomorphine; Convulsants; Corpus Striatum; Electroencephalography; Haloperidol; Humans; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Pentylenetetrazole; Rats; Seizures | 1976 |
Editorial: Alternatives to levodopa.
Topics: Apomorphine; Bromocriptine; Humans; Levodopa; Parkinson Disease | 1976 |
Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in Parkinsonism.
Topics: Adult; Apomorphine; Drug Therapy, Combination; Haloperidol; Humans; Male; Metoclopramide; Parkinson Disease; Sleep; Sulpiride; Vomiting | 1976 |
Therapy of Morbus Parkinson and radical-induced neurotoxicity in the rat--in vivo voltammetric studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Apomorphine; Corpus Striatum; Dopamine; Electrochemistry; Free Radicals; Haloperidol; Hydroxyindoleacetic Acid; Male; Memantine; Neurotoxins; Parkinson Disease; Rats; Rats, Wistar; Rotenone; Serotonin; Substantia Nigra | 1992 |
[Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
Topics: Administration, Sublingual; Adult; Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease | 1992 |
Raised resting energy expenditure in Parkinson's disease and its relationship to muscle rigidity.
Topics: Apomorphine; Calorimetry, Indirect; Energy Metabolism; Female; Humans; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Rest | 1992 |
Levodopa challenge test in Parkinson's disease.
Topics: Apomorphine; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1992 |
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
Topics: Aged; Apomorphine; Chlorpromazine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Sulpiride | 1992 |
Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery.
Topics: Administration, Oral; Aged; Apomorphine; Female; Hip Fractures; Humans; Infusion Pumps; Injections, Subcutaneous; Intestinal Obstruction; Levodopa; Male; Middle Aged; Parkinson Disease | 1992 |
Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine.
Topics: Aged; Apomorphine; Blood Pressure; Domperidone; Female; Heart Rate; Humans; Male; Middle Aged; Parkinson Disease | 1992 |
Brain implants in man do not break down the blood-brain barrier to dopamine and domperidone.
Topics: Adult; Aged; Apomorphine; Blood-Brain Barrier; Brain; Domperidone; Dopamine; Drug Implants; Female; Humans; Male; Middle Aged; Parkinson Disease | 1992 |
The clinical use of apomorphine in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Drug Administration Schedule; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Compliance | 1992 |
[Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease | 1992 |
Time course of tolerance to apomorphine in parkinsonism.
Topics: Aged; Analysis of Variance; Apomorphine; Drug Tolerance; Humans; Infusions, Intravenous; Middle Aged; Parkinson Disease; Time Factors | 1992 |
Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Dose-Response Relationship, Drug; Humans; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies | 1992 |
The dopaminergic response in multiple system atrophy.
Topics: Adult; Aged; Apomorphine; Atrophy; Brain Stem; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Terminology as Topic | 1992 |
Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
Topics: Adult; Apomorphine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1992 |
Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine.
Topics: Adult; Aged; Apomorphine; Brain; Cerebral Cortex; Cerebrovascular Circulation; Chromatography, High Pressure Liquid; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease; Psychomotor Performance; Tomography, Emission-Computed | 1992 |
[Effect of apomorphine on the bladder of parkinsonian patients].
Topics: Aged; Aged, 80 and over; Apomorphine; Domperidone; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Urinary Bladder Diseases; Urodynamics | 1992 |
Rectal apomorphine: a new treatment modality in Parkinson's disease.
Topics: Administration, Rectal; Apomorphine; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1992 |
[Subcutaneous apomorphine in major motor oscillations of parkinsonian patients].
Topics: Aged; Apomorphine; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1992 |
123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Benzamides; Humans; Iodine Radioisotopes; Levodopa; Middle Aged; Parkinson Disease; Pyrrolidines; Receptors, Dopamine; Tomography, Emission-Computed, Single-Photon | 1992 |
[Nasolabial allergic reaction to intranasal administration of apomorphine in Parkinson disease].
Topics: Administration, Intranasal; Angioedema; Apomorphine; Humans; Injections, Subcutaneous; Lip; Male; Middle Aged; Nose; Parkinson Disease | 1992 |
Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Carbidopa; Domperidone; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance | 1992 |
Intranasal apomorphine in parkinsonian on-off fluctuations.
Topics: Administration, Intranasal; Adult; Aged; Apomorphine; Humans; Middle Aged; Parkinson Disease | 1992 |
Apomorphine in malignant syndrome due to levodopa withdrawal.
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1992 |
Paradoxical akinetic response to apomorphine in parkinsonism.
Topics: Apomorphine; Benserazide; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1992 |
Continuous subcutaneous apomorphine infusion in Parkinson's disease.
Topics: Apomorphine; Humans; Infusion Pumps; Infusions, Parenteral; Male; Middle Aged; Parkinson Disease | 1992 |
Induction of mania by apomorphine in a depressed parkinsonian patient.
Topics: Apomorphine; Bipolar Disorder; Depressive Disorder; Female; Humans; Injections, Subcutaneous; Middle Aged; Neurologic Examination; Parkinson Disease | 1992 |
Time interval between repeated injections conditions the duration of motor improvement to apomorphine in Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Apomorphine; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 1992 |
A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Deoxyglucose; Female; Globus Pallidus; Levodopa; Macaca fascicularis; Male; Parkinson Disease; Thalamic Nuclei | 1992 |
Rectal apomorphine in Parkinson's disease.
Topics: Administration, Rectal; Aged; Apomorphine; Drug Evaluation; Female; Humans; Male; Middle Aged; Parkinson Disease; Suppositories; Time Factors | 1991 |
MPTP lesions and dopaminergic drugs alter eye blink rate in African green monkeys.
Topics: Animals; Apomorphine; Blinking; Chlorocebus aethiops; Dopamine Agents; Haloperidol; Male; MPTP Poisoning; Oxazines; Parkinson Disease; Receptors, Dopamine; Substantia Nigra; Sulpiride | 1991 |
Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior.
Topics: Amphetamine; Animals; Apomorphine; Axons; Denervation; Disease Models, Animal; Female; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Rotation; Substantia Nigra; Tyrosine 3-Monooxygenase | 1991 |
Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine.
Topics: Aged; Apomorphine; Brain Mapping; Cerebrovascular Circulation; Female; Fingers; Humans; Male; Middle Aged; Motor Cortex; Movement; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 1992 |
Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.
Topics: Administration, Sublingual; Aged; Apomorphine; Humans; Injections, Subcutaneous; Middle Aged; Parkinson Disease | 1991 |
The apomorphine test in parkinsonian syndromes.
Topics: Aged; Apomorphine; Diagnosis, Differential; Female; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Muscular Atrophy; Neurologic Examination; Olivopontocerebellar Atrophies; Parkinson Disease; Parkinson Disease, Secondary; Prognosis; Supranuclear Palsy, Progressive | 1991 |
Changes in blood-brain barrier permeability are associated with behavioral and neurochemical indices of recovery following intraventricular adrenal medulla grafts in an animal model of Parkinson's disease.
Topics: Adrenal Medulla; Amphetamine; Animals; Apomorphine; Behavior, Animal; Blood-Brain Barrier; Capillary Permeability; Cerebral Ventricles; Corpus Striatum; Dialysis; Dopamine; Female; Movement; Parkinson Disease; Rats; Rats, Inbred Strains | 1991 |
Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease.
Topics: Administration, Sublingual; Aged; Apomorphine; Female; Humans; Male; Middle Aged; Parkinson Disease | 1991 |
Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations.
Topics: Administration, Sublingual; Adult; Apomorphine; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pilot Projects | 1991 |
Positive and negative interactions in the behavioural expression of D1 and D2 receptor stimulation in a model of Parkinsonism: role of priming.
Topics: Animals; Apomorphine; Behavior, Animal; Benzazepines; Disease Models, Animal; Dopamine Antagonists; Hydroxydopamines; Male; Oxidopamine; Parkinson Disease; Raclopride; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Stereotyped Behavior | 1991 |
Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Injections, Intravenous; Levodopa; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1991 |
The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts.
Topics: Animals; Apomorphine; Body Weight; Carbidopa; Corpus Striatum; Drinking; Female; Fetal Tissue Transplantation; Hydroxydopamines; Levodopa; Mesencephalon; Motor Activity; Nervous System; Oxidopamine; Parkinson Disease; Rats; Rotation; Stereotyped Behavior; Time Factors | 1991 |
Absorption of apomorphine by various routes in parkinsonism.
Topics: Absorption; Administration, Cutaneous; Administration, Oral; Administration, Sublingual; Animals; Apomorphine; Biological Availability; Drug Therapy, Combination; Infusions, Parenteral; Levodopa; Parkinson Disease | 1991 |
Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.
Topics: Aged; Apomorphine; Blood Pressure; Cerebrovascular Circulation; Domperidone; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Tomography, Emission-Computed, Single-Photon | 1991 |
Challenge tests to predict the dopaminergic response in untreated Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Apomorphine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1991 |
[Apomorphine in the treatment of Parkinson disease].
Topics: Adult; Aged; Apomorphine; Female; Humans; Male; Middle Aged; Parkinson Disease; Prognosis | 1991 |
Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Self Administration | 1991 |
Possible mechanisms of action of adrenal transplants in Parkinson's disease.
Topics: Adrenal Medulla; Aging; Animals; Apomorphine; Brain Tissue Transplantation; Bucladesine; Caudate Nucleus; Cerebral Ventricles; Dominance, Cerebral; Dopamine; Fetal Tissue Transplantation; Hydroxydopamines; Male; Motor Activity; Oxidopamine; Pain; Parkinson Disease; Rats; Rats, Inbred Strains; Sensory Thresholds; Substantia Nigra; Transplantation, Heterotopic | 1990 |
Intranasal apomorphine in Parkinson's disease.
Topics: Administration, Intranasal; Aged; Apomorphine; Female; Humans; Levodopa; Male; Parkinson Disease; Pilot Projects | 1991 |
The motor response to sequential apomorphine in parkinsonian fluctuations.
Topics: Adult; Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Psychomotor Performance | 1991 |
Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.
Topics: Administration, Oral; Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Substance-Related Disorders | 1991 |
Buspirone in the treatment of levodopa induced dyskinesias.
Topics: Adult; Aged; Apomorphine; Buspirone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1991 |
The motor response to repeated apomorphine administration in Parkinson's disease.
Topics: Aged; Apomorphine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Reaction Time | 1991 |
Antiparkinsonian effects of caffeine depend upon pavlovian drug conditioning processes.
Topics: Animals; Apomorphine; Caffeine; Conditioning, Classical; Functional Laterality; Hydroxydopamines; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Rotation; Substantia Nigra | 1990 |
The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain Tissue Transplantation; Carbidopa; Corpus Striatum; Female; Fetal Tissue Transplantation; Hydroxydopamines; Levodopa; Mesencephalon; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Stereotyped Behavior; Substantia Nigra | 1990 |
Mechanisms of action of adrenal medulla grafts: the possible role of peripheral and central dopamine systems.
Topics: Adrenal Medulla; Adrenalectomy; Amphetamine; Animals; Apomorphine; Blood-Brain Barrier; Cerebral Ventricles; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Hydroxydopamines; Male; Models, Biological; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Transplantation, Heterotopic | 1990 |
Phenotypic plasticity of locus coeruleus noradrenergic neurons after transplantation into the dopamine-depleted caudate in the rat.
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Caudate Nucleus; Dopamine; Female; Fetal Tissue Transplantation; Graft Survival; Hydroxydopamines; Locus Coeruleus; Motor Activity; Neuronal Plasticity; Neurons; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Transplantation, Heterotopic | 1990 |
A functional assessment of embryonic dopaminergic grafts in the marmoset.
Topics: Amphetamine; Animals; Apomorphine; Brain Tissue Transplantation; Callitrichinae; Corpus Striatum; Disease Models, Animal; Dopamine; Fetal Tissue Transplantation; Functional Laterality; Hydroxydopamines; Mesencephalon; Motor Activity; Motor Skills; Oxidopamine; Parkinson Disease | 1990 |
Apomorphine in the diagnosis and treatment of parkinsonian tremor.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Apomorphine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor | 1990 |
Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Carbidopa; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Intranasal apomorphine: a new treatment in Parkinson's disease.
Topics: Administration, Intranasal; Aged; Apomorphine; Humans; Middle Aged; Neurologic Examination; Parkinson Disease | 1990 |
Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Apomorphine; Behavior, Animal; Carbidopa; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease; Sural Nerve; Transplantation, Heterotopic | 1990 |
Subcutaneous apomorphine in the treatment of Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1990 |
[Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Disorders | 1990 |
['New wine in old bottles'; therapy for Parkinson disease using subcutaneous apomorphine].
Topics: Aged; Antiparkinson Agents; Apomorphine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Marijuana for parkinsonian tremor.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Diazepam; Drug Combinations; Humans; Levodopa; Marijuana Smoking; Parkinson Disease; Tremor | 1990 |
Migraine attacks induced by subcutaneous apomorphine in two migrainous parkinsonian patients.
Topics: Aged; Apomorphine; Female; Humans; Injections, Subcutaneous; Middle Aged; Migraine Disorders; Parkinson Disease | 1990 |
The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism.
Topics: Aged; Apomorphine; Dopamine; Humans; Levodopa; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1990 |
Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Drug Tolerance; Ergolines; Humans; Infusion Pumps; Levodopa; Lisuride; Middle Aged; Movement Disorders; Parkinson Disease | 1990 |
Induction of dyskinesias.
Topics: Animals; Apomorphine; Delayed-Action Preparations; Levodopa; Movement Disorders; Parkinson Disease; Rats; Receptors, Dopamine | 1990 |
An encapsulated dopamine-releasing polymer alleviates experimental parkinsonism in rats.
Topics: Acrylic Resins; Animals; Apomorphine; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Implants; Hydroxydopamines; Male; Motor Activity; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Polyvinyls; Rats; Rats, Inbred Strains | 1989 |
Side-effects of subcutaneous apomorphine in Parkinson's disease.
Topics: Apomorphine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Side-effects of subcutaneous apomorphine in Parkinson's disease.
Topics: Aged; Apomorphine; Drug Evaluation; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease | 1989 |
Apomorphine test for dopaminergic responsiveness.
Topics: Apomorphine; Diagnosis, Differential; Double-Blind Method; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1989 |
Severe oedema after subcutaneous apomorphine in Parkinson's disease.
Topics: Apomorphine; Edema; Humans; Infusions, Parenteral; Male; Middle Aged; Parkinson Disease | 1989 |
Sublingual apomorphine and Parkinson's disease.
Topics: Administration, Sublingual; Aged; Apomorphine; Female; Humans; Male; Middle Aged; Parkinson Disease | 1989 |
[The placebo effect: between mind and brain].
Topics: Animals; Apomorphine; Brain; Conditioning, Psychological; Disease Models, Animal; Humans; Parkinson Disease; Placebos | 1989 |
Motor response following repeated apomorphine administration is reduced in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Reaction Time | 1989 |
Subcutaneous apomorphine in Parkinson's disease.
Topics: Apomorphine; Bromocriptine; Drug Therapy, Combination; Humans; Injections, Subcutaneous; Levodopa; Middle Aged; Parkinson Disease | 1989 |
Peripheral pharmacokinetics of apomorphine in humans.
Topics: Adult; Aged; Apomorphine; Dopamine; Dose-Response Relationship, Drug; Humans; Injections, Intravenous; Injections, Subcutaneous; Levodopa; Middle Aged; Parkinson Disease | 1989 |
Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.
Topics: Aged; Apomorphine; Carbidopa; Drug Resistance; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine | 1989 |
Apomorphine infusion for motor fluctuations in Parkinson's disease.
Topics: Apomorphine; Drug Therapy, Combination; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 1987 |
Subcutaneous apomorphine in parkinsonian on-off oscillations.
Topics: Adult; Aged; Apomorphine; Domperidone; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Injections, Subcutaneous; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1988 |
Subcutaneous apomorphine in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Time Factors | 1988 |
Subcutaneous apomorphine for on-off oscillations in Parkinson's disease.
Topics: Apomorphine; Drug Evaluation; Humans; Injections, Subcutaneous; Middle Aged; Parkinson Disease | 1988 |
Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine.
Topics: Aged; Apomorphine; Drug Therapy, Combination; Eructation; Esophageal Motility Disorders; Esophagus; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peristalsis | 1989 |
A conditioned anti-parkinsonian drug effect in the hemi-parkinsonian rat.
Topics: Animals; Apomorphine; Conditioning, Classical; Corpus Striatum; Dopamine; Hydroxydopamines; Male; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains | 1986 |
Chronic treatment with bromocriptine induces behavioral supersensitivity in rats.
Topics: Animals; Apomorphine; Bromocriptine; Dopamine Antagonists; Humans; Hydroxydopamines; Male; Oxidopamine; Parkinson Disease; Pyrrolidines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior | 1986 |
The effects of dopamine agonists on human cardiovascular and sympathetic nervous systems.
Topics: Adult; Aged; Apomorphine; Blood Pressure; Bromocriptine; Cardiovascular System; Catecholamines; Dopamine; Dopamine beta-Hydroxylase; Female; Heart Rate; Hemodynamics; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Parkinson Disease; Pulse; Sympathetic Nervous System | 1985 |
Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release.
Topics: Amphetamine; Animals; Antibodies; Apomorphine; Behavior, Animal; Brain; Dialysis; Dopamine; Female; Fetus; Graft Survival; Humans; Immunosuppression Therapy; Neurons; Parkinson Disease; Rats; Rats, Inbred Strains; Transplantation, Heterologous | 1988 |
Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain; Disease Models, Animal; Ergolines; Levodopa; Lisuride; Male; Motor Activity; Parkinson Disease; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior | 1987 |
Diurnal responsiveness to apomorphine.
Topics: Aged; Apomorphine; Circadian Rhythm; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease; Receptors, Dopamine | 1987 |
Continuous dopaminergic stimulation in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Humans; Levodopa; Lisuride; Parkinson Disease | 1987 |
Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug.
Topics: alpha-Methyltyrosine; Animals; Apomorphine; Body Temperature; Dogs; Dose-Response Relationship, Drug; Guinea Pigs; Haloperidol; Male; Methyltyrosines; Parkinson Disease; Piperazines; Rats; Rats, Inbred Strains; Reserpine; Stereotyped Behavior | 1986 |
GABA-mimetic drugs enhance apomorphine-induced contralateral turning in rats with unilateral nigrostriatal dopamine denervation: implications for the therapy of Parkinson's disease.
Topics: Alkynes; Aminocaproates; Animals; Antiparkinson Agents; Apomorphine; Drug Synergism; gamma-Aminobutyric Acid; Isoxazoles; Male; Motor Activity; Nicotinic Acids; Parkinson Disease; Rats; Rats, Inbred Strains | 1987 |
Actions of levodopa and dopamine in the central nervous system.
Topics: Animals; Apomorphine; Binding Sites; Brain; Central Nervous System; Chlorpromazine; Dihydroxyphenylalanine; Dopamine; Haplorhini; Hydrazines; Methyltyrosines; Neurotransmitter Agents; Parkinson Disease; Rabbits; Rats; Receptors, Cholinergic; Receptors, Neurotransmitter; Reserpine; Substantia Nigra; Synapses; Synaptic Transmission | 1971 |
Biochemical aspects of experimentally induced parkinsonism.
Topics: 5-Hydroxytryptophan; Amines; Amino Acids; Animals; Antiparkinson Agents; Apomorphine; Basal Ganglia; Biogenic Amines; Brain; Carboxy-Lyases; Catechol O-Methyltransferase Inhibitors; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Dopamine beta-Hydroxylase; Haplorhini; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Rats; Tyrosine 3-Monooxygenase; Visual Cortex | 1972 |
The use of dopaminergic receptor stimulating agent (Pribedil, ET 495) in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Apomorphine; Dioxoles; Drug Evaluation; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease; Piperazines; Pyrimidines; Time Factors | 1974 |
[Apomorphine in the biochemical concept of Parkinson's tremor].
Topics: Animals; Apomorphine; Brain Chemistry; Dihydroxyphenylalanine; Drug Therapy, Combination; Humans; Parkinson Disease; Receptors, Drug; Tremor | 1974 |
Unexpected findings with apomorphine and their possible consequences.
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Chemical Phenomena; Chemistry; Dose-Response Relationship, Drug; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Humans; Injections, Subcutaneous; Levodopa; Movement Disorders; Parkinson Disease; Structure-Activity Relationship; Uremia | 1974 |
Short- and long-term approaches to the "on-off" phenomenon.
Topics: Apomorphine; Carbidopa; Dietary Proteins; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1974 |
Levodopa, manganese, and degenerations of the brain.
Topics: Administration, Oral; Animals; Apomorphine; Blood Urea Nitrogen; Brain Diseases; Carbon Radioisotopes; Chemical Phenomena; Chemistry; Chronic Disease; Dietary Proteins; Dopamine; Drug Therapy, Combination; Growth Hormone; Humans; Injections; Levodopa; Manganese Poisoning; Movement Disorders; Neutron Activation Analysis; Parkinson Disease; Psychoses, Substance-Induced; Radioisotopes | 1974 |
Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Drinking Behavior; Electric Stimulation; Electromyography; Feeding and Eating Disorders; Feeding Behavior; Humans; Hydroxydopamines; Levodopa; Motor Neurons; Muscle Contraction; Nerve Degeneration; Neural Pathways; Parkinson Disease; Parkinson Disease, Secondary; Perceptual Disorders; Rats; Reflex, Stretch; Substantia Nigra | 1974 |
Levodopa and related drugs.
Topics: Amantadine; Apomorphine; Dihydroxyphenylalanine; Humans; Hydrazines; Hypotension; Mental Disorders; Movement Disorders; Nausea; Parasympatholytics; Parkinson Disease; Pyridoxine | 1973 |
Effect of apomorphine on growth hormone release in humans.
Topics: Adolescent; Adult; Apomorphine; Dystonia Musculorum Deformans; Female; Growth Hormone; Humans; Male; Middle Aged; Parkinson Disease; Torticollis | 1973 |
Coupling of hypotensive and anit-Parkinson effects with two dopaminergic drugs.
Topics: Apomorphine; Blood Pressure; Brain; Carbidopa; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Synergism; Humans; Hydrazines; Hypotension; Parkinson Disease; Time Factors | 1971 |
Levodopa in the treatment of Parkinsonism.
Topics: Animals; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Dihydroxyphenylalanine; Dopamine; Esters; Humans; Hydrazines; Manganese Poisoning; Methylation; Methyldopa; Mice; Movement; Parkinson Disease; Parkinson Disease, Secondary; Phenylacetates | 1971 |
"Catecholamines" in the brain.
Topics: Animals; Apomorphine; Brain; Dihydroxyphenylalanine; Dopamine; Humans; Manganese Poisoning; Parkinson Disease | 1970 |
Apomorphine in Parkinsonian tremor.
Topics: Apomorphine; Humans; Injections, Intravenous; Parkinson Disease; Tremor | 1970 |
Dopamine analogues for studies of parkinsonism.
Topics: Apomorphine; Dopamine; Humans; Parkinson Disease; Piperidines | 1970 |
Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats.
Topics: Animals; Apomorphine; Chemistry, Pharmaceutical; Compulsive Behavior; Dextroamphetamine; Dihydroxyphenylalanine; Dopamine; Extrapyramidal Tracts; Humans; Iproniazid; Male; Methyldopa; Parkinson Disease; Phenethylamines; Psychopharmacology; Rats | 1967 |